Pichia pastoris: an eukariotic system for the expression of recombinant therapeutic molecules by BARISON ERIKA
 1
   
 
 
 
UNIVERSITA’ DEGLI STUDI DI VERONA 
 
 
 
DIPARTIMENTO DI 
Patologia 
 
DOTTORATO DI RICERCA IN 
Biomedicina Traslazionale 
 
 
CICLO XXII 
 
 
TITOLO DELLA TESI DI DOTTORATO 
 
Pichia pastoris:  
AN EUKARIOTIC SYSTEM FOR THE EXPRESSION 
OF RECOMBINANT THERAPEUTIC MOLECULES 
 
S.S.D. MED04 
 
 
 
Coordinatore: Prof. Cristiano Chiamulera 
 
 
Tutor: Prof. Marco Colombatti 
 
 
 
Dottoranda: Dott.ssa Erika Barison 
 
 
 
ANNO ACCADEMICO 2009 – 2010 
 2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3
ABSTRACT 
 
 Rationally designed anticancer agents targeting cell-surface antigens or 
receptors, such as Immunotoxins, represent a promising approach for treating 
cancer patients. The Immunotoxin IL4PE40 derives its activity to induce 
apoptosis from the 40 kDa PE fragment (Pseudomonas exotoxin A) and its 
specificity from the permuted form of interleukin-4. IL4PE40 produced in E. coli 
was extracted from inclusion bodies and purified by affinity chromatography, in 
its active form. However, the clinical translation of therapeutic molecules 
produced in E. coli is often difficult, due to endotoxin contaminations and 
laborious protocols of inclusion bodies purification that make hard the 
reproducibility of the isolation procedures. To overcome these disadvantages, I 
cloned the IL4PE40 gene into a yeast expression vector for use in the Pichia 
pastoris yeast. In the literature it is reported that P. pastoris can secrete grams per 
liter of foreign proteins in a protein-poor medium that is inexpensive and 
chemically defined. The presence of a signal peptide at the N-terminus of the 
recombinant protein allows the secretion of native protein within the culture 
medium. In addition, the low level of endogenous proteins secreted in the culture 
medium facilitates the purification steps of the final product. In my work the yield 
of IL4PE40 produced by yeast was optimized by yeast codon usage and by testing 
different induction conditions. After optimization the yeast P. pastoris was able to 
produce 120 µg of full-length Immunotoxin from 1 liter of culture, which is far 
from results obtained with non-toxic proteins by other workers. Moreover, 
although after optimization the yield increased, proteins obtained from optimized 
cultures of P. pastoris show a considerable level of degradation. The translocation 
of toxic fusion proteins in the cytosol during biosynthesis may lead to such low 
protein production. Additionally, it appears that proteases cleaving the 
recombinant molecules cold be present in the yeast medium. Preliminary cleavage 
assays with native PE and literature data suggest that several proteases (serine 
proteases and subtilisins) could cooperate in the IL4PE40 cleavage. Planned 
experiments to overcome these limitations are also described in my thesis.  
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RIASSUNTO 
 
 L’ideazione di farmaci antitumorali che riconoscono recettori o antigeni 
della superficie cellulare, come le Immunotossine, rappresentano un approccio 
promettente per il trattamento di pazienti affetti da cancro. La capacità di indurre 
l’apoptosi dell’Immunotossina IL4PE40 deriva dal frammento di 40 kDa della 
tossina PE (Pseudomonas esotossina A) e la sua specificità dalla forma permutata 
dell’interleuchina-4. IL4PE40 prodotta da E. coli è estratta dai corpi d’inclusione 
e purificata nella sua forma attiva tramite cromatografia di affinità. Comunque, la 
translazione clinica di molecole terapeutiche prodotte da E. coli è spesso 
difficoltosa, a causa di contaminazioni da endotossine e di protocolli laboriosi per 
la purificazione dei corpi d’inclusione che rendono difficile la riproducibilità della 
procedura di isolamento. Per superare questi svantaggi, ho clonato il gene di 
IL4PE40 in un vettore d’espressione per il lievito Pastoris pastoris. In letteratura 
è riportato che P. pastoris è in grado di secernere grammi per litro di proteine 
eterologhe in un terreno povero di proteine, economico e chimicamente definito. 
La presenza di un peptide segnale all’N-terminale della proteina ricombinante 
permette la secrezione della proteina nativa nel terreno di coltura. Inoltre il basso 
livello di secrezione di proteine endogene nel terreno di coltura, facilita  i passaggi 
di purificazione del prodotto finale. Nel mio lavoro la resa di IL4PE40 prodotta 
dal lievito è stata ottimizzata dal utilizzo del “codon usage” del lievito e 
dall’analisi di diverse condizioni di induzione. Dopo l’ottimizzazione P. pastoris è 
in grado di produrre 120 µg di Immunotossina da un litro di coltura; questo 
quantità è lontana dai risultati ottenuti in altri lavori con proteine non tossiche. 
Inoltre, benché dopo l’ottimizzazione la resa sia aumentata, le proteine ottenute da 
colture ottimizzate di P. pastoris mostrano un considerevole livello di 
degradazione. La translocazione della proteina tossica nel citosol durante la 
biosintesi potrebbe portare ad una dminuzione della produzione. Inoltre, sembra 
che nel terreno del lievito siano presenti proteasi in grado di degradare la molecola 
ricombinante. Saggi di degradazione con la PE nativa e dati della letteratura 
suggeriscono che diverse proteasi (serine e subtilisine) potrebbero cooperare nella 
degradazione di IL4PE40. Nella mia tesi sono inoltre descritti esperimenti 
pianificati per superare queste limitazioni.  
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ABBREVIATIONS 
 
 
IPTG:  isopropyl-β-D-thiogalactoside. 
h: hours 
min: minutes 
PBS: phosphate-buffered saline 
Sec: seconds 
r.t.: room temperature 
o.n..: over night 
Fv: Variable fragment 
scFv: single chain variable fragment 
mAb: monoclonal antibody 
CLL: chronic lymphocytic leukaemia 
VLS: Vascular leak syndrome 
PE: Pseudomonas exotoxin A 
PE38: 38 kDa fragment of Pseudomonas exotoxin A 
PE40: 40 kDa fragment of Pseudomonas exotoxin A 
IL-4: interleukin-4 
CP-IL4: circularly permuted interleukin-4 
EF-2: Elongation factor-2 
DT: diphtheria toxin 
RIP: ribosome inactivating protein 
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 Fig. 1.1: Schematic diagram of 
the strategy applied for 
recombinant protein production. 
1.1 PRODUCTION OF RECOMBINANT PROTEINS: HISTORICAL 
 OUTLINE 
Recombinant DNA is a form of DNA that does not exist naturally, in which a 
DNA fragment, such a gene, is introduced into an existing DNA, such as a 
bacteria plasmid [Jeremy M., et al., 2007]. A recombinant protein is a protein that 
is derived from recombinant DNA.  
The recombinant DNA technique was first proposed by Peter Lobban, and 
then realized by Cohen and others [Cohen SN., et al., 1973]. This technique 
foreseed the gene isolation and amplification and gene insertion into  bacteria. 
Recombinant DNA technology was made possible by the discovery, isolation and 
application of restriction endonucleases by Werner Arber, Daniel Nathans, and 
Hamilton Smith, for which they received the 1978 Nobel Prize in Medicine.  
 
1.1.2 General strategy of gene cloning and 
recombinant protein production 
The procedure to express the recombinant 
proteins foresee three steps: 
1) Identification of interest gene: the gene 
coding for the protein object of study can come 
from genomic DNA or from a preexistent 
plasmid construct. Through a polymerase chain 
reaction (PCR) the gene is amplified and the 
restiction endonuclase sites are inserted into the 
sequence.  
2) Identification of the appropriate 
expression system: the gene is inserted into the 
expression plasmid and the new construct is 
transfected into the host cells. 
3) Production of the recombinant  
4) protein: the protein expression can be 
constitutive or induced. The recombinant protein 
is then purified and used in appropriate tests. 
 14
1.2 IDENTIFICATION OF INTEREST GENE: THE IMMUNOTOXIN 
 Cancer remains the second most common cause of death in our society, 
and advanced disease is often refractory to surgical, chemotherapeutic, and 
radiologic interventions. Conventional therapies are often ineffective in 
eradicating the neoplastic disease, particularly in case of relapse. New biologic 
therapies may complement established therapeutic strategies. 
 
1.2.1 DEFINITION OF IMMUNOTOXINS 
 The concept of Immunotoxins can be derived from the work of  Paul 
Erlich in 1906. The Immunotoxins are protein toxins connected to a cell binding 
ligand of immunologic interest (Fig. 1.2). Classically Immunotoxins were created 
by chemically conjugating an antibody to a whole protein toxin, or, for more 
selective activity, by using a protein toxin devoid of its natural binding domain 
[Moolten FL, et al., 1970; Krolick KA, et al., 1980]. Proteins smaller than 
monoclonal antibodies (mAbs), like growth factors and cytokines, have also been 
chemically conjugated and genetically fused to protein toxins [Cawley DB, et al., 
1980].  
BINDING DOMAIN
Antibody –derived
molecules
Growth factors
Cytokines
Bacterial toxins
TOXIC DOMAIN
Plant toxins
(RIPs)
Other ligands
or enzymes
(RNase)
Binding
domain
Toxic
domain
 
Fig. 1.2: Schematic diagram showing the Immunotoxin organization. 
 
1.2.1.1 Immunotoxins compared with other surface-targeted therapies 
 One type of surface-targeted biologic therapy is represented by the use of 
“naked” monoclonal antibodies (mAb) (i.e. mAb used as such without any other 
therapeutic compound). Examples include rituximab [Akhtar S, et al., 2002]  and 
alemtuzumab [Keating MJ, et al., 2002], which kill cells after binding. 
Humanized mAbs are clinically effective in up to half of the patients via 
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mechanisms of apoptosis induction, antibody-dependent cytotoxicity, and 
complement-dependent cytotoxicity.  
 Patients with malignant cells resistant to apoptosis, and patients whose 
immune system will not perform antibody- or complement- dependent 
cytotoxicity, may be resistant. To kill cells directly without relying on these 
mechanisms, a second type of surface-targeted therapy is used, one in which 
mAbs are conjugated to radionuclides. These agents induce responses in patients 
who are resistant to unlabeled mAbs [Cheson B, et al.,  2002]. However, 
radioimmunotherapy is limited by the potency of the radionuclide and the small 
number of radionuclide molecules that can be added to each mAb molecule.  
 A third type of surface-targeted therapy involves conjugating 
chemotherapy molecules to mAbs, which in many cases are more potent and 
cause less non-specific damage than radionuclides. Examples include 
gemtuzumab ozogamicin, a conjugate of an anti-CD33 mAb and calicheamicin 
[Nabhan C, et al., 2002], which is approved for the treatment of acute 
myelogenous leukaemia (AML), and the anti-CD30-monomethyl auristatin E 
conjugate (cAC10-vcMMAE), under development for Hodgkin’s disease (HD) 
and non-Hodgkin’s lymphoma (NHL) [Francisco JA, et al., 2003]. In the case of 
gemtuzumab ozogamicin, cells that are multi-drug resistant are, as would be 
expected, resistant to the target chemotherapeutic [Naito K, et al., 2000]. 
Currently under development is a fourth type of surface-targeted therapy, which 
employs ribonucleases conjugated to mAbs [Hursey M, et al., 2002]. 
 Immunotoxins which are distinct from these approaches, target the surface 
of cancer cells with considerable potency, using protein toxins capable of killing a 
cell with a single molecule [Yamaizumi M, et al., 1978; Eiklid K, et al., 1980]. 
Irrespective of the cell cycle or cellular division, Immunotoxins can inactivate 200 
ribosomes or elongation factor-2 (EF-2) molecules per minute. [Hall, W. A. and 
Fodstad, 1992; Hall, W. A. 1997]  These potent proteins include plant toxins and 
single-chain bacterial toxins.[Carroll SF, et al.,  1987].  
 
1.2.1.2 Production of Immunotoxins  
 Chemical conjugates of carrier portion and toxin generally involve either 
reducible disulfide (S-S) or non-reducible thioether (S-C) bonds [van Oosterhout 
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YV, et al.,  2001]. A thioether bond is appropriate if the ligand is conjugated to a 
toxin in the part that does not translocate to the cytosol, such as the binding 
domain [Pai LH, et al., 1996]. Otherwise, a disulfide bond is commonly used. 
 Derivatization of the toxin requires only reduction in the case of ricin toxin 
A-chain (RTA) and its mutants, and also in the case of PE35, since both contain 
only one cysteine each. Derivatization of the ligand requires care to produce 
sulphydryls without harming the molecule, unless the ligand also has a single 
cysteine. Once the ligand and toxin are derivatized, they must be conjugated and 
the correct toxin-ligand ratio must be purified. The difficulty and cost of these 
multiple steps have pushed development of recombinant toxins, which may be 
produced in Escherichia coli transformed with a plasmid encoding the 
recombinant toxin. A common method of producing material for clinical trials is 
harvesting recombinant protein from insoluble bacterial inclusion bodies 
[Kreitman RJ, et al.,  1996; Kreitman RJ, et al., 2000; Buchner J, et al., 1992]. 
The insoluble protein can be washed extensively with detergent to remove 
endotoxin, solublized, denatured, and reduced. The recombinant protein is then 
renatured and purified by a chromatography column proper at the protein features. 
Other published methods of producing  recombinant toxins from E. coli involve 
harvesting the protein from cytoplasm or cell lysate [Shao Y, et al., 2001] and 
then using an affinity column to capture the diluted protein. Eukaryotic expression 
systems normally fail with recombinant toxins since eukaryotic EF-2 is highly 
susceptible to the toxin. However, insect, plant and yeast cells can produce active 
toxin [Choo AB,  et al., 2002; Woo JH, et al., 2004] because during biosynthesis 
the toxin is driven in the secretory pathway and then accumulated in the culture 
medium.   
 
1.2.1.3 Immunotoxins and clinical trials 
 Hematologic malignancies are optimal for treating with Immunotoxins, 
since malignant cells are often intravascular and accessible to intravenously 
administered drug, and since patients often lack sufficient immunity to make 
antibodies against the toxin. That said, only a handful of antigens have been used 
to target Immunotoxins to hematologic malignancies in patients. These are 
summarized in table 1.1. 
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 Targeting solid tumors with Immunotoxins is much more difficult than 
targeting hematologic tumors. Not only are the cellular junctions tighter and the 
tumor cells more tightly packed, but the patients are less immunosuppressed and 
more likely to make neutralizing antibodies to the toxin. Below, recent published 
information regarding solid tumor Immunotoxin trials, along with recent 
preclinical development, is discussed. The findings are summarized in table 1.1. 
 
Table 1.1: Immunotoxins tested clinically in recent years. 
(modified from Pastan, I et al., 2007). 
Toxins include recombinant ricin A chain (rRA), blocked ricin (bR), deglycosylated ricin A chain 
(dgA), pokeweed antiviral protein (PAP), truncated diphtheria toxin (DT388 or DAB 389), 
truncated Pseudomonas exotoxin (PE38 or PE40), and mutated diphtheria toxin (CRM107). Non-
monoclonal antibody (mAb) ligands include interleukin-2, -4, and -13 (IL-2, IL-4, and IL-13); 
granulocyte-macrophage colony stimulating factor (GM-CSF); epidermal growth factor (EGF); 
transforming growth factor (TGFα); and transferring (Tf). PE404A is PE40 with alanine substituted 
for cysteine at positions 265, 287, 372, and 379. PE38QQR is PE38 with 2 glutamine residues and 
1 arginine replacing the 3 lysine residues of PE38 at positions 590, 606, and 613. Diseases include 
non-Hodgkin’s lymphoma (NHL, B- or T-cell), cutaneous T-cell lymphoma (CTCL), Hodgkin’s 
disease (HD), chronic lymphocytic leukemia (CLL), carcinoma in situ (CIS), acute myelogenous 
leukemia (AML), metastatic tumor involving the cerebrospinal fluid (CSF cancer), renal cell 
carcinoma (renal cell), small cell lung cancer (SCLC), Acute lymphoblastic leukemia (ALL) and 
hairy cell leukemia (HCL). 
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1.2.2 TOXIC DOMAIN 
 The toxins that have been used to construct Immunotoxins are natural 
products of plants, bacteria, and fungi that all inactivate protein synthesis through 
different mechanisms (Table 1.2) 
Toxins Mechanisma 
Plant  
Ricin Inactivates ribosomes 
Abrin Inactivates ribosomes 
Ricin A-chain Inactivates ribosomes 
 
 
Bacterial  
Diphtheria toxin Catalyzes transfer of ADP-ribose to EF-2 
Cross-reacting material 107 Catalyzes transfer of ADP-ribose to EF-2 
Pseudomonas aeruginosa exotoxin A Catalyzes transfer of ADP-ribose to EF-2 
Pseudomonas aeruginosa exotoxin  
fragments (PE38, PE40) 
Catalyzes transfer of ADP-ribose to EF-2 
  
Fungal  
α-sarcin Inactivates ribosomes 
a
 ADP: adenosine diphosphate; EF: elongation factor. 
Table 1.2: Immunotoxin mechanisms of action. 
(Modified from Hall W. A., Methods in Molecular Biology, vol. 166: 
Immunotoxin Methods and Protocols. Humana Press Inc. Totowa, NJ) 
 
1.2.2.1.Plant toxins 
 Plant holotoxins (also referred to as class II ribosome-inactivating proteins 
–RIPs II) include ricin, abrin, mistletoe lectin, and modeccin. Hemitoxins, or class 
I ribosome-inactivating proteins -RIPs I- , include PAP, saporin, bryodin 1, 
bouganin, and gelonin [Bolognesi A, et al., 2000]. As shown in figure 1.3, 
holotoxins contain both binding and catalytic domains, whereas hemitoxins 
contain only catalytic domains.  
RIP I RIP II
Signal
peptide Catalytic domain C-term linker Binding domainSignalpeptide Catalytic domain
Catalytic domain Binding domainCatalytic domainMature and  active
form
Translated
and inactive
form
S-S bound
 
Fig. 1.3: Schematic diagram showing the RIP I and RIP II organization. 
Holotoxins (RIP II) contain catalytic and binding domains disulfide-bonded together,  
while hemitoxins (RIP I) contain only catalityc domain.  
The toxin inactive precursor is translated in the endoplasmic reticulum of plant cells.  
 The loss of the signal peptide and the C-terminus makes the RIPs toxic. 
 19
1.2.2.1.1 Mechanism of action of plant toxins 
 The plant toxins have been shown to prevent the association of elongation 
factor-1 and -2 (EF-1 and EF-2) with the 60s ribosomal subunit by removing the  
A4324 in 28s rRNA [Endo Y, et al., 1987]. Apoptosis has been shown to be 
involved in cell death induced by plant toxins [Bolognesi A, et al., 1996; Hughes 
JN, et al., 1996; Bergamaschi G, et al., 1996]. Only the enzymatic domain of both 
holo- and hemitoxins translocates to the cytosol, so the binding domains of 
holotoxins must be removed by reduction of the disulfide bond prior to 
translocation. Exactly how plant toxins move from the cell surface to the cytosol 
is unknown; the process probably differs for each plant toxin.  
 The intracellular transport of ricin is dependent on sorting receptors that 
cycle between the endoplasmic reticulum (ER) and the terminal compartments of 
the Golgi [Wesche J,  et al.,  1999]. It has been shown that glycolipids that bind 
ricin may be transported from endosomes to the Golgi and that the Lysine-aspartic 
acid-glutamic acid-Leucine (KDEL) ER retention sequence, if added to ricin, 
enhances the delivery of this plant toxin to the cytosol [Tagge E, et al., 1997]. 
 
Fig. 1.4:  Mechanism of ricin internalization and intoxication. 
From www.ncbi.nlm.nih.gov/bookshelf/ 
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1.2.2.1.2 Attempts to construct fusion toxins using plant toxins 
 The cytotoxicity of both plant and bacterial toxins is optimal when the 
catalytic domain alone translocates to the cytosol [Mohanraj D, et al., 1995] . A 
binding domain can be translocated to the cytosol if placed within the catalytic 
domain, but cytotoxic activity is significantly reduced [Kreitman RJ., et al., 
1992].  
 In the ‘90s several recombinat toxins were constructed using portions of 
plant toxins such as the A-chain of ricin (RTA) [Cook JP, et al., 1993] or whole 
toxins such as PAP [Dore JM, et al., 1997] or SAP [Fabbrini MS, et al., 1997; 
Tetzke TA, et al., 1997]. For these molecules, it is not known whether (1) the 
recombinant toxin enters the cytosol of target cells intact, or (2) the ligand is 
unstable after internalization, permitting the catalytic domain alone to translocate 
to the cytosol. The ability of even stable ligands to predictably separate from the 
catalytic domain is an important feature of recombinant toxins [Kreitman RJ, 
1997] and a unique feature among all toxins provided by the bacterial toxins PE 
and DT. 
 
1.2.2.2 Bacterial Toxins 
1.2.2.2.1 Mechanism of Action of Bacterial Toxins 
 Both the Pseudomonas exotoxin A (PE) and the diphtheria toxin (DT) 
enzymatically ADP-ribosylate EF-2 in the cytosol [Carroll SF, et al.,  1987]. They 
each catalyze the ADP-ribosylation of histidine-699 of EF-2, which is post-
translationally modified to a diphthimide residue [Phan LD, et al., 1993]. Despite 
their similar action, PE and DT differ greatly in their amino acid sequence, and in 
fact PE’s enzymatic domain is near the carboxyl terminus, while DT’s is near the 
amino terminus. Conversely, PE’s binding domain is near its amino terminus, and 
DT’s is near its carboxyl terminus (Fig.1.5). 
 
Ia II IIIIbPseudomonas exotoxin A (PE)
A T BDiphtheria toxin (DT)
 
Fig. 1.5: Schematic structure of Pseudomonas exotoxin A (PE) and Diphtheria toxin (DT). 
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1.2.2.2.2 Mechanism of intoxication of PE 
 Full-length 613-amino-acid PE, as shown in figure 1.5, is a single-chain 
protein containing 3  functional domains [Hwang J, et al., 1987; Allured VS, et 
al., 1986].  Domain Ia (amino acids 1-252) is the binding domain, domain II 
(amino acids 253-364) is responsible for translocating the toxin to the cytosol, and 
domain III (amino acids 400-613) contains the ADP-ribosylating enzyme that 
inactivates EF-2 in the cytosol. The catalytic process of ADP-ribosylation has 
been shown to involve the His440 and Glu553 toxin residues [Li M, et al., 1996]. 
His440 binds nicotinamide adenine dinucleotide (NAD) via Adenosine 
monophosphate (AMP) ribose. The carboxyl group of the Glu553 side chain, 
through a water-mediated hydrogen bond with Tyr481 and Glu546, allows Tyr481 
to bind NAD through a ring-stacking mechanism. The function of domain Ib 
(amino acids 365-399) is unknown. Thus, a current model of how PE kills cells 
contains the following steps (Fig. 1.6) : 
(1) The C-terminal residue (Lys613) is removed by a carboxypeptidase in the 
plasma or culture medium [Hessler JL, et al.,  1997]. 
(2) Domain Ia binds to the a 2-macroglobulin receptor that is present on animal 
cells and is internalized via endosomes to the trans-reticular Golgi [Kounnas MZ., 
et al., 1992]. 
(3) After internalization, the protease furin cleaves domain II between amino acids 
279 and 280 [Chiron MF, et al., 1994]. 
(4) The disulfide bond between cysteines 265 and 287, which joins the 2 
fragments generated by proteolysis, is reduced [McKee ML, et al., 1999]. 
(5) Amino acids 609 to 612 Arginine - glutamic acid - aspartic acid - leucine 
(REDL) bind to an intracellular sorting receptor that transports the 37 kDa 
carboxy terminal fragment from the trans-reticular Golgi apparatus to the ER 
[Chaudhary VK, et al., 1995; Kreitman RJ, et al., 1995].  
(6) Amino acids 280 to 313 mediate translocation of the toxin to the cytosol 
[Theuer C, 1994; Theuer CP, et al., 1993].  
(7) The ADP-ribosylating enzyme within amino acids 400 to 602 inactivates EF-2 
[Carroll SF, et al., 1987].  
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(8) While inhibition of protein synthesis is sufficient to induce cell death 
eventually, recent experiments indicate that cell death from toxins is facilitated by 
apoptosis [Keppler-Hafkemeyer A, et al., 2000; Brinkmann U, et al., 1995]. 
 
1.2.2.2.3 Mechanism of intoxication of DT 
 DT is a single-chain protein 535 amino acids in length. It is composed of 
an enzymatic A domain (amino acids 1-193) and a binding B domain (amino 
acids 482-535) [Rolf JM, et al., 1990]. A third domain, which is the translocation 
or transmembrane (T) domain, is located in the center of the molecule [Choe S, et 
al., 1992] (Fig. 1.5). Based on DT’s 3-dimensional structure in the presence and 
absence of NAD [Bell CE , et al.,  1996], DT is thought to undergo these steps to 
kill cells (Fig. 1.6):  
(1) DT is proteolytically cleaved outside the cell between Arg193 and Ser194 
[Williams DP, et al.,  1990], which is within a disulfide loop formed by Cys186 
and Cys201.  
(2) DT binds on the cell surface via residues 482 to 535 to a complex of heparin-
binding Epidermal growth factor (EGF)-like growth factor precursor and CD9 
[Rolf JM, et al., 1990].  
(3) DT internalizes into an endosome and unfolds at low pH [D’Silva PR, et al., 
1998], and the disulfide bond linking amino acids 186 and 201 is reduced.  
(4) The TH8 (amino acids 326-347) and TH9 (amino acids 358-376) domains 
form a hairpin, which inserts into the membrane of the endosome and forms a 
channel through which the enzymatic fragment translocates to the cytosol [Kaul P, 
et al., 1996], probably from early endosomes [Lemichez E, et al.,  1997]. 
(5) In the cytosol, NAD binds to the active-site cleft of DT (amino acids 34-52), 
and the ADP ribose of NAD is transferred to EF-2 [Wilson BA, et al.,  1994; 
Bennett MJ, et al.,  1987]. 
(6) As with PE, cell death is facilitated by apoptosis [Brinkmann U, et al., 1995].  
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Fig. 1.6: Mechanism of intoxication of DT and PE 
 
1.2.2.2.4 Mutated bacterial toxins for fusing to ligands 
 The structures of mutated and truncated forms of DT and PE are shown in 
figure 1.7. To improve specificity, toxins for labeling mAbs are mutated to 
prevent their binding to normal cells. DT is mutated by converting Leu390 and 
Ser525 each to phenylalanine, resulting in CRM107 [Greenfield L, et al., 1987]. 
Truncated forms of PE and DT include PE40, containing amino acids 253 to 613 
of PE, and Diptheria toxin A and B domains (DAB 486), containing the first 485 
amino acids of DT [Hwang J, et al., 1987; Kondo T, et al., 1988; Williams DP, et 
al., 1987]. Shorter versions more recently used include PE38, composed of amino 
acids 253 to 364 and 381 to 613 of PE, and DT388 or DAB 389, containing the 
first 388 amino acids of DT [Siegall CB, et al., 1989; Kreitman RJ, et al., 1993; 
Williams DP, et al., 1990; Chaudhary VK, et al., 1991]. To allow the ADP-
ribosylating domain to translocate to the cytosol without the ligand, the ligand is 
placed at the amino terminus of PE and at the carboxyl terminus of DT. Another 
form of PE has an altered carboxyl terminus from the Arginine-glutamic acid-
aspartic acid-leucine-lysine (REDLK) to the KDEL sequence, which binds with 
higher affinity to the KDEL receptor and results in increased cytotoxicity 
[Kreitman RJ, et al., 1995]. Immunotoxins containing mutants of PE ending in 
KDEL (ie, PE38KDEL or PE40KDEL) are more cytotoxic than comparable 
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Immunotoxins where the PE mutant ends in the native sequence REDLK 
[Kreitman RJ, et al., 1995; Kreitman RJ, et al., 1993; Seetharam S, et al., 1991]. 
The translocated fragment of PE38 is 35 kDa in length beginning with Gly280, 
and since methionine in this position does not alter activity, the new mutant PE35 
is produced; it begins with a methionine at position 280 and contains amino acids 
281 to 364 and 381 to 613 [Theuer CP, 1993]. This molecule would not be 
appropriate for fusing to ligands, but since it contains a single disulfide bond, it is 
ideal for chemically conjugating to ligands. 
Ia II IIIIbPseudomonas
exotoxin A (PE)
Ia II IIIIbPE4E
Lys57 His246
Arg247
His249
Glu57 Glu246Glu247Glu249
II IIIIbPE40
II IIIPE38
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DAB 389 (DT388)
A T B
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Fig. 1.7: Schematic structure of mutated bacterial toxins for fusing to ligands 
 
1.2.3 THE BINDING DOMAIN 
 In the design of an Immunotoxin a variety of binding domains can be used 
to selectively deliver the drug to the intended cell target; besides monoclonal 
antibodies and fragments thence derived, other small proteins are appropriate to 
fulfil this function, e.g. growth factors and cytokines. Such molecules impart 
specificity to the Immunotoxin by virtue of the overexpression of antigen tumor 
associated on the plasma membrane and some receptors for growth factors, 
cytokines on tumor cells [Kreitman, R. J. 2006].  
 
1.2.3.1 Antibodies and its fragments 
 Antibodies are oligomeric proteins belonging to the immunoglobulin (Ig) 
superfamily and represent the characterizing element of the humoral adaptive 
immune system.  
 The basic structure of an antibody comprises four polipeptidic chains: two 
identical light chains of approximately 25 kDa in size and two identical heavy 
chains of 50 kDa. Disulphides and weak molecular interactions link two heavy 
chain – light chain heterodimers yielding the basic structure of a four-chain 
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Fig. 1.8: Diagram of the antibody 
structure. 
[Modified from Goldsby, R. A. et al., 2003]. 
antibody of 150 kDa. The variable domains of the light (VL) and heavy (VH) 
chains together form the antigen binding site; the constant regions of the two 
heavy chains constitute the so-called Fragment Crystallizable (Fc) portion which 
is responsible for the effector functions of the antibody, and it also contributes to 
the in vivo structural stability of the antiboig (Fig. 1.8) [“Kuby Immunology 5th 
edition”, Goldsby, R. A. et al., ed. Goldsby, R. A., 2003]. 
 Initially antibodies were 
purified from the serum of animals 
priorly immunized with an antigen 
yielding a polyclonal pool of reactive 
immunoglobulins. Despite their high 
binding affinity, polyclonal antibodies 
are unsuitable for therapeutic use, due 
to their heterogeneous composition. 
The production of monoclonal 
antibodies (mAbs) was made possible 
by the introduction of the hybridoma technology, a historical breakthrough for 
immunology and the emerging field of immunotherapeutics. The direct clinical 
employment of murine mAbs is hindered by the short half-life in the bloodstream 
and by the strong immunogenicity triggered in humans. The inevitable immune 
response of the patient to the mouse protein (also referred to as HAMA, “Human 
Anti-Mouse Antibody”) leads to a rapid clearance of the mAb and is often 
accompanied by hypersensitivity reactions [Schrama, D. et al., 2006].  
 The drawbacks of murine mAbs have been overcome with the introduction 
of chimeric or humanized mAbs (Fig. 1.9). Chimerization involves the linking of 
the variable domains from a murine mAb to the constant portions of a human 
immunoglobulin. The advances of molecular biology have allowed the 
construction of hybrid genes that code for antibody molecules in which variable 
(V) and constant (C) regions are of murine and human origin, respectively [Carter, 
P. J., 2006]. To obtain humanized antibodies the sequences coding for the sole 
murine CDRs are “grafted” onto a human IgG [Carter, P. J., 2006].  
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Fig. 1.9: Schematic diagram of fully murine, 
chimeric, humanized and fully human antibodies. 
 
 A growing number of antibodies now in clinical trials are fully human, as 
they are generated either 
from IgG-knockout 
transgenic mice bearing the 
genes for human 
immunoglobulins or from the 
employment of new 
technologies like phage-
display [Lonberg, N., 2005; 
Konthur, Z., 2005]. 
Alternative strategies for 
generating human mAbs are for instance the obtainment of hybridomas from 
patient’s lymphocytes, the cloning of an immunoglobulin cDNA from a single 
lymphocyte or other methods like ribosome-, mRNA-, or yeast- display [Carter, P. 
J., 2006]. 
 The employment of whole immunoglobulins as carrier molecules to 
deliver a toxin to cancerous cells may imply a certain degree of non selective 
activity for an IT, owing to non-specific binding of the antibody Fc portion. 
Furthermore, the big size of these molecules can hinder their penetration in tumor 
tissue, especially in the case of solid tumors. As a consequence antibody 
fragments were developed. They are smaller molecules that still maintain an 
unaltered binding capability and specificity to the antigen [Plückthun, A., 1992]. 
In figure 1.10 several examples of different types of antibody fragments were 
reported [Plückthun, A., 1992; Holliger, P. and Hudson, P. J., 2005].  
 
Fig. 1.10: Schematic representation of different possible antibody configurations. The 
domain-based structure of immunoglobulins could be manipulated to yield a wide repertoire of 
antibody formats ranging from 15 kDa to 100 kDa insize. [Modified from Carter, P. J., 2006]. 
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1.2.3.2 Cytokines and growth factors 
 Other ligands utilized for building Immunotoxins are the cytokines and the 
growth factors; although these bind also to normal cells, yours receptors are 
overexpressed in several hematological and solid tumour cells. Cytokines and 
growth factors are effective targeting agents because their affinity for their cell 
surface receptors can be higher than that of monoclonal antibodies. Moreover the 
receptors of these molecules are able to internalise yours ligand, and than also the 
respective cytokine/growth factors-based Immunotoxin with great efficiency by 
receptor-mediated endocytosis [Kelley, V. E., et al., 1988]. Furthermore, being of 
human origin they are non immunogenic. 
 Possible drawbacks of using  cytokines and growth factors as carrier 
molecules is their rapid clearance in vivo and the agonistic effects often exerted by 
these molecules linked to the toxic moiety, witch could promote proliferation of 
the targeted cells when the amount of Immunotoxins bound are insufficient to kill 
the target cell [Fracasso, G., et al., 2004]. A further disadvantage is the presence 
of circulating ligands or soluble receptors that compete for the IT [Fracasso, G., et 
al., 2004]. The cytokines/growth factors that were used as targeting agents are IL-
2, IL-4 and IL-6 [Chadwick, D. E., et al., 1993; Ogata, M., et al., 1989;Walz, G., 
et al, 1989], TNF [Gould, D. J., et al., 1998; Hoogenboom, H. R., et al., 1991], 
epidermal growth factors (EGF) [Chandler, L. A., et al., 1998;Di Massimo, A. M., 
et al., 1997; Hirota, N., et al., 1989; Matsui, H., et al., 1989; Ozawa, S., et al., 
1989; Banker, D. E., et al., 1989; Volmar, A. M., et al., 1987], fibroblast growth 
factor (FGF) [Davol, P., et al., 1995; Dazert, S., et al., 1998; Lappi, D.A., et al., 
1995; Lin, P.H., et al., 1998], granulocyte-macrophage colonise stimulating factor 
(GM-CSF) [Lappi D. A., et al., 1993; Burbage, C., et al., 1997], transferrin (Tfn) 
[Shannon, K. M., et al., 1990; Candiani C., et al., 1992; Chignola, R., Anselmi, 
C., et al., 1995; Chignola, R., Foroni, R., et al.,  1995; Colombatti, M., et al., 
1990; Nicholls, P. J., et al., 1993] and nerve growth factor (NGF) [Benedetti, G., 
et al., 1994; Book, A. A., et al., 1992; Rossner, S., et al., 1994; Wiley, R. G., et 
al., 1995]. 
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Fig. 1.11: Schematic model of IL4R subunits. 
Modified from Kawakami M, et al., 2003. 
1.2.3.2.1 IL4  
 Interleukin-4 (IL-4) is a pleiotropic Th2-derived immune cytokine, which 
is predominantly produced by activated T lymphocytes, mast cells, and basophils 
[Paul WE, 1991; Puri RK, et al., 1993; Puri RK, 1995]. IL-4 has been shown to 
have various activities in many different cell types, such as T cells, B cells, 
monocytes, endothelial cells, and fibroblasts [Paul WE, 1991; Puri RK, et al., 
1993; Puri RK, 1995]. To induce biological activities, IL-4 must bind to its 
specific receptor, which is generally present on the plasma membrane of target 
cells. IL-4 by itself has been shown to have modest antiproliferative activity on 
hematopoietic malignant cell lines and solid tumor cell lines in vitro and in vivo 
[Toi M , et al., 1992; Topp MS, et al., 1993].  
 
1.2.3.2.1.1 IL4-Receptor (IL4R) 
 IL-4 receptors are overexpressed on a variety of hematologic and solid 
malignant tumor cell lines including malignant melanoma, breast carcinoma, 
pancreatic tumour, ovarian carcinoma,  esothelioma, glioblastoma, renal cell 
carcinoma, head and neck carcinoma, and AIDS-associated Kaposi’s sarcoma 
[Puri, R. K.,et al., 1993; Puri, R. K.,et al., 1995; Puri, R. K., et al., 1991; Obiri, N., 
et al., 1993; Obiri, N., et al., 1994; Hussain, S. R.,  et al., 1994; Hoon, S. R., at al., 
1997; Toi, M., et al., 1992; Morisaki, T., et al., 1992; Puri, R. K.,1996; Kreitman, 
R. J., et al., 1994; Kawakami, K., et al., 2000; Puri, R. K., et al. 1996; Leland, P., 
et al., 2000; Gallizi, J. P., et al., 1989]. Normal cells including hematopoietic cells 
(e.g. resting T cells, B cells, and monocytes), fibroblasts, and endothelial cells 
also expressed IL-4R [Paul WE, 1991; Puri RK, et al., 1993; Puri RK, 1995; Puri 
RK, et al., 1994; Puri RK, 
et al., 1996]; however, 
receptor numbers were 
significantly lower 
compared to most tumor 
cell lines.  
 Several studies 
suggested that the immune 
cells express type I IL-4R 
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(IL-4Rα and IL-2Rγ chains) [Russell SM, et al., 1993; Kondo M, et al., 1993; 
Murata T, et al., 1995], and tumor cells express type II IL-4R (IL-4Rα and IL-
13Rα1 chains) [Kawakami K, et al.,  2000; Murata T, et al., 1995; Obiri NI, et al., 
1995; Obiri NI, et al., 1994]. Some cells instead express all three (IL-4Rα, IL-
2Rγ, and IL-13Rα1) chains (type III IL-4R), however, whether all three chains 
form an IL-4R complex in immune or tumor cells is not clearly known as yet (Fig. 
1.11). 
 Although the significance of overexpression of IL-4R on solid tumor cell 
lines is still not known, the advantage of overexpression of these receptors has 
taken by designing a receptor targeted cytotoxic agent for possible cancer therapy. 
A recombinant fusion proteins comprised of IL-4 and Pseudomonas exotoxin has 
produced for possible treatment of recurrent human glioma. [Puri RK, et al., 
1994].  
 
1.2.4 RECOMBINANT FUSION PROTEIN BETWEEN INTERLEUKIN-4 
 AND Pseudomonas EXOTOXIN (IL4-PE) 
 In 1989, Ogata Masato and colleagues first cloned a recombinant 
Immunotoxin in witch the cell binding domain of PE was replaced by murine IL-4 
(IL4-PE40) [Ogata M., et al., 1989]. The fusion gene product, was found to be 
highly toxic to a murine T-cell line (CT.4R) but to have no effect on human cell 
lines lacking receptors for murine IL-4. In addition, a chimeric protein composed 
of a mutant form of PE40 that had very low ADP-ribosylating activity (PE40 
asp553) had displayed mitogenic activity similar to that of IL-4 rather than 
cytotoxic activity, showing that ADP-ribosylating activity was essential for 
cytotoxicity. Moreover an excess amount of IL4 or a neutralizing monoclonal 
antibody to IL-4 blocked the cytotoxicity of IL4-PE40 [Ogata M., et al., 1989]. 
 In 1991, Puri Raj K. and co-workers demonstrated the presence of IL4 
receptor on murine solid tumors of nonlymphoid origin and the IL4-PE40 ability 
to inhibit the protein synthesis in these cells. The specificity of action was 
demonstrated through the IL4 receptor blocking [Puri, R.K., et al., 1991]. 
 Because murine IL4 does not bind to the human IL-4R [Morrison, B., et 
al., 1992], it was not possible to evaluate the activity of these chimeric toxins on 
human cells. In 1993, Debrinski Waldemar and co-workers constructed the 
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chimeric toxin with the human IL-4 fuses to a gene coding a mutant form of PE in 
which 4 amino acid residues (Lys57, His246, Arg247 and His249), all in domain Ia of 
PE, are changed to glutamates (PE4E). This mutation abolishes the binding of PE 
to its receptor [Chaudhary VK, et al., 1990]. Use of different type of IL4R+ target 
cells (i.e. carcinomas of the lung, kidney, ovary, breast, colon [Obiri, N. I., et al, 
1993; Puri RK, et al., 1993; Tungekar, M. F., et al., 1991], malignant stomach, 
liver, prostate, adrenal, and cervix as well as melanoma and epidermoid 
carcinoma [Debinski W, et al., 1993]) has demonstrated that IL4-PE4E 
cytotoxicity is mediated by the presence of the IL4R. Other works documented 
the ability of hIL4 to eradicate tumors in immunocompetent animals [Golumhek, 
P. T., et al., 1992; Tepper, R. I., et al., 1989].  
 IL4 has been originally identified as a B cell growth factor and it has been 
shown to affect a variety of hematopoietic cells, such as T lymphocytes [Yokota, 
T., et al.,  1986]. The activation of peripheral blood lymphocytes increases the 
number of hIL4R on blood cells. hIL4-PE4E was very cytotoxic to PHA-activated 
peripheral blood lymphocytes, indicating the possibility of the use of this chimeric 
toxin for intervention in some specific immune responses. Furthermore, hIL4-
PE4E may diminish antibody responses against itself by targeting cells 
participating in the immune response [Debinski W, et al., 1993].  
 The Immunotoxin design proceeded with the carrier affinity and 
specificity optimization and the development of cytotoxic activity of toxin. Often 
fusion of one protein to another impairs the activity of one or both proteins. This 
can occur if one or both proteins require one or both termini free for optimal 
activity. Alternatively, connection of one protein to another can impair the ability 
of either protein to properly fold. It has been reported that transforming growth 
factor α, IL2, IL3, IL4, IL6, GM-CSF, and insulin-like growth factor I all bind 
with 20- to 250-fold reduced affinity after fusion to another protein [Curtis, B. M, 
et al., 1991; Edwards, G. M., et al., 1989; Debinski W., et al., 1993; Williams DP 
, et al., 1990; Prior, T. I., et al., 1991]. At the beginning, the options available for 
improving the function of a fusion protein were limited to switching the order of 
the two proteins, attaching linkers in between the two proteins, or mutating one of 
the proteins to decrease junctional effects [Edwards, G. M., et al., 1989; 
Brinkmann, U, et al., 1992]. When the hIL4 is fused with the fragment or whole 
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PE, the chimeric proteins bind to the IL4R with only ~ l% of the affinity of native 
IL4 [Debinski W., et al., 1993;]. Several studies have indicated that the carboxyl 
terminus of IL4 is important for binding [Le, H. V , 1991; Ramanathan, L , 1993]; 
therefore, it is likely that the large toxin molecule attached to the carboxyl 
terminus blocks the binding of IL4 to the IL4R. A new strategy for fusing the two 
proteins is developed, in which the toxin is fused to the new carboxyl terminus of 
circularly permuted forms of IL4. A circular permuted protein is a mutant protein 
in which the termini have been fused and new termini created elsewhere in the 
molecule. Several circularly permuted proteins have been made but none of these 
have been fused to other proteins [Pan, T. & Uhlenbeck, O. C.,1993].  
 The strategy for construction of the DNA encoding CP-IL4 was to amplify 
the first and second parts of IL4 sequence, so that the 5' end of the first fragment 
and the 3' end of the second fragment are identical and encode the GGNGG 
linker. The two fragments therefore anneal in reverse order to form a template for 
the final PCR step with the final PCR product CP-IL4. With this strategy two 
differets CP-IL4 were constructed: IL4(38-37) and IL4(105-104). [Kreitman RJ, 
et al., 1994] (Fig. 1.12). 
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Fig. 1.12: Construction of circularly permuted forms of IL4 (CP-IL4)  
 The circularly permuted IL4 (CP-IL4) was fused to a PE so that the 
junction would be in an entirely new location and allow the IL4 to bind in a more 
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native fashion [Kreitman RJ, et al., 1994]. The CP-IL4-PE38 study showed that 
IL4(37-38)-toxin bound the IL4R positive cells better than IL4(105-104)-toxin. 
Moreover the toxin fused to the new carboxyl terminus (amino acid 37) of CP-IL4 
improved binding about 10-fold over a molecule in which the toxin was fused to 
the native carboxyl terminus (amino acid 129) of IL4. The new junction site 
decreased the impairment in IL4R-binding. [Kreitman RJ, et al., 1994]. 
 
1.2.4.1 Clinical trials of IL4-PE recombinant Immunotoxin 
 The first attempts to use the CP-IL4-PE38 in clinical trials are described in 
1993 by Theuer C.P. and Pastan I. [Theuer C.P., et al., 1993]. With the first 
chemical Immunotoxin produced clinical results were disappointing. But the 
recombinant Immunotoxins circumvented problems such as immunogenicity that 
may limit the clinical usefulness.  
 Afterwards, in 2000, Rand R.N. described the intratumoral administration 
of CP-IL4-PE38 Immunotoxin in patient with high-grade glioma based on the 
consideration that human glioblastoma cells but not normal brain cells express 
numerous receptors for IL4 [Rand R.N., et al., 2000]. 
 Several studies were conducted in the phase I/II clinical trials to CP-IL4-
PE38 as treatment against glioblastoma tumor, testing the maximal tolerated 
concentration, the better volume administrated [Rand R.N., et al., 2000], the 
administration way (intratumoral or intravenously) [Garland L., et al., 2005],  the 
infusate viscosity to increase the volume of distribution [Mardor Y, et al., 2009]. 
These studies showed the efficacy of Immunotoxin to reducing or remitting the 
glioma solid cancer [Kawakami, K, et al., 2001; Kawakami M., et al., 2002; 
Weber F.W, et al., 2003; Kawakami M., et al., 2003; Garland L., et al., 2005; 
Shimamura T., et al., 2006, Rainov N.G., et al., 2006; Mardor Y, et al., 2009; Puri 
S., et al., 2009]. 
 In 2009, Oh S. described the possibility to use a bispecific targeted toxin 
simultaneously recognizing human epidermal growth factor and interleukin-4 
receptors to treat the metastatic breast carcinoma in a mouse model. [Oh S., et al., 
2009]. This bispecific molecule was also mutagenized to reduced the toxin 
immunogenicity. The bispecific ligand-directed toxin (BLT) was created cloning 
both human epidermal growth factor (EGF) and interleukin-4 cytokines onto the 
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same single-chain molecule with truncated Pseudomonas exotoxin (PE(38)). Site-
specific mutagenesis was used to mutate amino acids in seven key epitopic toxin 
regions that dictate B-cell generation of neutralizing antitoxin antibodies. The 
BLT Immunotoxin was significantly effective against established systemic human 
breast cancer and prevented metastatic spread. Moreover the mutagenesis reduced 
immunogenicity by approximately 90% with no apparent loss in in vitro or in vivo 
activity [Oh S., et al., 2009]. 
 
1.2.5 PROBLEMS AND OPPORTUNITIES IN IMMUNOTOXIN 
 DEVELOPMENT 
 The problems, including immunogenicity, unwanted toxicity, difficulty in 
production, limited half-life, and resistance, will be considered below, along with 
potential opportunities for improved development of Immunotoxins. 
 
1.2.5.1 Immunogenicity 
 Based on a wide range of clinical trials, the incidence of immunogenicity 
after a single cycle of Immunotoxin ranges from 50% to 100% for solid tumors, 
and from 0% to 40% for hematologic tumors [Olsen E, et al., 2001]. The immune 
response against the Immunotoxins leads to the appearance of measurable of 
neutralizing anti-IT antibodies. These antibodies lower the levels of biologically 
active Immunotoxin and compromises efficacy. Several approaches can be used to 
prevent immunogenicity. The method most useful is PEGylation, which not only 
blocks immunogenicity but also prolongs half-life [Onda M, et al., 2003; 
Tsutsumi Y, et al.,  2000]. Immunologic studies have found a large number of B-
cell and T-cell epitopes on Pseudomonas exotoxin [Roscoe DM, et al., 1997; 
Roscoe DM, et al., 1994; Nagata S, et al., 2004]. The mutagenesis of 7 amino acid 
contained in 7 key epitopic toxin regions that dictate B-cell generation of 
neutralizing antitoxin antibodies reduced immunogenicity by approximately 90% 
with no apparent loss in in vitro or in vivo activity [Oh S., et al., 2009]. 
 
1.2.5.2 Unwanted Toxicity 
 A variety of toxicities have been observed with Immunotoxins that have 
limited the dose and hence the efficacy. The most common toxicity is the vascular 
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leak syndrome (VLS) that is characterized by an increase in vascular permeability 
resulting in tissue edema and, ultimately, multiple organ failure [Baluna R. and 
Vitetta E.S., 1997]. 
 Studies have shown that RTA binds directly to endothelial cells, while 
truncated PE requires a ligand that cross-reacts with the endothelium [Kuan C, et 
al.,  1995]. Such studies led to a mutant form of RTA that shows less VLS in an 
animal model [Kreitman RJ, et al., 1993].  
 Hepatotoxicity, a typical side effect of recombinant Immunotoxins, is 
attributed to the binding of basic residues on the Fv to negatively charged hepatic 
cells [Schnell R, et al., 1998, Onda M, et al., 2001]. Renal toxicity due to 
Immunotoxins is less well defined and could be non-specific at least in part 
because the kidneys are the dominant route of excretion of recombinant 
Immunotoxin [Huston JS, et al.,  1988]. 
 
1.2.5.3 Difficulty in Production 
 Originally, chemical conjugates were made for clinical trials since 
manufacturers of recombinant toxins faced problems of endotoxin contamination 
and low yield. Advances in the production of other recombinant proteins for 
clinical use have solved many of these problems and have allowed large-scale 
production of recombinant toxins in prokaryotic system with high purity and 
reasonable cost. The optimization of an eukaryotic system to Immunotoxin 
expression could exceed the endotoxin contamination problem with reduction of 
production time maintaining low the production costs. 
 
1.2.5.4 Potential for Future Development 
 For many types of disease, Immunotoxins are unlikely to work by 
themselves. Their half-lives may be too limited for diffusion to occur into solid 
tumor masses. It is possible that combination with other therapeutic agents having 
non-overlapping toxicities will result in better responses. Similarly, treatment of 
microscopic disease may be useful after cytoreduction by surgery, chemotherapy, 
or radiotherapy.  
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1.3 IDENTIFICATION OF THE APPROPRIATE EXPRESSION SYSTEM 
 
1.3.1 PROKARIOTIC EXPRESSION SYSTEM 
 The recombinant expression of genes is of great interest for both 
biotechnology and basic research in the context of protein function and structure. 
The prokaryotic expression system was the first employed to recombinant protein 
production [Service R. F., 2002; Christendat, D et al., 2000]. 
 The most commonly used expression system is Escherichia coli. Protein 
production in bacteria offers several advantages over other hosts such as short 
doubling times, well-established methods for genetic manipulation, and simple, 
inexpensive cultivation. However, the overexpressed proteins often accumulate in 
insoluble and inactive deposits called inclusion bodies [Marston, F. A., 1986; 
King, J, et al., 1996]. It has been shown that proteins tend to aggregate with 
increasing concentration, whereas low protein concentrations favour the formation 
of the correctly folded protein [Zettlmeissl, G, et al., 1979]. Thus, a decrease in 
protein synthesis rate will lead to an increase in the yield of functional protein. 
This was confirmed experimentally by recombinant protein expression under 
suboptimal conditions, i.e., the reduction of the cultivation temperature from 37 to 
30°C in E. coli [Schein, C. H. and Noteborn, M. H. M., 1988]. However, inclusion 
bodies also offer some advantages, as the overexpressed protein is often highly 
enriched and protected from proteolytic degradation [Cheng, Y, et al., 1981].  
 
1.3.1.1 The key parameters for the E. coli proteins expression 
1.3.1.1.1 Expression level optimization 
 Sometimes the levels of protein expression in the bacterial system are low 
despite the use of strong transcriptional and translational signals. The following 
approaches can be used to optimize expression levels. 
 The variation of  induction conditions such as the time, the temperature of 
induction and the concentration of the inducer. 
 Examining the codon usage of the heterologous protein. Not all 61 mRNA 
codons are used equally. Each organism bears the major and the rare codons.  
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Codon Residue 
AGG Arginine 
AGA Arginine 
CGG Arginine 
CGA Arginine 
GGA Glycine 
AUA Isoleucine 
CUA Leucine 
CCC Proline 
Table 1.3: 
Favourable codon for E. coli. 
Usually, the frequency of the codon usage reflects 
the abundance of their cognate tRNAs. Therefore, 
when the codon usage of your target protein differs 
significantly from the average codon usage of the 
expression host, this could cause problems during 
expression such as mRNA instability, the premature 
termination of transcription and/or translation, the 
frameshifts, deletions and misincorporations (e.g. 
lysine for arginine) or the inhibition of protein 
synthesis and cell growth. As a consequence, the  
expression levels is often low.  
The expressed levels can be improved by the replacing codons that are rarely 
found in highly expressed E. coli genes with more favourable codons throughout 
the whole gene (Table 1.3) 
 Moreover it is possible co-expressing the genes encoding for a number of 
the rare codon tRNAs. There are several commercial E. coli strains available that 
encode for a number of the rare codon genes. (Table 1.4) 
 
Strain Rare codon tRNA encoded  
BL21 (DE3) CodonPlus-RIL arginine (AGG, AGA), isoleucine 
(AUA) and leucine (CUA) 
BL21 (DE3) CodonPlus-RP arginine (AGG, AGA) and proline 
(CCC) 
Rosetta  AGG/AGA (arginine), CGG 
(arginine), AUA (isoleucine) 
Rosetta (DE3) CUA (leucine)CCC (proline), and 
GGA (glycine) 
Table 1.4: 
 E. coli strains that encode the rare codon tRNAs. 
 
 Examining the second codon. The most used by E. coli is AAA lysine 
(13.9%) while a number of other codons are not used at all [Looman et al., 1987]. 
 Minimizing the GC content at the 5'-end. A high GC content in the 5'-end 
of the gene of interest usually leads to the formation of secondary structure in the 
mRNA. This could result in interrupted translation and lower levels of expression. 
Thus, higher expression levels could be obtained by changing G and C residues at 
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the 5'-end of the coding sequence to A and T residues without changing the amino 
acids. 
 The addition of a a highly-expressed fusion partner often results in high 
level expression. 
 Using protease-deficient host strains (e.g. BL21) can sometimes enhance 
accumulation by reducing proteolytic degradation.  
 
1.3.1.1.2 Improving protein solubility 
 In many cases the expressed protein is accumulated in inclusion bodies. 
Several strategies are available to improve the solubility of the expressed protein. 
 Reducing the rate of protein synthesis or changing the growth medium. 
 Co-expression of chaperones and/or foldases. The best characterized E. 
coli systems are: GroES-GroEL, DnaK-DnaJ-GrpE , ClpB.  
 Periplasmic expression. Secretion of the target protein to the periplasm has 
a number of distinct advantages: 
- the oxidizing environment of the periplasm allows for the formation of 
disulfide bonds, which does not occur in the reducing environment of the 
cytoplasm;  
- the periplasm contains two foldases, disulfide oxidoreductase (DsbA) and 
disulfide isomerase (DsbC), that catalyze the formation and isomerization of 
disulfide bonds; 
- reduced proteolysis (since less proteins are present).  
- allows for the accumulation of proteins that are toxic in the cytoplasm.  
Secretion is achieved by the addition of a leader sequence (signal peptide) to the 
N-terminus of the target protein. Most used leader sequences are pelB and ompT. 
Unfortunately, expression yield are usually much lower and not all expressed 
protein is secreted into the periplasm but is also found in the medium, the 
cytoplasm and the cytoplasmic membrane. 
 Using specific host strains. Two strains are commercially available 
(Novagen): AD494, which has a mutation in thioredoxin reductase (trxB) and 
Origami, a double mutant in thioredoxin reductase (trxB) and glutathione 
reductase (gor). These strains have a more oxidizing cytoplasmic environment. 
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 The addition of a soluble fusion partner often improves the solubility of 
the recombinant protein. 
 
1.3.1.1.3  Expression of a protein toxic to the host strain 
 Low expression levels or no expression at all can also be caused by 
toxicity of the target protein. Many promoters are not very tightly regulated and 
show some degree of expression before the addition of the inducer. Different 
approaches can be used to give a more tightly regulated expression [Suter-
Crazzolara, C. and Unsicker, K., 1995]. 
 Constitutive expression of a protein repessing the inducible promote leaky.
 Use a more tightly regulated promoter.  
 Use a lower copy number plasmid.  
 Constitutive expression of phage T7 lysosyme from a compatible pLysS or 
pLysE plasmid. Lysozyme binds to T7 RNA polymerase and inactivates the 
enzyme. After the addition of IPTG the expression level of the polymerase will be 
much higher than that of lysosyme and this will overcome the repression.   
 Use of elevated levels of antibiotics. 
 Use the "plating" method for inoculating cultures. Cultures are inoculated 
by scraping off agar plates. A single colony of plasmid-containing cells is 
suspended in 200 µl water and vigorously shaken. This suspension is plated on a 
agar plate containing the appropriate antibiotic and incubated over night at 37°C. 
All colonies are scrapped-of and suspended in 400 ml of medium (OD600=0.4). 
The culture can be grown to the desired OD600 and induced to start expression 
[Suter-Crazzolara, C. and Unsicker, K., 1995]. 
 
 Some proteins are so toxic for the cells that they do not only inhibit growth 
but also kill them. Several approaches are possible to decrease the effects of 
protein toxicity through the periplasmic expression (the proteins that are toxic in 
the cytoplasm is secreted in the periplasm or in the medium culture) or the 
inclusion bodies accumulation (the proteins misfolded are not toxic in the 
cytoplasm).  
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1.3.1.2 Two approaches to optimize the protein expression in E. coli 
 To produce a recombinant protein the interest gene must be inserted into 
an expression plasmid. This plasmid must have an replication origin (ori), a gene 
for the antibiotic resistance, an promoter to induced the protein production, a 
multi cloning site to insert the recombinant gene; a periplasmic signal sequence 
and the tags for the purification can be present. 
 To speed up protein production, a strategy of parallel expression of a 
protein from a variety of vectors containing different tags and/or fusion partners, 
and a variety of E. coli host strains can be adopted. This approach should not only 
gain us a lot of time but also result in a larger number of successfully expressed 
proteins. 
1. The expression of a protein in a basic E. coli host strain from a variety 
vectors with different tags and/or fusion partners. Our first screen is to 
express a protein in a single host strain (e.g. BL21 (DE3)) from several 
vectors with different tags as fusion partners. 
2. The expression of a protein from a standard vector in a number of 
different E. coli host strains. The choice of the host strains depends more on 
the nature of the heterologous protein.  
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1.3.1 EUKARIOTIC EXPRESSION SYSTEMS 
 To overcome the prokaryotic system limits, as the absence of post-
traslational modifications or the ardous refolding protocols, the recombinant DNA 
technology was applied with different eukaryotic expression systems as the plant 
cell or transgenic plants systems, mammalian cell systems, insect cell systems and 
yeast cell systems. The first three systems will be treated briefly; our attention will 
be focused in the widening of the yeast expression system, the host cells chosen 
for the optimization of immunutoxin production in this work. 
 
1.3.1.1 PROTEINS PRODUCTION IN PLANT CELL SYSTEMS 
 The development of methods for the introduction of foreing genes into 
plants has led to a revolution in plant research and plant breeding. Nowadays large 
areas are in use for the cultivation of such crops, including genetically modified 
cotton, corn and soybean [Hooykaas P.J.J., 2001], flowers with novel colours or 
prolonged vase life [Suzuki S., et al., 2007; Yu YX., et al., 2004], potatoes with 
optimized starch composition [Zhang L., et al., 2008], rice grain with pro-vitamin 
A to prevent vitamin A-deficiency in the diet [Nestle M., 2001], and plants that 
can be used as edible vaccines [Gomez E., et al., 2009; Tacket CO, 2009; 
Mestecky J, et al., 2008]. Plant transformation relies on the totipotency of certain 
plant cells. In figure 1.13 several methods to create transgenic plants are shown. 
 
 
 After plant cells have been transformed, it is essential that the transformed 
cells can be recognized, isolated or specifically propagated through the bacterial 
antibiotic resistance genes converte into plant-expressed forms or through the 
Fig. 1.13: 
Transformation and 
regeneration of 
plants. Many plant 
organs, tissues or cell 
types can be used for 
transformation. The 
targets for plant 
transformation are: 1, 
chemical treatment; 2, 
electroporation; 3, 
whiskers; 4, particle 
bombardment; 5, 
Agrobacterium.   
[Modified by Crouzet 
P. and Hohn B., 2002; 
Hooykaas P.J.J., 2001] 
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genes that confer tolerance at the herbicides or thank at the visible markers as the 
β-glucuronidase (GUS) gene [Jefferson et al., 1987], the firefly luciferase genes 
[Ow et al., 1986] and the jelly fish green fluorescent protein (GFP) [Haseloff et 
al., 1997].  
 Plants are an attractive host for synthesis of many industrial and 
pharmaceutical proteins, offering significant advantages in safety and cost over 
alternative foreign protein expression systems [Twyman et al., 2003; Ma et al., 
2005; Streatfield, 2007]. The main advantages associated with plants include the 
low cost of agricultural biomass production, elimination of downstream 
processing requirements for vaccines expressed in edible plant tissues, post-
translational modification and production of correctly folded and assembled 
multimeric proteins, low risk of contamination with pathogens and endotoxins 
such as those occurring in mammalian and bacterial systems, and the avoidance of 
ethical problems associated with transgenic animals and animal materials.  
 Table 1.5 show an example of foreign protein produced in whole plants. 
 The products that are currently being produced in plants include bioactive 
peptides, vaccine antigens, antibodies, diagnostic proteins, nutritional 
supplements, enzymes and biodegradable plastics. The economic driver that is 
burgeoning this industry includes the ability to synthesize animal proteins, cost 
benefits, safety issues (lack of pathogen contamination) and easy scale up [Fischer 
et al., 2004; Lal et al., 2007; Rybicki, 2009; Sharma et al., 2004; Spok, 2007; 
Stoger et al., 2002; Twyman et al., 2003]. Apart from many advantages, there are 
some problems associated with plants for their use as bioreactors which include 
differences in glycosylation patterns in plants and humans, inefficient expression 
and environmental contamination. However the the transgenic plant-based 
products commercially available in the market and the products in phase II / I or 
pre-clinical trials were produced successfully (Tables 1.6 and 1.7) but none of 
these is an Immunotoxin. 
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Table 1.5:  Example of foreign proteins produced in whole plants using plant viral vectors. 
[Modified by Sharma A. K., Sharma M. K .,2009] 
 
Table 1.6: Transgenic plants-based products commercially available in the market 
[Modified by Sharma A. K., Sharma M. K .,2009] 
 
 
Table 1.7: List of the products in phase II, I or preclinical trials. 
[Modified by Sharma A. K., Sharma M. K .,2009] 
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1.3.1.2 PROTEINS PRODUCTION IN MAMMALIAN CELLS 
 Cultivated mammalian cells have become the dominant system for the 
production of recombinant proteins for clinical applications because of their 
capacity for proper protein folding, assembly and post-translational modification.  
 In 1986 human tissue plasminogen activator (tPA, Activase; Genentech, S. 
San Francisco, CA, USA) became the first therapeutic protein from recombinant 
mammalian cells to obtain market approval. The recombinant proteins are 
expressed in immortalized Chinese hamster ovary (CHO) cells, cell lines derived 
from mouse myeloma (NS0), baby hamster kidney (BHK), human embryo kidney 
(HEK-293) and human retinal cells. The development of a manufacturing process 
for a recombinant protein in mammalian cells usually follows a well-established 
scheme (Fig. 1.14).  
 Initially, the recombinant gene with the necessary transcriptional 
regulatory elements is transferred to the cells [Ringold, G., et al., 1981; 
Gopalkrishnan, R.V. et al., 1999]. In addition, a second gene is transferred that 
confers to recipient cells a selective advantage. In the presence of the selection 
agent, which is applied a few days after gene transfer, only those cells that express 
the selector gene survive [Balland, A. et al, 1988]. The most popular genes for 
selection are dihydrofolate reductase (DHFR), an enzyme involved in nucleotide 
metabolism, and glutamine synthetase (GS). 
 
Fig 1.14: Cell line generation and development for cell culture processes for the generation of 
recombinant proteins of interest (o.i.). The wavy lines indicate subcultivations of individual cell 
lines that are in a screening program to obtain the final producer. Vials indicate banks of cells 
frozen in liquid nitrogen. Spinner flasks represent scale-down systems for process optimization, 
and bioreactors represent large-scale production processes.  [Modified by Wurm F M., 2004] 
 
 Following selection, survivors are transferred as single cells to a second 
cultivation vessel, and the cultures are expanded to produce clonal populations 
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[Barnes, L.M., 2004; Jones, D. et al., 2003]. Eventually, individual clones are 
evaluated for recombinant protein expression, with the highest producers being 
retained for further cultivation and analysis. From these candidates, one cell line 
with the appropriate growth and productivity characteristics is chosen for 
production of the recombinant protein. 
 Although the basic concepts have not changed since the mid-1980s, the 
productivity of recombinant cell lines has increased dramatically in the past two 
decades. Overall, efforts have led to improvements in vectors, host cell 
engineering, medium development, screening methods and process engineering 
and development [Wurm F M., 2004]. 
 Two main formats have been employed for the large scale production of 
recombinant proteins in mammalians cells: cultures of adherent cells [Loumaye, 
E. et al. 1998; Spier, R. & Kadouri, A., 1997] and suspension cultures [Barnes, 
L.M., et al. 2000; Bödecker, B.G.D., et al. 1994; Wurm, F.M. & Bernard, A.R., 
1999; Jones, D. et al., 2003]. The latter is by far the most common. 
  
1.3.1.2.1 Immunotoxins produced with mammalian cell systems 
 In the table 1.8, some Immunotoxins produced in the mammalian cell 
system are summarized.  
 
Immunotoxin Description Reference 
ImmunoRNase The IT is expressed in myeloma cells. 
 
Krauss J, et al., 2009 
VEGF165-PE38 Vascular Endothelial Growth Factor 
165 fused to PE38. 
 
The IT is expressed to mesenchymal 
stem cells that were used as a vehicles 
for delivery the drug. 
 
The IT is expressed in HEK293 cells. 
 
 
 
 
 
 
Hu CC, et al., 2009 
 
Hu CC, et al., 2010  
Gb-H22 (scFv) Granzyme B fused to the scFv anti-
CD64. The IT is  expressed in human 
293T cells 
 
Stahnke B, et al.,  2008 
Ki4-angiogenin C-term 
Ki4-angiogenin N-term 
The anti-CD30 scFv (Ki4) fused to 
the C- and N- terminal of angiogenin. 
These ITs are expressed in human 
293T cells 
 
Stöcker M., et al., 2003 
Table 1.8: Some Immunotoxins produced in the mammalian cell systems. 
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1.3.1.3 PROTEINS PRODUCTION IN INSECT CELLS 
 The introduction of the functional expression of recombinant proteins, the 
use of baculovirus vectors to produce proteins for purification has become one of 
the most widely-used viral gene delivery systems. Extensive engineering to 
simplify and accelerate the process of recombinant virus construction has made 
this system accessible to virtually any modern biological laboratory.  
 Viruses are a natural choice for exploitation as gene transfer vectors due to 
their inherent ability to package nucleic acids and deliver them to susceptible 
cells. Because of several unique features, such as extremely high levels of gene 
expression, accessibility, and an excellent biosafety profile, baculoviruses have 
been one of the most popular viral vectors for expression of recombinant proteins 
since their introduction in 1983. The majority of commercially-available 
baculovirus vector systems are based on the budded form of the Autographa 
californica multiple nucleopolyhedrosis virus (AcMNPV) [Funk, C.J., et al., 
1997].  Baculovirus vectors are generally propagated in cells originally isolated 
from Spodoptera frugiperda (Sf9 or Sf21) [O’Reilly, D.R., et al., 1992]. These 
cells are commonly used for production of recombinant proteins such as enzymes, 
nuclear receptors, G protein-coupled receptors, ion channels, cytochrome P450s, 
secreted proteins, etc. that have been expressed in a functional form. 
 Insect cell over-expression has the advantage over bacterial expression that 
since the cells are eukaryotic post-translational modifications of a protein are in 
many respects identical to those carried out in mammalian cells [Jarvis, D.L., 
1997]. The major difference between proteins produced in insect and mammalian 
cells is in the composition of carbohydrate modifications added post-
translationally [Kost, T.A, et al., 2005].  
 To construct a baculovirus vector the recombinant gene expression 
cassette must be inserted into the viral genome. In its original conformation (Fig. 
1.15A) [Smith, G.E., et al., 1983; Pennock, G.D., et al., 1984] this was 
accomplished by subcloning the viral polyhedrin protein gene locus into a plasmid 
vector and inserting the gene of interest into the polyhedrin gene such that its 
expression is controlled by this highly active late viral promoter. This plasmid is 
transfected into insect cells along with baculovirus DNA and homologous 
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recombination is allowed to bring the recombinant gene into the viral DNA 
[Smith, G.E., et al., 1983; Pennock, G.D., et al., 1984]. 
 In figure 1.15 four major themes in construction of recombinant viral 
genomes are illustrated.  
 
Fig. 1.15: Methods of insertion of transgene expression cassettes for construction of 
recombinant baculovirus genome. (A) Homologous recombinantion in insect cells [Kitts, P.A., 
et al., 1990; Kitts, P.A. and Possee, R.D., 1993]. A commercially-available system was developed 
by Oxford Expression Technologies and is termed flash- BAC™. (B) Site-specific transposition in 
bacterial cells [Luckow, V.A., et al., 1993]. This system has been commercialized under the name 
Bac-to-Bac™ by Invitrogen. (C) Directed in vitro cloning of restriction fragments into viral DNA 
[Ernst, W.J., et al., 1994; Lu, A. and Miller, L.K., 1996]. A commercially-available system was 
developed by Invitrogen. (D) Site-specific recombination  in vitro.[Modified by J. P. Condreay 
and T. A. Kost. , 2007]. 
 
 In addition to its role as an insect cell protein expression system, 
baculovirus mediated gene delivery into mammalian cells has recently evolved 
into a particularly useful research tool [Kost, T.A., et al., 2005; Hofmann C, et al., 
1995; Boyce, F.M. and Bucher, N.L., 1996].  
 In summary, the versatile baculovirus system continues to be widely used 
in pharmaceutical discovery research programs. The applications of this powerful 
viral vector system will evolve with further advances in the understanding of 
baculovirus biology and the interaction of modified viruses with mammalian cells. 
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1.3.1.3.1 Immunotoxin produced with insect cell system 
 In the table 1.9 two Immunotoxins produced in the insect cell system are 
reported.  
 
Immunotoxin Description Reference 
scFv-mel-FLAG Recombinant melittin-based cytolytic 
Immunotoxin 
Choo AB., et al., 2002 
DTctGMCSF The human granulocyte-macrophage 
colony stimulating factor (GMCSF) 
fused by truncated form of DT lacking 
the binding domain. 
Williams MD., et al.,1998 
Table 1.9: Immunotoxins produced in the insect cell systems. 
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1.3.1.4 PROTEINS PRODUCTION IN YEAST SYSTEMS 
 
 Yeasts are among the earliest-domesticated microorganisms. They are 
unicellular, eukaryotic fungi, the cells having a membrane-bounded nucleus and 
membrane bounded mitochondria. Yeasts occur in many habitats, usually 
associated with numerous other living things. There are approximately 700 known 
yeast species in 100 genera [Spencer A.I.R and Spencer J.F.T, 2002]. Most of the 
ascomycetous yeasts are in the genus Pichia (91species), and the nonsporulating 
forms in Candida (163 species), Cryptococcus and Rhodotorula (34 species each) 
(Kurtzman and Fell, 1998).  
 Humans have cultivated yeast since the dawn of agriculture to make beer, 
bread, and wine. As a domesticated microorganism and sexual eukaryote, the 
budding yeast Saccharomyces cerevisiae is the most commonly used industrial 
yeast and has emerged as a remarkably tractable eukaryotic model system. Other 
widely studied unicellular fungi, particularly the fission yeast Schizosaccaromyces 
pombe and the orange bread mould Neurospora crassa, share many of the traits 
that make S. cerevisiae attractive to investigate and are useful for analysing 
numerous genetic phenomena with no parallel in the budding yeast. Yeasts belong 
to the kingdom of fungi, along with moulds, smuts, and mushrooms. They share a 
common cellular architecture and rudimentary life cycle with multicellullar 
eukaryotes such as plants and animals [Mell J.C. and Burgess S.M., 2002]. As 
nonpathogenic, nonmotile microorganisms, yeasts are easily propagated and 
manipulated in the laboratory. An important theme of yeast biology is the use and 
study of homologous recombination, a process by which a broken piece of DNA 
uses a homologous DNA template as a substrate for repair. Yeast use this process 
to fix DNA damage, to switch mating types, and to segregate homologous 
chromosomes during meiosis.  
 Like all eukaryotes, yeast cells have numerous membrane bound 
organelles, including a nucleus, endosymbiotic mitochondria, the peroxisome, and 
the organelles of the secretory pathway. The budding yeast carries its genome of 
nearly 6000 genes in 12 megabase pairs of DNA on 16 linear chromosomes in the 
nucleus. The genome is very compact for a eukaryote: the number and size of 
genes are relatively small and the density of genes is relatively high. Genetic 
redundancy in the yeast genome is low, facilitating the analysis of gene function. 
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The life cycle of the budding yeast is rudimentarily similar to that of any sexual 
eukaryote, alternating between haploid and diploid states, containing one and two 
sets of chromosomal complements, respectively. Cells divide by budding; a 
mother cell buds to produce a genetically identical daughter cell. Before the 
daughter is released, copies of each chromosome (called sister chromatids) 
segregate by mitosis. In a haploid, there is one of each chromosome in the 
complement. When two haploid cells mate and fuse, they yield a diploid cell, 
which contains two of each chromosome. These pairs are called homologous 
chromosomes. A diploid can either grow by budding or undergo meiosis, a double 
round of cell division yielding four haploid spores held together in an ascus. As in 
other eukaryotes, yeast cells age. A mother cell produces a limited number of 
daughter cells. Life span in yeast is under the control of a genetic programme that 
shares features in common with multicellular animals [Mell J.C. and Burgess 
S.M., 2002]. 
 
1.3.1.4.1 STEPS FOR THE RECOMBINANT PROTEINS PRODUCTION  
 IN THE  YEAST SYSTEMS 
 The protein expression in Escherichia coli or in yeast such as 
Saccharomyces cerevisiae or Schizosaccharomyces pombe has been preferred for 
investigations where a high yield of expressed functional protein is the main goal. 
Among the various yeast expression systems used thus far for the production of 
foreign proteins, the baker’s yeast Saccharomyces cerevisiae and the fission yeast 
Schizosaccharomyces pombe account for the most commonly used forms. The 
choice of one over the other or even the selection of other yeasts like Pichia 
pastoris, Hansenula polymorpha, Kluyveromyces lactis, Yarrowia lipolitica or 
Candida utilis will depend on the scope of the investigation. Irrespective of the 
host used, successful expression includes the introduction of the foreign DNA into 
the yeast cells, the maintenance of the foreign DNA in the host, and the assurance 
of efficient expression. 
 
1.3.1.4.1.1 Introduction of foreign DNA and its stability in yeast cells   
 The genetic transformation of yeast was first made possible by the 
development of methods in which foreign DNA, in the presence of calcium and 
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polyethylene glycol, was introduced into spheroplasts produced by enzymatic 
removal of the cell wall. Meanwhile, various newer, time and transformation-
efficient methods, like the lithium acetate method [Ito et al., 1983], or 
electroporation techniques [Becker and Guarente, 1991], have also ensured the 
successful transfer of DNA into host cells that retain an intact cell wall.  
 Successful translation of foreign DNA in yeast depends on the vectors 
used as well as the species or strain of host cells [Kingsman et al., 1985; Stearns 
et al., 1990; Rose and Broach, 1990]. 
 For selective growth in yeast, all plasmids are equipped with selectable 
markers – yeast genes that complement specific auxotrophies of the host strain 
used. Thus, yeast leu2- mutants can grow in media lacking leucine only when they 
are transformed with plasmids bearing the LEU2 gene. The other most commonly 
used selectable markers are HIS3, URA3, TRP1 or LYS2 genes, which confer 
auxotrophy to strains incapable of synthesizing histidine, uracil, tryptophan or 
lysine, respectively.  
 
1.3.1.4.1.2 Efficient expression  
 Efficient transcription can be achieved by the promoter and terminator 
sequences that flank the foreign DNA. A series of efficient promoters for 
expression in S. cerevisiae, such as the GAL4, ADH, PGK or GAPDH promoters, 
are derived from the 5’ flanking regions of glycolytic genes of this organism. 
Terminator regions are fragments often derived from the PGK, PHO5 or TRP1 
genes and are in general not as well characterized as promoters. Careful 
consideration of all these factors, however, does not necessarily guarantee 
successful expression of the foreign protein. In some cases, instability is due to 
degradation by yeast endogenous proteases, and the use of yeast strains deficient 
in some of the proteases might help to overcome the problem. 
 Yeast cells have been used for the production of various proteins of 
clinical or other commercial interest. In many cases, proteins are produced by 
using a secretion system involving the prepro-a-factor leader region of S. 
cerevisiae [Zsebo et al., 1986; Wood et al., 1985; Bitter et al., 1988; Barr et al., 
1988].  
 
 51
 
1.3.1.4.2 Recombinant protein production with the Pichia pastoris expression 
 system 
 The production of a functional protein is intimately related to the cellular 
machinery of the organism producing the protein. The yeast Pichia pastoris is a 
useful system for the expression of milligram-to-gram quantities of proteins for 
both basic laboratory research and industrial manufacture. The fermentation can 
be readily scaled up to meet greater demands, and parameters influencing protein 
productivity and activity, such as pH, aeration and carbon source feed rate, can be 
controlled [Higgins DR and Cregg JM , 1998]. Compared with mammalian cells, 
Pichia does not require a complex growth medium or culture conditions, is 
genetically relatively easy to manipulate, and has a eukaryotic protein synthesis 
pathway. Some proteins, such as G protein-coupled receptors, that cannot be 
expressed efficiently in bacteria, Saccharomyces cerevisiae or the insect 
cell/baculovirus system, have been successfully produced in functionally active 
form in P. pastoris [Cereghino GPL, et al 2001; Cereghino GPL, et al., 2002; de 
Jong LAA, et al., 2004]. This methylotrophic yeast is particularly suited to foreign 
protein expression for a number of reasons, including ease of genetic 
manipulation, e.g. gene targeting, high-frequency DNA transformation, cloning 
by functional complementation, high levels of protein expression at the intra- or 
extracellular level, and the ability to perform higher eukaryotic protein 
modifications, such as glycosylation, disulphide bond formation and proteolytic 
processing [Cregg JM, et al., 2000]. Pichia can be grown to very high cell 
densities using minimal media [Veenhuis M, et al., 1983; Wegner G., 1990] and 
integrated vectors help genetic stability of the recombinant elements, even in 
continuous and large scale fermentation processes [Romanos M., 1995]. Simple 
purification of secreted recombinant proteins is possible due to the relatively low 
levels of native secreted proteins [Cregg JM, et al., 1993]. Therefore, the powerful 
genetic techniques available, together with its economy of use, make P. pastoris a 
system of choice for heterologous protein expression. 
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1.3.1.4.2.1 The Pichia pastoris history  
 The Phillips Petroleum Company was the first to develop media and 
protocols for growing P. pastoris on methanol in continuous culture at high cell 
densities (>130 g/dry cell weight [Cereghino JL and Cregg JM. 2000]). During 
the 1970s, P. pastoris was evaluated as a potential source of single-cell protein 
due to the ability of this yeast to utilize methanol as sole carbon source. 
Unfortunately, the oil crisis of the 1970s caused a dramatic increase in the cost of 
methane (the source of the methanol). Simultaneously, the price of soybeans, the 
major alternative source of animal feed, fell. However, in the following decade, 
Phillips Petroleum, together with the Salk Institute Biotechnology/ Industrial 
Associates Inc. (SIBIA, La Jolla, CA, USA), studied P. pastoris as a system for 
heterologous protein expression. The gene and promoter for alcohol oxidase were 
isolated by SIBIA, who also generated vectors, strains and corresponding 
protocols for the molecular manipulation of P. pastoris. What began more than 20 
years ago as a program to convert abundant methanol to a protein source for 
animal feed has developed into what are today two important biological tools: a 
model eukaryote used in cell biology research, and a recombinant protein 
production system. Pichia has gained widespread attention as an expression 
system because of its ability to express high levels of heterologous proteins. As a 
result, recombinant vector construction, methods for transformation, selectable 
marker generation, and fermentation methods have been developed to exploit the 
productive potential of this system [Rosenfeld SA, et al.,  1999]. Research 
Corporation Technologies (Tucson, AZ, USA) are the current holders of the 
patent for the P. pastoris expression system, which they have held since 1993, and 
the P. pastoris expression system is available in kit form from Invitrogen 
Corporation (Carlsbad, CA, USA). 
 
1.3.1.4.2.2 Comparison between E. coli and P. pastoris expression systems 
 Over the past three decades, Escherichia coli has been extensively used as 
a cellular host for protein expression. However, the broad application of this 
system with proteins derived from eukaryotic genomes that require post-
translational modifications has been problematic. Successful expression of 
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recombinant proteins in E. coli is thus very dependent on the primary, secondary, 
tertiary and functional characteristics of the protein of interest. As E. coli is a 
prokaryote, the inability to correctly fold the foreign protein and perform other 
post-translational modifications limits the types of proteins that can be expressed. 
Since the protein product may be typically obtained as insoluble, miss-folded 
inclusion bodies, subsequent solubilization and re-folding steps are required and 
the folding conditions need to be carefully optimized [Makrides SC., 1996; 
Marston FA. 1986; Majerle A, et al., 1999; Chen BP and Hai T. 1994; 
Koganesawa N, et al., 2001] . Development of such folding conditions may be 
difficult to achieve and time consuming [Wang P, et al.,  2000; Tsujikawa M, et 
al.,  1996] and these factors can result in significant losses, lower productivities 
and increased costs of manufacture of the expressed protein. Moreover E. coli 
expressed proteins also tend to retain their amino-terminal methionine, which may 
affect protein stability [Chaudhuri TK, et al., 1999; Takano K, et al., 1999] and 
cause immunogenicity. Since E. coli has no capacity to glycosylate recombinant 
proteins, this constraint is an important factor that can alter the function of certain 
proteins [Meldgaard M, et al., 1994; Jenkins N, et al., 1996]. 
 A large variety of the proteins that cannot be expressed in E. coli at the 
correct level of post-translational maturation have subsequently been produced in 
the methylotrophic yeast, Pichia pastoris [Monsalve RI, et al., 1999]. For 
example, this trend can been exemplified from the comparative studies by 
Lueking et al. [Lueking A, et al., 2000], where expression vectors for E. coli and 
P. pastoris were constructed and tested by cloning various cDNAs from a human 
fetal brain expression library. From the 29 different cDNA clones that were in the 
correct reading frame, all were found to produce soluble proteins in P. pastoris. 
With the E. coli expression system on the other hand, only nine clones resulted in 
soluble proteins, 15 were detected as inclusion bodies and five were not expressed 
at all. This outcome is undoubtedly due to differences in the protein folding 
environment and the inability of E. coli to perform post-translational 
modifications [Lueking A, et al., 2000]. Other proteins, generated as mis-folded, 
insoluble inclusion bodies through expression in E. coli but obtained as soluble 
and correctly folded proteins when expressed in P. pastoris, include antigen 5 
(Ag5) from the yellow-jacket, paper-wasp and white-face hornet wasp species 
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[Monsalve RI, et al., 1999; King Te P, et al., 1995], herring antifreeze protein [Li 
ZJ, et al., 2001; Ewart KV, et al., 1996], prourokinase [Holmes WE, et al., 1985] 
and human transferring [Hershberger CL, et al., 1991; Mason AB, et al., 1996].  
 P. pastoris expression systems therefore offer significant advantages over 
E. coli expression systems for the production of many heterologous eukaryotic 
proteins. As noted above, this feature is particularly relevant for target proteins 
containing multiple disulphide bonds or requiring glycosylation, phosphorylation, 
the absence of an amino-terminal methionine or no oligomer formation for the 
correct assembly of the mature protein. P. pastoris expression systems, besides 
permitting the authentic protein to be secreted in soluble form, also has the 
capability of producing large quantities of the recombinant protein. Developments 
with this system include the choice of various P. pastoris strains and vectors that 
enable a wide choice of promoters, secretion signals and selectable markers to be 
made.  
 
1.3.1.4.2.3 P. pastoris EXPRESSION STRAINS 
 Numerous strains of P. pastoris with a wide range of genotypes are now 
available. The choice of a specific strain is determined by the required application. 
The genotype and phenotype characteristics of a number of the more useful strains 
are summarized in table 1.10.  
 
Strain Genotype Phenotype Reference 
SMD1168 His4, pep4 Mut+, His-, pep4- White CE, et al., 1995 
GS115 his4 Mut+, His- Cregg JM et al., 1985 
KM71 His4, aox1:ARG4, arg4 Muts, His-,  
X-33 Wild type - Li ZJ et al., 2001 
MP-36 - - Paifer E, et al., 1994 
SMD1165 His4, prb1 Mut+, His-, prb- Abdulaev NG et al., 1997 
SMD1163 his4, prb1, pep4 Mut+, His-, pep4-, 
prb- 
Sreekrishna K, et al., 1997 
MC100-3 Arg4 his4 aox1 ∆:: 
SARG4 
 aox2∆:: Phis4 
Mut-, His-, Gellissen G., 2000 
Inan M and Meagher MM. 
2001 
Table 1.10: Genotype and phenotype of P. pastoris strains. 
[Modified by Daly R. and Hearn M.T.W., 2005] 
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 The SMD1168 and SMD1168H strains, for example, are defective in the 
vacuole peptidase A (pep4). This enzyme is responsible for activating 
carboxypeptidase Y and protease B1 and, hence, these SMD1168 and SMD1168H 
strains are also defective in these proteases [White CE, et al., 1994]. Strains such 
as KM71, GS115 and SMD1168 are defective in the histidine dehydrogenase gene 
(his4). Their use allows transformants to be selected based on their ability to grow 
in non-histidine containing media. The strains SMD1168 and GS115 both contain 
a functional copy of the alcohol oxidase 1 gene (AOX1) responsible for 
approximately 85% of the utilization of methanol by the alcohol oxidase enzyme. 
These strains therefore have a wild-type methanol utilization phenotype 
designated as Mut+ [Inan M and Meagher MM. 2001]. The KM71 strain, 
however, contains a non-functional AOX1 (aox1) and relies on the alcohol 
oxidase enzyme being produced from an alternative gene called AOX2. The 
AOX2 enzyme has the same specific activity as AOX1 but has a much lower 
expression level (weaker promoter) and can only consume methanol slowly, 
hence the phenotype of these strains are termed ‘methanol utilization slow’ (Muts) 
[Inan M and Meagher MM. 2001; Cregg JM, , et al., 1993]. 
 
1.3.1.4.2.4 AOX pathways 
 Methylotrophic yeasts such as P. pastoris can use methanol as a sole  
carbon source. The 
methanol is oxidised to 
formaldehyde by alcohol 
oxidase in the 
peroxisome (Fig. 1.16) 
[Tschopp JF, et al., 1987; 
Cereghino JL and Cregg 
JM., 2000; Couderc R 
and Baratti J. 1980].  
 Alcohol oxidase is 
an oligomeric flavo-
protein and contains an 
FAD and the analogue 
 
Fig 1.16: The methanol pathway in P. pastoris. 
 1. alcohol oxidase; 2. catalase; 3. foemaldehyde 
dehydrogenase; 4. formate dehydrogenase; 5. 
dihydroxyacetone synthase; 6. dihydroxyacetone kinase; 7. 
fructose 1,6-biphosphate aldolase; 8. fructose 1,6-
bisphosphatase. [Modified by Cereghino J.L., Cregg J.M. 
2000]. 
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mFAD non-covalently attached to accomplish electron transfer. AOX is strongly 
repressed by many alternate carbon sources such as glucose and glycerol and is 
induced by carbon starvation and methanol. When P. pastoris cultures are grown 
on methanol as a carbon source, it has been shown that the AOX mRNA can 
comprise up to 5% of the total polyA-RNA pool [Cregg JM and Higgins DR. 
1995]. The reaction catalysed by AOX requires O2 and forms H2O2 and 
formaldehyde. The alcohol oxidase is not specific for methanol and can oxidize 
other primary alcohols; however, as the number of carbons in the alcohol 
increases, the activity of the enzyme decreases. The H2O2 produced by the AOX 
reaction is converted to H2O by peroxisome catalase [Gellissen G. 2000]. The 
conversion of methanol to formaldehyde is the rate-limiting step in utilizing 
methanol and is regulated by increasing the amount of AOX enzyme in the cells. 
This is demonstrated by the observation that when the methanol concentration is 
increased suddenly, the growth of the cells is inhibited [Couderc R and Baratti J. 
1980]. The formaldehyde produced in this reaction is then further oxidized either 
through a cytosolic dissimilatory pathway, which yields energy, or an assimilatory 
pathway for the generation of biomass [Gellissen G, et al.,  1992]. The first step in 
the assimilatory pathway is the activation of DHAS, which is present in the 
cytoplasm and is under the control of a methanol-induced promoter [Gellissen G. 
2000; Tschopp JF, et al., 1987] The formaldehyde is converted into 
dihydroxyacetone and glucose 3-phosphate [Gellissen G. 2000]. In the 
dissimilatory pathway, the formaldehyde is converted to formate by FLD and then 
to CO2 by FMDH [Gellissen G. 2000]. Peroxisome proteins such as AOX are 
thought to undergo rapid turnover [Tschopp JF, et al., 1987]. This turnover, 
combined with the enzyme’s low affinity for O2, means that the AOX protein 
levels can be high, e.g. up to 30% total cellular protein (TCP), and the 
peroxisomes can occupy up to 80% of the cell volume when P. pastoris is grown 
on methanol as a sole carbon source [Gellissen G. 2000]. As FMDH and DHAS 
are required for methanol utilization their levels can comprise up to 20% TCP 
[Gellissen G. 2000; Cereghino JL and Cregg JM. 2000]. 
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1.3.1.4.2.5 Expression vectors 
 There are many commercially available vectors that can be used to express 
foreign proteins in P. pastoris.  
 Since some vectors do not contain a vector-copy of a secretion signal 
upstream from the multiple cloning sites, these vectors can be used for either 
intracellular expression or for extracellular expression by cloning the protein 
together with its own native secretion signal.  
 Other vectors contain a vector-copy of a signal sequence such as the alpha-
mating factor pre-pro leader sequence (α-MF) prior to the cloning site, resulting in 
secretion of the desired gene product.  
 The first generation of P. pastoris expression vectors, such as pHIL-D2 or 
pPIC9 (Fig. 1.17), contained the functional histidine dehydrogenase gene (HIS4), 
which can be used as a selectable marker following transformation into his4 
(histidine dehydrogenase-deficient strain) P. pastoris by the 
integration/transformation method of choice. In order to obtain high protein 
expression levels with these His+ transformants, further analysis to detect tandem 
multi-copy integration events of the expression cassette is required.  
 Subsequently, a gene conferring resistance to GS418 (kanamycin) was 
added to these vectors to produce the pPIC9K expression vector (Fig. 1.17). 
 
Fig 1.17: Vector diagrams of pHIL-D2, pPIC9 and pPIC9K. 
 
 This approach allows transformation and selection for His+ transformants 
that are resistant to high levels of GS418 (kanamycin) and therefore can contain 
multiple copies of the expression vector. Several problems have, however, been 
documented with the use of the above-mentioned vectors. Firstly, the large size of 
these vectors (9.0–9.3 kb) makes in vitro cloning steps more difficult [Sears IB, et 
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al., 1998], and integration of such large vectors typically results in transformants 
that are genetically less stable [Romanos MA et al., 1992]. Secondly, as not all 
applications require specific targeting for gene replacement, the 3’AOX1 gene 
region in the vector is not required. As the use of the HIS4 gene does not directly 
select for multi-copy integrants (and the gene itself is large), these constraints 
have led to efforts to find alternate selection markers in order to directly obtain 
multi-copy integrants, as well as to decrease vector size, resulting in the 
generation of vectors based on the ability of the Sh ble gene product to confer 
resistance to the antibiotic zeocin (Fig. 1.18). These zeocin-resistant vectors 
contain only the 5’AOX1 promoter region and the AOX1 transcription terminator 
as well as the Sh ble gene. Although these vectors cannot be used directly for 
AOX1 gene replacement, transformants can be selected for hyper-drug resistance 
containing multiple copies of the expression cassette. The Muts phenotype (aox1) 
may still result if the AOX1 gene is disrupted [Vassileva A, et al., 2001]. In these 
zeocin-based vectors (3.3–3.6 kb), the expression cassette is also flanked by 
unique BamH1 and BglII sites that enable construction of a vector containing 
multiple, tandem expression cassettes (in vitro multimers). 
 Zeocin-resistant vectors are 
also available with α-MF (for 
secreted expression), no signal 
sequence (for intracellular or native 
signal extracellular expression) as 
well as with the choice of either the 
AOX1 or GAP promoter. This type 
of multimer cassette vector assembly 
has also been applied successfully for 
the co-expression of proteins in P. 
pastoris.  
 
1.3.1.4.2.6 Expression plasmid transformation/integration into the yeast 
genome 
 P. pastoris is transformed by integration of the expression cassette into the 
chromosome at a specific locus to generate genetically stable transformants 
 
Fig1.18: Vector diagrams of pPICZ A, B, C  
and pPICZalpha A, B, C. 
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[Sreekrishna K, et al., 1997; Cregg JM and Higgins DR., 1995]. Chromosomal 
integration is more desirable than the use of episomal plasmid expression systems 
as episomal plasmids tend to have low copy number, and this will affect the 
amount of product expressed. The size of the plasmid may also affect the stability 
in the host since large episomal plasmids can be lost during repeated generations 
as they are mitotically unstable [Romanos MA et al., 1992; Thiry M, and 
Cingolani D. 2002]. In addition, transformants containing episomal plasmids need 
to be cultured under continual ‘selection based’ media conditions in order to 
maintain the transformed population of cells [Romanos MA et al., 1992]. This 
procedure may require the use of additives such as antibiotics, which in turn result 
in increased production costs [Thiry M, and Cingolani D. 2002].  
 Development of genetically stable expression strains is therefore highly 
desirable [Thiry M, and Cingolani D. 2002] with a rate of vector loss less than 1% 
per generation in the absence of selectable markers usually set as the target 
[Romanos MA. 1995]. Moreover, such integration vectors usually contain 
selectable markers that enable detection of the transformants. 
 Integration into the genome can occur via homologous recombination 
when the vector/expression cassette contains regions that are homologous to the 
P. pastoris genome and hence integration can occur via gene insertion or gene 
replacement (Fig. 1.19A–C). Integration by gene insertion can result in tandem 
multiple integration events due to repeated recombination events at a rate of 1–
10% of transformants [Clare JJ, et al., 1991]. Transformations that target gene 
replacement generally result in single copy transformants; however, gene 
replacement transformants are usually more genetically stable [Romanos MA et 
al., 1992; Clare JJ, et al., 1991]. Gene replacement is achieved by digesting the 
expression vector such that the 5’ and 3’ ends of the vector correspond to the 5’ 
and 3’ AOX1 regions of the AOX1 chromosomal locus. Transformation, 
therefore, results in site-specific eviction of the AOX1 gene (Fig. 1.19C). This 
event occurs at a frequency of 5–25% of the transformants [Sreekrishna K, et al., 
1997; Romanos MA. 1995]. The other transformants are either His+ conversions 
or of the Mut+ phenotype as a result of gene insertion events at either the his4 or 
AOX1 locus [Fig. 1.19A,B]. [Romanos MA. 1995].   
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 The introduction of the expression cassette into the yeast chromosome can 
be achieved in a variety of ways including spheroplast formation, electroporation 
and lithium chloride treatments. The spheroplast transformation method has been 
used to generate multi-copy transformants by using vectors such as pPIC9K and 
pPIC9 [Greenwald J, et al., 1998; Berger DH, et al., 2002]. This method requires 
several steps with the risk that contamination of the yeast may occur. Also, over-
digestion with the cell-lysing enzyme, zymolyase, can reduce cell viability. 
Electroporation has become increasingly popular and can be used successfully 
with zeocin-resistant vectors. This method requires fewer steps and the risk of 
contamination is reduced.  
 
 
 
1.3.1.4.2.7 Choice of promoter 
 As mentioned previously, the AOX1 enzyme has a poor affinity for 
oxygen and therefore P. pastoris compensates for this property by up-regulating 
the AOX1 promoter to drive expression of the AOX1 gene and produce larger 
amounts of the AOX1 enzyme. In fact, the abundance of the AOX enzyme can 
reach 30% of TCP content when grown on methanol as a sole carbon source 
[Gellissen G. 2000; Cregg JM, et al., 1993]. This strong AOX1 promoter can 
Fig. 1.19: Integration in the P. pastoris 
genome, by gene insertion (A and B) and 
gene replacement (C). 
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therefore be used to drive the expression of recombinant proteins to high levels 
even with a single integrated copy of the expression cassette [Cregg JM, et al., 
1993; Clare JJ, et al., 1991]. Other benefits of this promoter are that it can be 
switched off, as non-limiting amounts of carbon sources such as glycerol and 
glucose repress the AOX1 promoter at the transcriptional level and minimize the 
possibility of selecting non-expressing mutants/contaminants during biomass 
generation [Cregg JM, et al., 1993; Inan M and Meagher MM. 2001; Cereghino 
GPL and Cregg JM. 1999; Katakura Y., et al., 1998]. This characteristic also 
allows production of proteins that may be toxic to the P. pastoris cells, such as the 
anti-T cell Immunotoxin [Woo JH, et al., 2002], by growing the cells initially in 
repressive media and then inducing the protein expression when the biomass has 
been well established [Waterham HR, et al., 1997]. 
 If the transformant used for expression has a Mut+ phenotype, then this can 
result in the consumption of large amounts of methanol during the induction 
phase. Transformants with a Muts phenotype can therefore be used to reduce the 
amount of methanol required for expression.  
 Another promoter that has been used successfully with P. pastoris 
expression system is the constitutive YPT1 promoter, which is constructed from a 
GTPase gene product that is involved in the secretory pathway [Segev N, et al., 
1988]. Interestingly when the AOX1 promoter was induced with mannitol, 
significant amounts, 20.3 units/ml, of GUS were produced even though no 
methanol was present.  
  
1.3.1.4.2.8 Rare codons and truncated transcripts 
 When expressing recombinant non-yeast proteins, the codons of the gene 
encoding the protein may not be optimal to accommodate high expression levels 
of protein. Codons that are common in some species may be rare in P. pastoris 
and so expression can become limited to the amounts of available aminoacyl-
tRNA in the yeast cell [Romanos MA., et al., 1992]. Premature termination of 
translation can occur when specific aminoacyl-tRNA are depleted [Lueking A., et 
al., 2000; Clare JJ, 1991; Tull D, 2001; Eckart MR and Bussineau CM., 1996] and 
also transcription can be terminated if the DNA has a high proportion of AT bases 
[Sreekrishna K, et al., 1997; Romanos MA., 1995]. Altering the codon bias as 
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well as increasing the proportion of GC bases in the DNA can be used to improve 
expression levels. An example of this approach can be found in the expression of 
mouse epidermal growth factor (mEGF) in P. pastoris, where the gene was made 
synthetically with a codon bias reflecting that of the yeast.53 The gene for α-
amylase has also been synthetically made to improve codon usage and to also 
increase the percentage of GC bases [Tull D., et al., 2001] in an analogous P. 
pastoris expression system. The β-glucanase gene has been similarly enriched 
with increased GC content [Olsen O, et al., 1996], leading to higher expression 
levels of the corresponding protein, whilst an increase in GC content of tetanus 
toxin fragment gene also resulted in higher expression levels [Romanos MA et al., 
1992; Clare JJ, et al., 1991]. Anti-human anti-T cell Immunotoxin has also been 
expressed in P. pastoris using the native cDNA sequence where it was found to 
result in a premature termination of the transcript due to AT-rich sequences. 
Optimization of the codons resulted in successful transcription and expression of 
the recombinant protein [Woo JH., et al., 2002].  
  
1.3.1.4.2.9 Multi-copy integration number 
 It is often desirable to select for transformants containing multiple 
integration events as such clones potentially express significantly higher levels of 
the recombinant protein. A further advantage of selecting for multi-copy 
transformants is that if there is a mutation in one particular copy of the expression 
cassette, arising from the integration process, then the protein that results from 
this mutant copy may not contribute as significantly to the total amount of protein 
expressed [Eckart MR and Bussineau CM., 1996]. Multiple integration events 
occur relatively infrequently at a rate of 1–10% [Chen YS., et al., 2000]. The 
number of integrated copies of the expression cassette can affect the amount of 
protein expressed. As mentioned previously, a sensitive way to screen for multiple 
integration events is to use selective vectors that contain the Sh ble gene marker, 
which confers resistance to zeocin. Resistance to high concentrations of zeocin 
permits clones to be selected for multiple integration events as the Sh ble gene 
product binds to and inactivates zeocin in a dose-dependent manner [Monsalve 
RI, et al., 1999; Vassileva A, et al., 2001; Chen YS., et al., 2000]. In a study 
reported by Vassileva et al. [Vassileva A, et al., 2001], for example, the selection 
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effects for hyper-resistance to 100, 500, 1000 and 2000 mg/ml of zeocin were 
examined with the transformants analysed for copy number. It was found that 
transformants resistant to 100 mg/ml of zeocin generally contained one copy, 
those resistant to 500 mg/ml had two copies, those resistance to 1000 mg/ml had 
three copies and transformants resistant to 2000 mg/ml had four copies[Vassileva 
A, et al., 2001]. In contrast, other studies by Sarramegna et al. [Sarramegna V., et 
al., 2002] have found that transformants resistant to 1000 mg/ml zeocin had copy 
numbers of 15–25. 
 
1.3.1.4.2.11 Intracellular expression 
 When expressing recombinant proteins in yeast, it is important to consider 
whether intracellular expression or extracellular secretion is the objective. The 
intracellular expression is therefore an alternative to secretion and usually does 
not result in glycosylation, thus in some cases providing a more desirable method. 
Purification of intracellular expressed proteins, however, can be more difficult 
than for secreted proteins as the target protein typically represents less than 1% of 
the total intracellular proteins [Rees GS, et al., 1999]. However many proteins 
have been produced successfully in P. pastoris using intracellular expression 
systems, particularly membrane associated proteins [Vassileva A, et al., 2001]. 
 
1.3.1.4.2.12 Folding pathway and the use of signal sequences 
 The folding of proteins usually begins with the formation of secondary 
structures [Hlodan R and Hartl UF., 1994] and the rapid generation of disulfide 
bonds in the endoplasmic reticulum (ER) [Holst B, et al., 1996]. Many proteins, 
especially those that are naturally secreted, contain a proregion, which is required 
for correct folding and in some cases oligomerization. The mRNA of the pro-
region can also assist in stabilizing the protein mRNA by the formation of local 
secondary structures and hence resisting degradation [Romanos MA et al., 1992]. 
Although the pro-region is proteolytically removed to release the mature protein 
[Romanos MA., et al., 1992; Holst B, et al., 1996; Oka C, et al., 1999]. The pro-
protein is then transported into the Golgi where the pro-region is removed by 
dibasic endo-peptidases, such as kex2 or furin. From the Golgi, the recombinant 
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proteins are packaged into secretory vesicles and then delivered to the surface of 
the cell [Romanos MA., et al., 1992].  
 In order to direct proteins into the secretory pathway, a specific signal 
sequence is required. The signal sequence is usually a short amino-terminal pre-
sequence that typically contains a charged amino-terminal region followed by 
numerous hydrophobic residues (six to 15 amino acids) and a cleavage site 
recognised by signal peptidases [Romanos MA et al., 1992; Paifer E., et al., et al., 
1994]. The use of a native signal sequence can also be used successful with P. 
pastoris secretory expression systems.  
 When deciding that protein secretion is the preferred approach to be used 
for a particular target protein, a choice of the specific secretion signal must be 
made. This selection can be based on the protein’s own native secretion signal (if 
it has one), the S. cerevisiae alpha-mating factor pre–pro leader sequence (α-MF), 
the acid phosphatase signal sequence (PHO) or the invertase signal sequence 
(SUC2) [Li PZ., et al., 2001]. 
 The most commonly used signal sequence in P. pastoris secretion systems 
is the S. cerevisiae α-mating factor pre– pro leader sequence (α-MF). This 
sequence comprises a 19 amino acid signal peptide (pre-sequence), followed by a 
60 amino acid pro-region. In generating the construct, it is usual for the expressed 
protein to be separated from the pre-region by an endopeptidase site. Upon 
translation, the signal sequence is removed by signal peptidase and pro-region 
cleavage site is recognized by the yeast kex2 protease (kex2p), resulting in the 
release of the mature, fully processed protein [Raemaekers RJM, et al., 1999]. 
Kex2p is a type I membrane protein, located in the late Golgi compartments 
[Brake AJ, et al., 1984; Henkel MK, et al., 1999]. Kex2p is a serine protease 
[Smeekens SP., 1993; Henkel MK, et al., 1999; Rockwell Nathan C, et al., 1998], 
a member of the pro-hormone convertase family and is synthesized as a pre-
proenzyme [Powner D and Davey J., 1998], which requires activation to the 
mature enzyme via autocatalysis [Davey J, et al., 1998]. Kex2p recognizes basic 
pairs of amino acid residues such as Lys–Arg or Arg–Arg [Davey J, et al., 1998; 
Smeekens SP. 1993; Henkel MK, et al., 1999]. Further trimming of the amino-
terminal Glu–Ala residue repeats also occur in the Golgi by the ste13 gene 
product (ste13p). The ste13p is localized to the same late compartment as Kex2p 
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and is a type IV dipeptidyl aminopeptidase [Davey J, et al., 1998; Li PZ, et al., 
2001]. Some of the expressed recombinant proteins that have been produced using 
this system are summarized in table 1.11.  
 
Table 1.11: Summary of a range of foreign proteins produced using the Pichia expression 
system since 2002. [S. M. Patrick, et al., 2005] 
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 Although the α-MF pre–pro sequence has been used extensively, there are 
some instances where its application has been problematic. The main reason is 
due to the insertion of Glu–Ala dipeptide repeats between the amino-terminus of 
the mature recombinant protein and the Kex2p cleavage site. Although the Glu–
Ala repeats do improve the proportion of correctly cleaved material by preventing 
steric hindrance of the kex2p cleavage site [Sreekrishna K, et al., 1997], their 
presence results in the generation of a recombinant protein with Glu–Ala 
aminoterminal extensions. This can lead to N-terminal ragged ends due to 
differential amino-terminal processing because of the inability of the ste13p to 
process the large quantity of recombinant protein that is being produced [Brake 
AJ, et al., 1984]. As the presence of these amino-terminal dipeptide extensions is 
undesirable for many recombinant protein applications, the Glu–Ala repeats 
between the mature protein and the kex2p can be omitted as part of the cloning 
approach in order to achieve a more authentic amino-terminus. Omission of these 
Glu–Ala repeats, however, can result in a decreased efficiency in the Kex2p 
cleavage specificity. In this case, secretion of the pro-protein cleavage products 
that have long amino-terminal extensions corresponding to 9–11 amino acids of 
the α-MF pro-region has been observed [Henkel MK, et al., 1999]. The un-
cleaved Glu–Ala repeats left as amino-terminal extensions can cause other 
problems in terms of the protein structure and function. [Koganesawa N, et al., 
2001]. These Glu–Ala repeats may also have an effect on the immunogenicity of 
the recombinant protein. [Monsalve RI, et al., 1999]. 
 
1.3.1.4.2.14 Choice of culture condition for expression 
 The culture conditions used for P. pastoris expression systems are also an 
important factor to be considered in order to improve the productivity of a 
correctly processed protein.  
 Shaken-flask, small-scale expression methods are often the first stage 
employed in optimizing protein levels and selecting culture conditions. The levels 
of protein obtained from shaken-flasks are generally 10-fold lower than can be 
achieved with fermentors as the cell density is lower [White CE, et al., 1994] and 
the extent of aeration is often more limited [Romanos MA., 1995]. Barr et al. 
[Barr KA, et al., 1992] developed small-scale expression conditions that more 
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closely resembled the requirements of fermentor systems by ensuring high cell 
densities were generated through dramatic increases in the volume of the initial 
biomass generating cultures (1 l) and resuspending this biomass into small 
volumes of methanol induction media (50–75 ml).  
 The culture of P. pastoris transformants based on the AOX1 promoter can 
therefore be executed in two stages, firstly the generation of biomass in a 
repressive media, followed by the production phase where the cells are induced 
with methanol. The concentration of methanol used is also very important when 
optimizing expression levels. Increasing concentrations of methanol from 0.1 to 
1.0% v/v was found to increase the expression levels of human β-2-glycoprotein I 
domain V for Mut+ transformants [Katakura Y, et al., 1998]. Typically methanol 
concentrations of 0.5–1.0% v/v are used in P. pastoris systems. The accumulation 
of methanol can, however, have negative effects on the cell growth [Romanos 
MA., 1995] and can lead to decreased protein expression levels [Sarramegna V., 
et al., 2002]. Therefore, the optimal methanol level needs to be assessed for each 
specific protein produced. A methanol concentration of 3.1% v/v, for example, 
inhibited cell growth for production of β-2-glycoprotein I domain V [Katakura Y, 
et al., 1998], whereas expression levels of procarboxypeptidase A2 increased 3-
fold by increasing the methanol concentration in the induction media from 0.5 to 
5% v/v in a Mut+ phenotype transformant [Reverter D, et al., 1998]. The 
components and pH of the media can also make a difference to expression levels. 
When the media is buffered to pH values between pH 3.0 and 6.0, the amount of 
proteolysis of the recombinant protein is often reduced [Sreekrishna K, et al., 
1997; Cregg JM,  et al.,  1993].  
 The amount of proteolysis is also reduced if a peptone or yeast extract-
based media is used. Another way to reduce proteolysis is via the addition of 1% 
casamino acids [Clare JJ,  et al.,  1991]. Addition of L-arginine-hydrochloride or 
ammonium ions (in the form of ammonium phosphates) has also been used in an 
attempt to reduce proteolysis. Ammonium ions, in particular, seem to have the 
greatest effect at reducing proteolysis [Tsujikawa M, et al., 1996].  
 The length of induction also has an effect on the extent of proteolysis. 
Proteolysis was found to increase over time when the number of viable cells 
decreased. This may be overcome to some extent by replacing the media with 
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fresh media to kick-start the production phase again and prevent accumulation of 
extracellular proteases.  
 Recombinant proteins expressed in P. pastoris systems have also found to 
be degraded rapidly if they contain PEST sequences. These sequences include the 
motifs XFXRQ or QRXFX, which are known to be degraded in the lysosome 
[Sreekrishna K, et al., 1989]. Other additives such as the presence of 5mM EDTA 
can also assist in stabilizing the recombinant expressed protein [Sreekrishna K., et 
al., 1997] and thus increase its expressed yield.  
 The temperature in the induction phase has also been found to affect not 
only the amount of proteolysis but also the amount of protein expressed. For 
example, the expression levels of α-galactosidase A produced in P. pastoris were 
increased when the temperature was reduced to 25°C [Chen YS, et al., 2000]. The 
expression of human m-opioid receptor fusion protein was examined at numerous 
temperatures where it was found that the most functional protein was produced at 
15–20°C, with 2- fold higher expression than obtained at 25°C and 4-fold higher 
than at 30°C [Sarramegna V, et al., 2002]. Production of herring anti-freeze 
protein was also compared at 30 and at 23°C and again it was found that 10-fold 
more protein was produced at the lower temperature of 23°C. The amount of 
proteolysis occurring after 2 days of induction was also less at 23°C than at 30°C. 
These observations can be attributed to the 23°C cultures having a higher cell 
viability compared with the 30°C culture, even though the biomass in each culture 
was equal. The lower temperature can also be proposed to more efficiently 
stabilize the cell membranes and reduce the rate of protease release from the cells 
to the supernatant [Li ZJ, et al., 2001]. The effects of decreased temperatures in 
the induction phase have also been reported in other studies [Brake AJ., et al., 
1984]. 
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1.3.1.4.2.15 Glycosylation 
 Glycosylation is the most common post-translational modification to 
proteins preceeding protein secretion. Approximately 0.5–1.0% of the translated 
proteins in eukaryotic genomes are glycoproteins. Glycosylation occurs in the 
lumen of the endoplasmic reticulum after protein translation. (Fig. 1.20) 
 
Fig. 1.20: Model for the biosynthesis of N- and O-linked glycoproteins in eukaryotes. 
[Modified from Christine M. Szymanski & Brendan W. Wren, 2005] 
 
 The initial stage in Asn-glycosylation is transfer of a pre-assembled 
Glc3Man9GlcNAc2 unit from dolichyl pyrophosphate to amide groups of 
asparagine residues, in the lumen of the ER by the enzyme UDP-GlcNAc : 
dolichol PGlcNAc- transferase [Dennis JW., et al., 1999; Lis H and Sharon N. 
1993; Herscovics A and Orlean P., 1993]. This stage of glycosylation is similar in 
both yeast and mammalian cells. In the secretory pathway, the oligosaccharide is 
trimmed further by the removal of the three glucose residues by glucosidase II and 
I. The α-1,2-linked mannose residue is also removed by α-1,2-mannosidases to 
give Man8GlcNAc2 (Fig. 1.21). 
  The glycoprotein is then transported to the cis-Golgi where further 
processing occurs [Dennis JW., et al., 1999]. In mammalian systems this 
additional processing includes further removal of mannose residues and 
incorporation of fucose (fuc), galactose (gal), N-acetyl-neuraminic acid (NeuAc), 
N-glycolylneuraminic acid (NeuGc), N-acetyl-galactosamine (Gal- NAc), N-
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acetyl-glucosamine (GlcNAc) and 
sialic acid [Li PZ, et al., 2001] by 
Golgi enzymes such as fucosyl-
transferase and N-acetylglucosaminyl- 
transferase, galactosyl-transferase and 
sialyl-transferase [Khandekar SS, et 
al., 2001]. Phosphate groups may also 
be incorporated into the 
oligosaccharide structure at this stage 
in the form of mannose-1-phosphate to create a phospho-diester linkages 
[Martinet W, et al., 1998; Kobayashi H, et al., 1986]. In yeast Golgi, however, 
mannoses are added and the oligomannose units can be linked α-1,6 to the α-1,3 
mannose in the Manα-1,3-Manβ-1,4-GlcNAc2 inner core [Herscovics A and 
Orlean P., 1993]. Glycosylation results in diverse structural heterogeneity of the 
protein population with some of this heterogeneity attributable to the tissue 
specific expression of Golgi glycosylation enzymes [Dennis JW., et al., 1999]. 
Within a given cell, two different molecules of the same protein translate may 
have different oligosaccharide heterogeneity, even when they have been exposed 
to the same enzymes and glycosylation machinery. Some of this heterogeneity 
must therefore be target protein specific and due to features in the sequence 
recognized by the various glycosylation enzymes [Yan BX, et al.,  1999]. The 
chain length of the oligosaccharides can be dependent on the surrounding residues 
where hydrophilic residues may result in the sequon having longer length 
oligosaccharides [Lis H and Sharon N. 1993]. Furthermore, for the sequon Asn–
Xaa–Ser/Thr, if Xaa is a proline, glycosylation is inhibited. A proline may also 
inhibit glycosylation if it is one amino acid displaced C-terminally to the sequon 
[Shelikoff M, et al., 1996]. The Xaa residue is important, for example, if it is a 
hydrophobic residue, such as tryptophan [Yan BX, et al., 1999] or phenylalanine 
[Shakin-Eshleman SH, et al., 1996], then the initial step of addition of 
Glc3Man9GlcNAc2 is inhibited. Negatively charged amino acids such as glutamic 
acid and aspartic acid also partially inhibit occupancy, whereas positively charged 
amino acids such as lysine, histidine and arginine promote core glycosylation and 
increase the occupancy levels [Yan BX, et al.,  1999]. 
 
Fig. 1.21: Structure of the core Asn-
linked oligosaccharide. The branch point 
where further oligosaccharides are added is 
indicated by the star. 
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 The glycosylation recognition sequon in P. pastoris, as is the case in other 
eukaryotic systems, is Asn–Xaa–Ser/Thr [Yan BX, et al.,  1999]. The 
glycosylation is more readily achieved if the sequon is Asn–Xaa–Thr rather than 
Asn–Xaa–Ser. Bause and co-workers [Doyon Y, et al.,  2002] have shown that 
there is a 10- fold decrease in Km for the glycosyltransferase to hexapeptides with 
the sequence Asn–Xaa–Ser, which accounts for the reduced efficiency of 
glycosylation observed at this site [Doyon Y, et al.,  2002]. The finding that 
carboxypeptidase Y had 70% sequon glycosylation if the sequon was Asn– Xaa–
Thr and only 25% glycosylated if the sequon is Asn–Xaa–Ser further validated 
this observation [Holst B, et al.,  1996]. 
 The disposition of the sequon in the tertiary structure of the protein is 
important for glycosylation. There is a competition between folding and 
glycosylation in the ER. Upon translation the protein begins to fold and if the 
sequon is buried in the core of the protein, the glycosylation machinery may not 
have enough time to glycosylate the sequon before it is hidden [Shelikoff M., et 
al., 1996]. The sequon itself may not be occupied, even when it is on the surface 
of the protein if the sequon residues are involved in strong hydrogen-bonding or 
have nearby disulphide bonds [Holst B, et al., 1996; Simons JF, et al., 1995; 
Doyon Y, et al., 2002]. As glycosylation is an integral component of the secretory 
pathway, alterations to the protein that result in its slower exit from the ER will 
also promote more extensive glycosylation [Holst B, et al.,  1996]. When two 
tandem sequon sites occur in the primary sequence then hyper-glycosylation may 
occur whilst three tandem sites will result in complete hyper-glycosylation. It is 
further been suggested by various investigators that . . . Asn–Asn–Thr–Thr . . . is 
the sequon for hyper-glycosylation [Bretthauer RK and Castellino FJ., 1999]. The 
location of the sequon in relation to the C-terminus is often a determining factor 
for the extent of glycosylation. Sequons that are located close to the amino-
terminus are exposed to the glycosylation machinery for longer than those that are 
close to the C-terminus [Tschopp JF, et al., 1987; Shelikoff M., et al., 1996]. The 
occupancy of some sequons may alter the rate of glycosylation of other sequons in 
the protein, while the presence of a surface accessible sequon does not guarantee 
occupancy.  
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1.3.1.4.2.15.1 Thermostability 
 The thermostability of some proteins has shown improvement upon 
glycosylation compared with the de-glycosylated counterpart [Tull D., et al., 
2001; Wang P, et al., 2000;Yoshimasu MA, et al. 2002; Daly R. and Hearn 
MTW., 2004]. Glycosylation can also improve stability of proteins that are not 
normally glycosylated in their native state [Olsen O, and Thomsen KK. 1991; 
Minning S, et al., 2001]. For this reason it is possible also to add glycosylation 
sites to improve the recombinant protein termostability [Jiang ST., et al., 2002; 
Boraston AB., et al., 2001]. The position of the oligosaccharide in the protein 
structure may therefore be more important in thermostability than the amount or 
length of the group [Olsen O. and Thomsen KK., 1991]. The increased 
thermostability observed for many proteins due to glycosylation can in many 
cases be attributed to the oligosaccharides contribution to the overall proteins 
structural stability [Olden K., et al., 1985]. Also, glycosylation has been shown in 
many cases to help prevent proteolysis [Yan BX., et al., 1999; Pratap J., et al., 
2000; Wang P., et al., 2000]. The stability against proteolytic attack is probably 
due to the steric effects that the oligosaccharide poses to prevent the protease from 
the protein surface. 
 The post-translational steps involved in folding and glycosylation are 
therefore not equivalent in yeast compared with higher eukaryotes [Sadhukhan R., 
et al., 1996].  
 
1.3.1.4.2.15.2 O-linked glycosylation 
 O-linked glycosylation occurs both in mammals and yeast but may occur 
at different recognition sites [Jenkins N., et al., 1996]. The oligosaccharides are 
added to the hydroxyl groups of serine or threonine residues in a protein [Li PZ., 
et al., 2001; Bretthauer RK., et al., 1999], and occur mainly in the Golgi apparatus 
[Dennis JW., et al., 1999]. Mammalian O-linked glycosylation is composed of N-
acetylgalactosamine, galactose and sialic acid [Cregg JM. and Higgins DR., 
1995]. In yeast, such as S. cerevisiae, the O-linked oligosaccharides usually 
comprise one to five mannose residues linked α-1,2 in arrangement [Duman JG., 
et al., 1998]. Although there is no definitive consensus sequon for O-linked 
glycosylation the probability of O-linked glycosylation is enhanced when there is 
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an unusual abundance of serine/threonine [Orlean P., et al., 1991] or when there 
are proline residues near the serine/threonine [Herscovics A. and Orlean P., 1993]. 
O-linked glycosylation is observed particularly in glycoproteins that are involved 
in the yeast mating systems [Herscovics A. and Orlean P., 1993]. 
 
1.3.1.4.2.15.3 Immunogenicity 
 Although yeast expression systems such as S. cerevisiae and P. pastoris 
have the benefits of eukaryotic folding pathways, the glycosylation pattern is 
different to humans and other mammalian systems. This may or may not be a 
problem depending on the target protein and the applications in which it is used. 
For instance, certain carbohydrate groups are antigenic and Food and Drug 
Administration (FDA) now require full carbohydrate characterization to be 
conducted if it is has pharmaceutical applications [Jenkins N., et al., 1996; Liu 
DTY., 1992] as glycosylation may change the function and characteristics of the 
recombinant protein [Eckart MR. and Bussineau CM., 1996]. Yeast expression 
systems, especially S. cerevisiae, hyperglycosylate with high mannose-type 
oligosaccharides and hence the recombinant protein can be recognized by 
mannose receptors when injected into mammalian species [Eckart MR. and 
Bussineau CM., 1996; Cregg JM., et al., 1993; Cregg JM, Higgins DR. 1995]. S. 
cerevisiae glycosylation has terminal α-1,3 linked mannose residues and it is this 
residue that is thought to be antigenic. P. pastoris does not have this terminal link 
[Cregg JM., et al., 1993; Scorer CA., et al., 1993] as the P. pastoris α-1,3 
mannosyltransferase activity is undetectable [Cregg JM, Higgins DR. 1995]; 
however, as it is still non-human glycosylation, it still may cause adverse immune 
responses [Eckart MR. and Bussineau CM., 1996; Cregg JM., et al., 1993; Dennis 
JW., et al., 1999; Lis H. and Sharon N., 1993; Goochee CF., et al., 1991]. 
Glycosylation may therefore have effects on the protein clearance rate [Jenkins 
N., et al., 1996; Tsujikawa M., et al., 1996; Khandekar SS., et al., 2001] . 
 
1.3.1.4.2.15.4 Culture conditions to prevent glycosylation  
 To reduce the extent of glycosylation for a particular recombinant protein, 
the host cells (yeast or mammalian) can be cultured in the presence of 
tunicamycin [Boraston AB., et al., 2001; Elbein AD., 1984]. Tunicamycin is a 
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sugar analogue that mimics the structure of UDP–GlcNAc and, as it is not 
incorporated into an oligosaccharide, tunicamycin is a competitive inhibitor of 
UDP–GlcNAc dolichol P-GlcNAc transferase [Villatte F., et al., 2001]. 
Unglycosylated expression can also be achieved by expressing in the presence of 
N-benzoyl–Asn–Leu–Thr–N-methylamide where it competes with expressed 
protein sequons for Asn-linked glycosylation machinery [Huylebroek D., et al., 
1990]. Other alternatives to prevent or reduce the amount of glycosylation are to 
use mutant expression cells, which lack the genes that encode some of the 
glycosylation machinery.  
 Other alternatives that result in complete de-glycosylation is removal of 
the sequon by site directed mutagenesis (SDM) or by enzymatically or chemically 
de-glycosylating the protein post-expression. Enzymes, such as peptide-N-
glycosidase F or endoglycosidase H, can accomplish enzymatic de-glycosylation. 
The reaction conditions may depend on the glycoprotein in question and choices 
of whether to denature the protein prior to de-glycosylation, which will require 
refolding, or whether to de-glycosylate the native protein. If the native protein is 
to be de-glycosylated considerations such as the reaction incubation time required 
to de-glycosylate the protein are important, as not all proteins are stable for long 
periods of time at the temperatures required by the de-glycosylation enzyme. If 
the protein is not stable, then compensations are required in the amount of enzyme 
needed in order to de-glycosylate the protein completely. Native protein de-
glycosylation reactions are also less efficient than denatured proteins as the 
protein itself may sterically hinder the cleavage site so even stable proteins may 
require further optimization. SDM can be used to alter a sequon so that 
glycosylation is completely inhibited. If this is done, the protein functionality 
needs to be re-assessed to ensure that the mutation has not negatively affected 
activity and structure. SDM of the glycosylation sequon was assessed for CD154 
protein where the Asn240 was mutated to Ala [Khandekar SS, et al., 2001]. If 
SDM is chosen, then prior analysis of the sequon in relation to the tertiary 
structure needs to be determined because the position of the sequon may be such 
that it is not occupied anyway, as it could be buried in the core of the protein, or 
the Asn may be involved in H-bonding. If this is the case, SDM is not required 
and may result in disrupting the protein structure. Deglycosylation of proteins 
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may also be required in order to obtain their crystal structures. Glycoproteins are 
typically more difficult to crystallize; however complete de-glycosylation may not 
be possible due to its effects on stability and activity [Bretthauer RK. and 
Castellino FJ., 1999]. Alternatives such as treatment of the glycoprotein with 
Endo H (rather than PNGase F), which leaves the GlcNAc, may help to stabilize 
the protein [Curvers S, et al., 2001]. 
 
1.3.1.4.2.16 Immunotoxins produced with Pichia pastoris expression system 
 In the table 1.12 the Immunotoxins produced in Pichia pastoris are 
summarized. 
 
Immunotoxins Description Reference 
ATF-SAP Amino-terminal fragment of human 
urokinase (ATF) fused to the plant 
ribosome-inactivating protein saporin 
 
Lombardi A., et al., 
2010 
A-dmDT390-bisFv(UCHT1) Bivalent anti-human T cell variable 
fragments fused to the truncated DT C-
terminus 
 
Woo JH, et al., 2008 
A-dmDT390-bisFv(G(4)S) Bivalent anti-human T cell variable 
fragments fused to the truncated DT C-
terminus 
Woo JH, et al., 2004 
Liu YY, et al., 2003 
Woo JH, et al., 2002 
 
DT390biscFv(C207) Diabody anti-monkey CD3 fusing to the 
truncated DT C-terminus 
 
Kim GB, et al., 2007 
scFvC6.5-
syncyt2Aa1(mychis(6)) 
scFv anti p185(HER-2) cell surface 
glycoprotein fused to the toxin from the 
bacterium Bacillus thuringensis 
Gurkan C and Ellar DJ, 
Aug. 2003 
Gurkan C. and  Ellar 
DJ, May. 2003 
Table 1.12: Immunotoxins produce in Pichia pastoris. 
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Aim’s work 
 
 E. coli is the host cell most frequently used for recombinant proteins 
production. However, this expression system has several disadvantages especially 
for the production of therapeutic proteins. For application purposes (e.g. 
therapeutic protocols) it is often needed to obtain high amounts of heterologous 
proteins, with rapid purification steps. The yeast P. pastoris allows the production 
of high amounts of recombinant proteins secreted in a protein-poor medium that 
makes the purification steps easy and quick. For these reasons I analysed the 
ability of P. pastoris to produce macromolecular drugs such as Immunotoxins. 
IL4(38-37)PE40 is a known and widely described Immunotoxin. 
 To produce this Immunotoxin in P. pastoris I followed these steps: 
- production of IL4(38-37)PE40 in E. coli; 
- production of IL4(38-37)PE40 in P. pastoris; 
- IL4(38-37)PE40 gene optimization with the codon usage of P. pastoris 
(IL4(38-37)PE40-opti);  
- comparison between IL4(38-37)PE40 and IL4(38-37)PE40-opti 
production; 
- optimization of several induction conditions to improve the yield and 
to decrease the degradation level of recombinant protein; 
- the produced proteins were preliminarily analyzed, with particular 
attention to the degradation phenomena taking place during culture and 
limiting the yield of the desired proteins. 
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2. MATERIALS AND METHODS 
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2.1 GENERAL MOLECULAR BIOLOGY AND BIOCHEMICAL 
TECNIQUES 
 
2.1.1 PCR amplification of specific DNA fragments 
The amplification of DNA fragments by polymerase-chain-reaction (PCR) 
was customized in order to fit the conditions required by specific templates and 
enzymes used in the reactions. All reactions were carried out using a GeneAmp 
PCR system 9700 thermocycler (Applied Biosystems). 
 
2.1.1.1 Site-specific mutagenesis 
To remove a restriction enzyme cleavage site or to change an amino acid 
codon the QuikChange® Site-Directed Mutagenesis Kit (Stratagene) was utilized 
following the data sheet instructions. 
 
 
2.1.2 Colony-PCR screening 
For a rapid screening of E. coli colonies obtained after transformation with the 
ligation reaction, a PCR is performed directly on bacterial cells. Using a sterile 
tip, cells from a single colony are picked from the bacterial medium-agar plate 
and dissolved in 10 µl sterile, deionized water in a PCR-tube; the same tip is 
dipped in 50-100 µl of bacterial medium broth with appropriate antibiotics in a 96 
wells plate, so that the positive bacterial clones can be recovered at the end of the 
screening. To each PCR tube are then added 15 μl of a concentrated reaction mix 
with: 2.5 µl of 10X reaction buffer (Fermentas), dNTPs mix (0.2 mM of each 
dNTP, Applied Biosystems), forward and reverse primers (10 pmoles each), 1 unit 
of Taq DNA polymerase (Fermentas). If necessary, also 5% DMSO is included. 
Cycling programme:    
94°C 5 min  
94°C 50 sec  
55°C 50 sec 35 cicli 
72°C 1 min 30 sec  
72°C 7 min  
4°C ∞   
 
The PCR reactions are analysed by agarose-gel electrophoresis and staining 
with ethidium bromide. Amplificates of the expected size signify recombinant 
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clones, that can be recovered from the small LB cultures and propagated for 
extraction of plasmid DNA. 
 
2.1.3 Plasmid DNA extraction from E. coli cultures 
Single colonies picked from LB-agar plates (or from small LB cultures for 
colony-PCR screening) re-inoculated in 5 ml for small-scale preparations 
(miniprep), or in 50 ml for medium-scale preparations (midiprep) of LB broth 
additioned with the appropriate antibiotics (100 µg/ml Amp or 25 µg/ml Zeocin);  
the culture is grown O.N. at 37 °C with shaking (250 rpm) and cells are recovered 
by centrifugation (5 min, 10000 rpm at RT in minifuge for mini-preps; 10 min, 
4000 xg at RT for midipreps) and the bacterial pellet is processed using the 
Wizard Plus SV Minipreps DNA Purification System (Promega) for mini-preps 
and the PureLink HiPure Plasmid filter Purification kit (Invitrogen) for midi-
preps, according to instructions provided by the manufacturers. Purity and 
concentration of plasmid DNA are assessed by agarose gel electrophoresis and by 
spectrophotometric absorbance at 280 nm. 
 
2.1.4 DNA digestion with restriction enzymes 
Enzymatic digestion of plasmid DNA was performed according to the 
indications provided by manufacturers. Typically, in each reaction 5-10 units of 
enzyme are used to cut 1 µg of DNA. Reactions are usually incubated for 1 hour 
at the recommended temperature.  
 
 Manufacturer Stock concentration 
XhoI New England Biolab 10 U/µl 
XbaI New England Biolab 10 U/µl 
PmeI New England Biolab 10 U/µl 
NcoI Roche 10 U/µl 
EcoRI New England Biolab 10 U/µl 
HindIII New England Biolab 10 U/µl 
SfiI Roche 10 U/µl 
NotI Roche 10 U/µl 
Table 2.1. List of restriction enzymes. 
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2.1.5 Ligation 
Vectors and inserts for the preparation of all constructs were purified after 
agarose gel electrophoresis using the QIAEX II Gel Extraction kit (QIAGEN), and 
eventually ligated with T4 DNA ligase (Invitrogen). A 20 µl reaction is prepared 
in a clean eppendorf tube containing 100 ng of vector, a five or seven-fold molar 
excess of insert fragment, the provided ligation buffer and 2.5 units of enzyme. 
The ligation is incubated 2 hours at RT and ON at 4°C, after which 5 µl are used 
for the transformation of CaCl2- competent E. coli cells (strain XL1blue). 
 
2.1.6 DNA sequencing 
The correctness of all plasmid constructs is confirmed by sequencing (BMR-
Genomics, Padova, Italy). Analysis of the DNA sequences was performed using 
Vector NTI Advance 10 software (Invitrogen). 
 
2.1.7 Western blotting analysis 
2.1.7.1 Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) 
The electrophoretic separation of proteins from crude extracts, supernatants or 
purified samples was performed according to standard laboratory procedures, 
using mini-gels with 5% acrylamide stacking and 10% separating slabs. 
Electrophoresis was conducted in Tris-Glycine buffer (25 mM Tris, 190 mM 
Glycine, 0,1% SDS), using the Mini-Protean III Cell apparatus (BioRad) under 
reducing conditions (samples were denatured by boiling for 5 minutes in Sample 
Loading buffer (4X) - 0.32 M TrisHCl pH 6.8, 6% SDS, 50% glycerol, 2% β-
mercaptoethanol, 0.006 g Bromophenol blue- ). A tension of 100 V was applied 
until the blue line (given by the bromophenol in the Sample Loading buffer) came 
out of the running gel. A protein size standard (PageRuler Prestained Protein 
Ladder Plus, Fermentas) was also loaded for molecular weight determination of 
the analyzed proteins. 
 
2.1.8 Immunoblotting 
2.1.8.1 Transfer of proteins on PVDF membrane 
Proteins separated by SDS-PAGE were blotted on polyvinylidene fluoride 
(PVDF) membranes (Immobilon–P, Millipore) following the manufacturer’s 
indications. The polyacrilamide gel and PVDF membrane were assembled as a 
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sandwich in a Mini Trans-Blot Electrophoretic Transfer Cell (BioRad) according 
to the manufacturer’s instructions. For proteins to be transferred, a tension of  100 
V was applied for 1 hour. 
 
2.1.8.2 Immunodetection 
After protein transfer, the PVDF membrane was incubated 30 min at 37 °C in 
blocking solution 5% w/v powder milk in 0.01% Tween-20, PBS under stirring. 
After blocking, the membrane was first incubated o.n. at 4°C with a primary 
antibody recognizing a specific epitope of the protein analysed. This was followed 
by incubation 45 min at r.t. with a horseradish peroxidase (HRP)-conjugated 
secondary antibody that interacts with the Fc portion of the primary antibody. 
Both antibodies were diluted in blocking solution and the membrane was rinsed 
twice for 5 minutes in 0.01 % Tween-20, PBS and twice for 5 minutes in PBS 
after each incubation. Bands corresponding to the immunoselected polypeptides 
were finally detected by a chemiluminescent reaction using the ECL Western 
Blotting Substrate (Pierce), according to the manufacturer’s instructions, and 
visualized by development of a photographic plate (Hyperfilm MP High 
performance autoradiography film - Amersham Biosciences).  
 
Antibody   Dilution Manufacturer  
Primary Anti-PE Rabbit polyclonal Ab 1:20000 SIGMA  
 Anti-c-myc Mouse mAb 1:2000 SIGMA  
 Anti-His6 Mouse mAb 1:1000 Ge-Healthcare 
 Anti-IL4R Mouse mAb 1:1000 Santa Cruz 
 Anti-IL4 Mouse mAb 1:500 Santa Cruz 
Secondary Anti-mouse-HRP Polyclonal Ab (HRP 
conj) 1:10000 DakoCytomation  
 
Anti-rabbit-
HRP 
Polyclonal Ab (HRP 
conj) 1:10000 SIGMA (A0545) 
Table 2.3: Antibodies employed for the Western blotting analysis. 
 
2.1.9 Protein quantification 
2.1.9.1 Spectrophotometric quantification 
Absorbance at 280 nm (Smart Spec 3000, Biorad) provides the quantification 
of purified proteins. One absorbance unit corresponds to 1.08 mg/ml of IL4PE40; 
it was determined using the software Vector NTI Advance 10.  
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2.1.9.2 Coomassie staining 
A further means of protein quantification is provided by Coomassie staining 
after electrophoresis of purified proteins. SDS-PAGE gels are stirred for 20 min at 
r.t. in Coomassie solution, followed by decoloration in Destaining solution until 
bands are clearly visible. Amounts of proteins in  discrete bands are assessed by 
comparison with known quantities of bovine serum albumin (BSA, Sigma). 
 
 
2.1.9.3 Bicincininic Acid Assay – BCA - (SIGMA) 
Proteins quantification through the BCA assay was performed according to the 
indications provided by the manufacturers. 
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2.2 RECOMBINANT IMMUNOTOXIN PRODUCTION AND 
PURIFICATION BY E. coli SYSTEM. 
 
2.2.1 Bacterial strains and culture media 
The E. coli Xl1blue strain (Stratagene) was used as the host for DNA 
manipulations and grown in LB medium (1% tryptone, 0.5% yeast extract, 1% 
NaCl; 2% agar in plates; 100 µg/ml ampicillin for the selection of plasmids). LB 
broth is used for transformation with Xl1-Blue cells. For  growth, maintenance 
and protein expression with BL21(DE3)pLysS E. coli strains is used whether LB 
medium or 2XYT medium (1,6% tryptone, 1% yeast extract, 0,5% NaCl; 2% agar 
in plates; 100 µg/ml ampicillin for the selection of plasmids). 
 
2.2.2 Bacterial expression plasmid 
For the molecular cloning of DNA sequences the vector pET20b(+) 
(Novagen) was used. 
pET20b(+) is an expression vector of 3716 bp carrying a multi-cloning site 
between T7 promoter and T7 terminator sequences. 
Vector pET20b(+), by virtue of the pelB signal peptide, promotes the 
periplasmic sorting of the protein coded by the inserted sequence, also providing a 
poly-histidine carboxy-terminal tag. pET 20b(+) carries an ampicillin resistance 
and the pBR322 origin of replication 
 
2.2.3 Cloning and construction of bacterial expression vectors 
The cDNA encoding the IL4(38-37) permuted form was kindly provided by 
dr. Robert J. Kreitman, National Institutes of Health (Bethesda, MD) in the 
pRKL4389 plasmid. The PE40 sequence was already available in our laboratory. 
The gene coding for the Immunotoxin IL4PE40 was insert in the pET20b 
plasmid, in frame with the pelB sequence at the 5’, and the poly-histidine tag at 
the 3’.  
 
2.2.4 Expression and purification of recombinant proteins 
E. coli BL21(DE3)pLysS cells were transformed with the plasmid of interest 
through heat-shock, cultured in 1 liter of selected medium with 100 µg/ml of 
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ampicillin. The cells were grown up to A600= 0.7, and induced with 1 mM IPTG 
for 3 h or o.n. The cells were harvested by centrifugation at 3000xg for 5 min. The 
cell pellet was kept at – 80°C before protein purification. 
 
2.2.5 Cell growth conditions and optimization protein induction  
To determine the optimal conditions that would result in a higher yield of the 
recombinant proteins, the inductions were performed under different conditions: 
- medium of induction: LB medium or 2XYT medium 
- time of induction: 3-4 h or o.n. 
 
2.2.6 Subcellular localization of recombinant proteins by SDS-PAGE analysis 
To determine the intracellular localization of recombinant proteins, the 
induced pellets were fractionated to extract the periplasmic fraction, the 
citoplasmic soluble fraction and the citoplasmic insoluble fraction.  
 The total pellet was kept as a control of total protein. Before harvesting the 
cells, 1 ml of culture was sampled and centrifuge at 10000×g for 1 min to remove 
the supernatant. Resuspend the pellet by mixing in 100 µl of PBS, giving a 
concentration factor of 10X. Add the 4X Sample Loading buffer for SDS-PAGE 
analysis. 
When using vectors with pelB signal sequences, target proteins may be 
directed to the periplasmic space. The leader is necessary, but not sufficient for 
export into the periplasm. To extract the periplasmic fraction centrifuge 40 ml of 
the culture at 10,000×g for 10 min at 4°C. Resuspend the cell pellet in 30 ml of 30 
mM Tris-HCl, 20% sucrose, pH 8. Then add 60 µl 0.5 M EDTA pH 8 (final 
concentration 1 mM), and incubate at room temperature for 10 min on the  
magnetic stir bar. Collect the cells by centrifugation at 4°C for 10 min at 10,000×g 
and remove all of the supernatant. Thoroughly resuspend the pellet in 30 ml of 
ice-cold 5 mM MgSO4 and stir the cell suspension slowly for 10 min on ice. 
During this step, the periplasmic proteins were released in the solution buffer. 
Centrifuge at 4°C for 10 min at 10,000×g to pellet the shocked cells. Transfer the 
supernatant (periplasmic fraction) into a clean tube. Maintain the cell pellet on ice. 
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Concentrate 1 ml of the periplasmic fraction by TCA precipitation and 
resuspend the pellet with a concentration factor of 10X. Add the 4X Sample 
Loading buffer for SDS-PAGE analysis. 
To isolate the soluble cytoplasmic fraction the mechanical disruption protocol 
was used. Through sonication the pellet was resuspend in 4 ml of cold 20 mM 
Tris-HCl, pH 7.5 to give a concentration factor of 10X. One µg/ml of lysozime 
was added and the mix was incubated 30 min at room temperature; the protease 
inhibitors (Complete – Roche- and 1mM PMSF) were added and the sample was 
sonicated (15 sec for 3 times). The lysate was centrifuged for 10 min at 14,000×g 
to separate the soluble (supernatant) from the insoluble (pellet) fractions.  
The insoluble cytoplasmic fraction may consist of cell debris and aggregated 
protein known as inclusion bodies. The insoluble pellet was washed two times 
with 20 mM TrisHCl, pH 7.5. The solution was centrifuged at 10000xg per 5 min 
and the supernatant was removed. The pellet was resuspend in 1.5 ml 1% SDS 
with heating and vigorous mixing. One hundred µl of sample were removed and 
than combined with 4X Sample Loading buffer. 
  
2.2.7 Inclusion bodies extraction through refolding and Immunotoxin 
purification by IMAC (Ni Sepharose 6 Fast Flow - GE Healthcare) 
Inclusion bodies extraction and refolding - To purify the recombinant 
proteins from the inclusion bodies, the protocol of previous paragraph was 
followed for the isolation of the soluble cytoplasmic fraction. from 1 liter of E. 
coli culture 
The pellet containing inclusion bodies was washed with 20 ml of 100 mM 
TrisHCl, 50 mM glycine. The pellet was weighed and resuspended with 100 mM 
TrisHCl, 50 mM glycine, 8 M urea to bring the inclusion bodies at the 
concentration of 20 mg/ml and incubated at r.t. for 60 min with stirring. The 
sample was centrifuged at 20000xg for 20 min. The supernatant was than 
transferred into a clean becker and 5 mM GSH and 0,5 mM GSSG were added. 
The mixture was incubate at 4°C o.n. with stirring. 
The recombinant proteins were refolded through dialysis in buffers containing 
0.1 M Tris, 0.4 M L-Arginine, 1 mM EDTA, 0.2 mM PMSF with decreasing 
concentration of urea: from 4M to 0M. 
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The last dialysis is carried out in the Ni-bind buffer utilized to load the refold 
proteins at the IMAC chromatography (50 mM Na2HPO4, 0.5 M NaCl).  
IMAC protein purification –  The “Ni Sepharose 6 Fast Flow resin” is highly 
stable and compatible with a wide range of common additives. This helps to 
maintain biological activity and increase product yield, while at the same time 
greatly expanding the range of suitable operating conditions. 
 The refolded sample was ultrafiltered (0.45 µm) and incubated 1 h at r.t. with 
the Ni-Sepharose 6 Fast Flow resin. 
The Ni-bind buffer with 20 mM imidazole was used to wash the resin (10 ml 
at a time to reach an OD280 ≤ 0,05). The tagged proteins were eluted with Ni-bind 
buffer with 500 mM imidazole; the elution was followed by spectrometric 
measurement at A280. The fractions were analyzed by SDS-PAGE. 
 
2.2.7 Immunotoxin purification by IMAC and refolding of inclusion bodies 
IMAC protein purification - To purify the recombinant proteins was used an 
alternative protocol, where the proteins were purified and then refolded. Six molar 
Guanidine-HCl was used to solubilise the inclusion bodies. Since under 
denaturing conditions the His6-tag is completely exposed, it could facilitate the 
binding to the Ni-resin.  
One liter of induced culture was centrifuged at 10000xg for 5 min at 4°C. The 
pellet was resuspended  in 100 ml of Lysis Buffer 1 (50 mM Na2HPO4, 0.5 M 
NaCl, pH 7.5) and 1 mM PMSF, 50 µg/ml DNasi and 10 mM MgCl2 were added. 
The mixture was incubated 10 min at 4°C, then 1% Triton X-100 and 0.1 mg/ml 
of lisozyme were added. The sample was sonicated on ice 3 times for 20 sec and  
then centrifuged at 13000xg for 20 min at 4°C. The pellet was resuspended with 
50 ml of Lysis Buffer 2 (50 mM Na2HPO4, 0.5 M NaCl, 6 M Guanidine-HCl) 
with PMSF, Triton X-100 and lisozyme. The sample was incubated 1 h at 30°C 
under agitation then centrifuged at 13000xg to 20 min at 4°C. The supernatant 
was collected and incubated  with the Ni-resin for 1 h at r.t. with agitation. The 
resin was packaged in the column and washed with 10 ml of Wash buffer (Lysis 
buffer 2 with 20 mM imidazole, pH 7.5), to reach an OD280 ≤ 0,05. The 
recombinant proteins were eluted with the Elution buffer (Lysis buffer 2 with 500 
mM imidazole, pH 7.5); the elution was followed by by spectrometric 
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measurement at A280. The fractions were analyzed by SDS-PAGE. Before loading 
the fractions in the poli-acrilamide gel, the samples containing Guanidine-HCl 
must be precipitated with 5% TCA to eliminated the denaturing agent. 
Refolding - The fractions containing the recombinant protein were collected. 
The total sample was diluted 4-6 times with Lysis buffer 1 without Guanidine-
HCl, to obtain a solution of 1M Guanidine-HCl. Add the Lysis buffer little by 
little, keeping the protein solution in the stirrer at 4°C. Centrifuge the sample to 
eliminate the incidental precipitate before dialysis start. 
The recombinant proteins were refolded through dialysis in buffers containing 
0,5 M NaCl, 50 mM TrisHCl, 0.4 M L-Arginine, 0.1 mM PMSF with decreasing 
concentration of Guanidine-HCl: from 0.5M to 0M. 
The sample was concentrate with Amicon Ultra (cut-off 10 kDa - 
MILLIPORE) until to reach 0.5-1 mg/ml of protein  concentration. 
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2.3 PRODUCTION OF RECOMBINANT IMMUNOTOXINS BY 
P. pastoris SYSTEM AND PURIFICATION 
 
2.3.1 Yeast strains and culture media 
The E. coli Xl1blue strain (Stratagene) was used as the host for DNA 
manipulations and was grown in low salt LB medium (1% tryptone, 0.5% yeast 
extract, 0.5% NaCl; 2% agar in plates; 25 µg/ml zeocin for the selection of 
plasmids). The P. pastoris GS115 (his4) and SMD1168 (his4, pep4) strains 
(Invitrogen) were used for the recombinant proteins production. 
P. pastoris was grown in YPD medium (1% yeast extract, 2% peptone and 2% 
dextrose; 2% agar in plates; 50 µg/ml zeocin for selection of transformants) and 
BMGY medium (1% yeast extract, 2% peptone, 100 mM potassium phosphate, 
pH 6.0, 1.34% yeast nitrogen base without amino acids, 4*10-5% biotin, 1% 
glycerol) for growth. BMMY medium (1% yeast extract, 2% peptone, 100 mM 
potassium phosphate, pH 6.0, 1.34% yeast nitrogen base without amino acids, 
4*10-5% biotin, 0.5% methanol) was used as induction medium for production of 
recombinant proteins. 
 
2.3.2 Yeast expression plasmids 
pPICZα A, B, and C are 3.6 kb vectors were used to express and secrete 
recombinant proteins in Pichia pastoris. Recombinant proteins are expressed as 
fusions to an N-terminal peptide encoding the Saccharomyces cerevisiae α-factor 
secretion signal. The vector allows high-level, methanol inducible expression of 
the gene of interest in P. pastoris. 
pPICZα contains the following elements: 
• 5′ fragment containing the AOX1 promoter for tightly regulated, methanol-
induced expression of the gene of interest (Ellis et al., 1985; Koutz et al., 
1989; Tschopp et  al., 1987a); 
• α-factor secretion signal for directing secreted expression of the recombinant 
protein;  
• Zeocin resistance gene for selection in both E. coli and Pichia (Baron et al., 
1992; Drocourt et al., 1990); 
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• C-terminal peptide containing the c-myc epitope and a polyhistidine (6xHis) 
tag for detection and purification of a recombinant fusion protein (if 
desired);  
• Three reading frames to facilitate in-frame cloning with the C-terminal 
peptide. 
 
2.3.3 Cloning and construction of yeast expression vectors 
The IL4PE40 gene used to produce the Immunotoxin in E. coli, was cloned in 
the pPICZα expression vector. The gene amplification was conducted with Pfu 
Ultra HF DNA Polymerase (2,5 U/µl – Stratagene). Amplified fragment was 
cloned in frame with the alpha-factor signal sequence. As described in the 
paragraph 1.3.1.4.2.12 of Introduction, to prevent the generation of a recombinant 
Immunotoxin with Glu-Ala aminoterminal extensions, the IL4PE40 gene was 
cloned usng the XhoI restriction site, and the Kex2 cleavage site was rebuilt 
through the forward PCR primer (Fig 2.1). For this reason the XhoI site contained 
in the IL4PE40 Immunotoxin sequence was removed by QuikChange® Site-
Directed Mutagenesis Kit. 
His6-tag TGA
ATG
α-factor segnal sequence
Ste13
segnal cleavage
Kex2
segnal cleavage
XhoI
MCS
XbaI
C-myc His6-tag TGA
A
ATG
Kex2
segnal cleavage
XhoI XbaI
C-myc His6-tag TGA
B
IL4PE40
Immunotoxin primer_forward:
5‘-GCA CTC GAG AAA AGA
C
IL4
-3‘
 
Fig. 2.1: A) Schematic diagram of pPICZα-cloning region. The Kex2 and Ste13 cleavage 
regions are evidenced. B) Primer forward used to clone the Immunotoxins in the pPICZα-
vector. Highlighted: in black bold type the XhoI cleavage site, in red the codon coding from Lys-
Arg (Kex2 cleavage site), in green the Immunotoxin start. C) Schematic diagram of IL4PE40 
cloning.  
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2.3.3 Sequence optimization 
To increase the yield of IL4PE40 Immunotoxin we have optimized the 
sequence with the codon usage of P. pastoris. A codon-modified cDNA of the 
Immunotoxin was generated by de novo gene synthesis by GenScript Corporation, 
Piscataway, NJ, USA. 
 
2.3.4 Pichia pastoris transformation and screening of transformants 
expressing Immunotoxin 
From five to 10 µg of plasmid containing the Immunotoxin gene were 
linearized with PmeI and then electroporated into GS115 and/or SMD1168 strains 
utilizing 400Ω, 1,5 V, and 25 µF with a Bio-Rad GenePulser (Bio-Rad 
Laboratories). Transformants expressing zeocin as selectable markers were 
obtained by spreading onto the YPD agar selection plate. The colonies obtained 
were re-streaked on fresh antibiotic selection plates to obtain pure colonies. 
From 5 to 20 single colonies from each transformation experiment were 
grown in 5 ml of BMGY medium (1% yeast extract, 2% tripton, 100 mM 
potassium phosphate, pH 6.0, 1.34% Yeast nitrogen base, 4 x 10-5% biotin, 1% 
glycerol, 50 µg/ml zeocin) until culture reaches an OD600 = 2-6 (logaritmic phase 
growth). The cell pellet was resuspended in BMMY (1% yeast extract, 2% tripton, 
100 mM potassium phosphate, pH 6.0, 1.34% Yeast nitrogen base, 4 x 10-5% 
biotin, 0.5% methanol, 50 µg/ml zeocin) at 1 OD600. The methanol and the 
histidine were added every 24h. At the end of the induction period (48h or 72h) 
the culture medium were harvested by centrifugation and then subjected to 
Western blotting to check the Immunotoxin expression level. 
 
2.3.5 Optimization of the induction conditions 
To determine the optimal conditions that would result in a lower proteolysis 
and a higher yield of the IL4PE40 Immunotoxin, cultures were performed under 
different conditions: 
- induction time (0h–72h) 
- temperature of induction (20°C, 25°C, 30°C) 
- effect of cell density at the induction start (1 OD600 or 10 OD600)  
- presence of 1% glycerol during the induction;  
 94
- concentration of methanol added daily (0.25%, 0.5%, 1%); 
- medium pH (pH 5, pH 6, pH 7); 
- presence of 5 mM EDTA; 
- condition culture before induction (inoculum induction in logarithmic 
phase or at saturation phase); 
- Yeast strain (GS115 or SMD1168); 
- Presence of an antifoam additive. 
 
2.3.6 Expression in shake flask cultures  
Induction with the culture in the log phase 
For small scale induction a single colony was grown in 3-5 ml of BMGY 
medium o.n. to reach the log phase (2-6 OD600). The culture was centrifuged at 
1500xg for 5 min and the pellet was resuspended in 5 or 10 ml of BMMY 
medium. The small scale induction was performed to test the different optimized 
conditions. 
For large scale production, a single colony was grown in 5 ml of BMGY 
medium for 6-8 hours. The whole culture was then transferred in 500 ml of 
BMGY medium to reach the log phase of growth. The culture was centrifuged at 
1500xg for 5 min and the pellet was resuspended in BMMY medium (from 1 to 4 
liter) at the optimized OD600. The inductions were then conducted for 48h or 72h.  
Induction with the culture at saturation  
For small scale shake flask culture, a single colony was grown in 50 ml of 
YPD medium in a 250 ml flask for 2 days at 30 °C, resuspended in 30 ml of 
BMMY medium, and induced for 3 days with the addition of methanol (0,5%) 
every 24 h. 
For large-scale culture, 50 ml of YPD medium was inoculated with 1 ml of 
frozen stock and grown for two days to establish a seed culture. Fifteen ml of seed 
culture were used to inoculate 300 ml of YPD medium and the inoculated medium 
was cultivated for 2 days. The cell pellet was resuspended in 200 ml of BMMY 
medium and induced for 3 days by adding methanol (0,5%) every 24 h. 
 
In both cases, at the end of the induction period, the cells were removed by 
centrifugation for 15 min at 1600xg and 4°C and the supernatant was transferred 
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to new tubes and centrifuged again for 30 min at 3200xg and 4°C to remove cell 
debris. The protein containing supernatant was filtrated through a 0.45 µm syringe 
filter and stored at -20°C for further use. Five-hundred microliter of supernatant 
were precipitated with 10% TCA to analyze the protein production before 
proceeding to the purification step. 
The collected supernatants were precipitated with 60% saturation with 
ammonium sulphate and resuspended in binding buffer (20 mM sodium phophate 
pH 7.4, 1.5 M NaCl, 10% glycerol, 20 mM imidazole, 1mM DTT), then dialyzed 
overnight against binding buffer  to remove traces of ammonium sulphate. 
 
2.3.7 Protein purification by IMAC (Ni Sepharose 6 Fast Flow - GE 
Healthcare) 
The concentrated supernatant was centrifuged at 4°C, 20,000×g for 15 min 
and filtered through a 0.45 µm filter syringe and applied to the Ni Sepharose 6 
Fast Flow resin. The sample was incubated for 1h at RT with the resin. This mix 
was then loaded onto the column and the flow-through was collected. The resin 
was washed with the binding buffer to reach an OD280 ≤ 0.05 and the bound 
proteins were eluted with 500 mM imidazole dissolved in the binding buffer. The 
eluted proteins were detected by SDS-PAGE and Western blotting. The fractions 
containing the his6-tagged protein were collected, concentrated by ammonium 
sulphate precipitation and dialyzed against PBS (137mM NaCl, 2,7mM KCl, 
10mM sodium phosphate dibasic, 2 mM Potassium phosphate monobasic, pH 
7.4). The final sample was sterilized with spin-x (0.2 µm) and quantified by SDS-
PAGE and BCA protein Assay (Sigma). 
 
2.3.8 Study of the glycosylation of non optimized IL4PE40 Immunotoxin 
producted in P. pastoris 
The glycosylation sites were predicted by CBS Prediction Servers  
(www.cbs.dtu.dk/services/). 
The presence of N-linked glycosylations on the IL4PE40 Immunotoxin 
produced in P. pastoris was initially analysed by in vitro deglycosylation of the 
supernatant using glycosidases EndoH and PNGaseF (New England-Biolabs) 
according to the supplier’s instructions.  
 96
 
2.3.9 Native Pseudomonas exotoxin A (PE) cleavage test 
The native PE was incubated for 1h at 30°C under agitation with: PBS as a 
control, only BMMY induction medium that was not inoculated with GS115, or 
BMMY cell-free after 48h of induction of GS115 transformed with the empty 
vector (αA) or BMMY cell-free with 1 mM PMSF (proteases inhibitor) after 48 h 
of induction of αA.  
In a second cleavage test the native PE was incubated for 1 h at 30°C under 
agitation in αA BMMY with: 1 or 5 mM of EDTA or Complete EDTA-free1X 
(Roche).  
The different samples were analysed by Western blotting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 97
2.4 CELL CULTURE TECHNIQUES 
2.4.1 Cell lines and growth media 
→ LNCaP: prostate carcinoma (left supraclavicular lymph node 
metastasis) cell line 
→ PT45: pancretic carcinoma cell line 
→ PACA44: pancretic carcinoma cell line 
→ CF-PAC1: ductual adenocarcinoma (liver metastasis) from a patient 
with cystic fibrosis; 
→ U251: glioblastoma cell line 
 
All cell lines were grown in flasks at 37 °C, 5% CO2, using the following 
medium: RPMI 1640 medium (with 40 mg/l folic acid, 2 g/l NaHCO3) 
(Biochromag) supplemented with 10% Fetal Calf Serum (FCS), 2 mM L-
Glutamine and antibiotics (100 U/ml penicilline and 100 µg/ml streptomycine-
sulphate). 
All supplements were added into the medium after sterilization through 0.22 
µm filters. 
The PT45, PACA 44, CF-PAC1 and U251 cell lines were grown in 
monolayer. To subculture the adherent cell lines the medium was removed, and 
the cells were detached with 0,25% (w/v) Tripsin-0.53 mM EDTA solution 
(SIGMA). An appropriate aliquot of the cell suspension was mixed with the 
complete growth medium. 
The LNCaP and 293FT cell lines were cultured in monolayer on a film of 
Polilysine (SIGMA) and subcultured as described above for the other adherent 
cells. 
Cell stocks were stored in liquid nitrogen tank at a concentration of 1 or 2*106 
cells/ml RPMI medium with 20% FCS and 10% DMSO. 
 
2.4.2 Flow-cytometry analysis 
2.4.2.1 Expression of IL4R by cell lines 
 PT45, CF-PAC1, PACA44, U251 and LNCaP cell lines were grown in 
T75 flasks to reach 50%-80% confluence and harvested by centrifugation at 1500 
x g, 5 min , 4 °C. After counting with a hemacytometer, cells were resuspended in 
a blocking buffer (0.5% w/v BSA in PBS) to a concentration of  2*105 cells/ml; 1 
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ml of the suspension was dispensed in each flow-cytometry tube and centrifuged 
as before. Cells were resuspended in 100 µl with 0.2 µg of anti-IL4R (Santa Cruz) 
and incubated on ice for 1 hour. Two washing steps followed, each with 2 ml of  
blocking buffer. For the detection of bound anti-IL4R cells were stained with an 
anti-mouse IgG-FITC secondary antibody (goat polyclonal from Beckman 
Coulter, 1:200 diluted). The incubation was for 30 minutes on ice in 100 µl of 
blocking buffer, followed by two washing steps with 2 ml blocking buffer each. 
Background fluorescence was assessed by staining the cells with anti-mouse IgG-
FITC in the sample without the anti-IL4R. At the end of the staining, cells in each 
tube were resuspended in 0.5 ml blocking buffer and the mean fluorescence 
intensity (MFI) of each sample was determined using BD Facs Canto (BD 
Bioscience). 
 
2.4.2.2 Binding of IL4PE40 to cells 
 The binding of IL4PE40 was analysed using PT45, U251 (IL4R+) and 
LNCaP (IL4R-) cell lines. The preparation of the samples was as above. In this 
case the cells were incubated with the increasing amounts of the IL4PE40 
Immunotoxin and then with an anti-His6 secondary antibody (mouse mAb from 
GE-Healthcare, 1:200 diluted in binding buffer) and then with the anti-mouse 
IgG-FITC tertiary antibody. At the end the cells were resuspended in 0.5 ml 
blocking buffer and the mean fluorescence intensity (MFI) was determined using 
BD Facs Canto. 
 
2.4.3 Cell proliferation assay (XTT) 
 LNCaP, PT45 or U251 cells were dispensed in a 96-well plate (PT45 and 
U251: 5000 cells/well, LNCaP: 10000 cells/well) in 100 µl of RPMI medium. 
After 24 h different toxin or Immunotoxin dilutions were added to the cells and 
the culture was further incubated at 37°C for 72 h. 
 
Proteins tested PE40, and IL4PE40 from E. coli; 
PE (SIGMA) 
 
Concentrations tested 
 
From 10-6M to 10-10M 
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A mix with 1 volume of 1 mg/ml XTT and 3 volume of RPMI without phenol 
red was prepared. The prostate-specific antigen solution(PSA 1000X)  was then 
added at the 1X final concentration. One hundred microliter of the mix were 
dispensed in each well. The absorption was measured at 450 nm after 20 min of 
incubation at 37°C. 
 
Table 2.3: Description of PE40-based constructs  
Construct Description Cloning 
 plasmid 
Cloning  
restriction sites 
pET20bIL4PE40 
XhoI mut 
Removal of XhoI 
digestion site 
cointained within 
the Immunotoxin 
sequence 
- - 
pPICZαIL4PE his Immunotoxin with 
his6-tag derived 
from bacterial 
expression vector 
pPICZα XhoI- XbaI 
pPICZαIL4PE40 -
opti 
Immunotoxin with 
codon usage 
optimized for 
yeast 
pPICZα XhoI- XbaI 
pPICZαIL4PE40  
opti_mut1 
Optimized 
Immunotoxin with 
1 furin-like 
cleavage site 
mutated 
- - 
pPICZαIL4PE40  
opti_mut2 
Optimized 
Immunotoxin with 
2 furin-like 
cleavage sites 
mutated 
- - 
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3.1 Expression of IL4R in different cell lines  
 The expression of IL4R in several tumors was extensively described in 
literature [Puri, R. K., et al., 1993; Puri, R. K., et al., 1995; Puri, R. K., et al., 
1991; Obiri, N., et al., 1993; Obiri, N., et al., 1994; Hussain, S. R.,  et al., 1994; 
Hoon, S. R., et al., 1997; Toi, M., et al., 1992; Morisaki, T., et al., 1992; Puri, R. 
K., 1996; Kreitman, R. J., et al., 1994; Kawakami, K., et al., 2000; Puri, R. K., et 
al., 1996; Leland, P., et al., 2000; Gallizi, J. P., et al., 1989].  
 A commercial mAb anti-IL4R was used in different tumor cell lines: 
pancreatic tumor (LNCaP), prostate tumor (PT45, CF-PAC1 and PACA44) and 
gliobastoma (U251) to test the presence of IL4 receptor by flow-cytometry. The 
IL4R presence on U251 cell surface was previously verified by S.R. Husain 
[Husain S.R., et al., 1998], for this reason this cell line was selected as a positive 
control. As shown in fig. 3.1 the pancreatic cell lines display a mean fluorescent 
intensity (MFI) higher than U251 and LNCaP cell lines. The latter shows a very 
low MFI. For this reason the LNCaP cell line was used as a negative control for 
binding and cytotoxicity assays. 
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Fig. 3.1: Flow-cytometry in different tumor cell lines. The LNCaP (white), PT45, CF-PAC-1, 
PACA44 (yellow) and U251 (green) cell lines were analysed. For each cell line the upper box 
shows the fluorescence profiles obtained by staining 106 cells with 1µg of anti IL4R, followed by 
secondary anti-mouse IgG-FITC. In the graphic below the values of MFI are shown. 2*104 events 
were recorded for each sample. 
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3.2 Cloning, expression and characterization of IL4(38-37)PE40 
Immunotoxin obtained in  the bacteria 
 
3.2.1 Amplification and expression of IL4(38-37)PE40 
 The IL4(38-37) coding sequence was kindly provided  by dr. Kreitman 
(National Institutes of Health. Bethesda, MD), whereas the PE40 sequence, a 
truncated version of Pseudomonas exotoxin A, derives from a construct already 
available in our laboratory. 
 The nucleotide sequence coding for PE40 was fused to the 3’-end of the 
IL4(38-37), generating a chimeric Immunotoxin in the pET20b(+) vector (Fig. 3.2 
A). The C-terminal His6-tag was exploited for purification and analytical 
purposes. 
~1400 bp
MW      1         2 3        4        5        6       7          n. colony
MW     9     10    11    12     13     14    15 16            n . colony
B C
~1400 bp
~1400 bp
IL4(37-38) PE40
Symbols:
PelB leader sequence
His6
AlaSerGly2ProGlu linker
A
 
 
Fig. 3.2: A) The expression construct for IL4PE40 Immunotoxin; B) IL4PE40 amplified 
through PCR; C) Screening of the colonies after transformation of E. coli cells with the 
ligation reaction: The positive colonies were numbers 2, 14 and 15.  
 
 The small-scale expression of the IL4PE40 Immunotoxin in BL21(λDE3) 
pLysS E. coli yielded an induced  protein of approximately 60 kDa, as visualized 
by Coomassie staining and immunoblotting with three different antibodies (Fig. 
3.3), consistent with the expected size for a fusion between the IL4(38-37) (14 
kDa) and PE40 (40 kDa). 
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Figure 3.3 Immunotoxin expression in E. coli. First panel: Coomassie staining of an SDS-PAGE 
gel; Blotted membranes: probing with rabbit anti-PE serum (second panel), with mouse anti-his6 
antibody (third panel) and with mouse anti-IL4 antibody (last panel). Abbreviations: NI, bacterial 
pellet from 50 μl of non-induced culture; Ind, bacterial pellet from 50 μl of induced culture. 
Induction was carried out with 1 mM IPTG at 30 °C for 3 hours. 
 
 These preliminary induction data show that the Immunotoxin is  expressed 
at low amount, suggesting the possibility of periplasmic accumulation. But from 
figure 3.4 it appears that most of the Immunotoxin is recovered in the inclusion 
bodies. 
 
72 kDa
55 kDa
36 kDa
28 kDa
Tot
 pellet
periplasm
cytosol
Inclusion bodies
 
 To increase the yield of recombinant Immunotoxin, three induction 
variables were tested: the induction temperature, the time of induction and the 
culture medium. The best yield of  recombinant protein was obtained after a 3h 
induction at 30°C, and the medium that allowed the highest Immunotoxin 
production was the LB medium (data not shown). 
 
3.2.2 Immunotoxin extraction: refolding and purification under native 
conditions 
 A bigger culture was induced and processed for extraction, denaturation 
and refolding of inclusion bodies through the procedure described in Materials 
Fig. 3.4: Western blotting analysis of samples taken 
from different cellular districts. Each sample 
corresponds to 200 µl of  culture. 
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and Methods (par. 2.2.4 of Material and Methods). The denaturing agent utilized 
was 8 M urea. 
 After the last dialysis of refolded IT in binding buffer, the sample was 
incubated 1h at r.t. with a resin that captures the his6-tag (Ni Sepharose 6 Fast 
Flow – GE Healthcare; IMAC chromatography), and the recombinant 
Immunotoxin was eluted with 500 mM imidazole. 
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Fig. 3.5: Coomassie staining of SDS-PAGE of samples purified by IMAC under native 
conditions. A) Immunotoxin purification from a culture induced at 30°C o.n.; B) Immunotoxin 
purification from a culture induced at 30°C for 3h. Abbreviations: FT: flow-through collected after 
sample binding to the resin; BSA: bovine serum albumin; Ind: induction. 
 
 The purification was carried out on the refolded Immunotoxin derived 
from a culture induced o.n. and a culture induced for 3h (Fig. 3.5). The eluted 
fractions obtained from the o.n. culture were contaminated with other proteins or 
fragments of Immunotoxin (Fig. 3.5A). Moreover after 3h of induction the eluted 
fractions showed a single band with the expected molecular weight (Fig 3.5B). 
However, figure 3.6 shows that the amount of Immunotoxin binding to the resin is 
very low: the Immunotoxin is found in similar amounts  in the refolded inclusion 
bodies (Fig. 3.6 red asterisk *) and in the flow-through (Fig. 3.6 black asterisk *). 
 
FT W FRIbR
before
column
72 kDa
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Fig 3.6: SDS-PAGE and Coomassie 
staining of samples from IMAC 
chromatography purification.  Twenty 
microliter of IbR and FT were loaded on 
the SDS PAGE. The red asterisk and the 
black asterisk indicate the IL4PE in the 
IbR and in the FT respectively. 
Abbreviations: IbR: inclusion bodies after 
refolding;  FT: flow-throught collected 
after sample binding to the resin; W: wash; 
FR: fractions collected;  BSA: bovine 
serum albumin. 
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 The purified Immunotoxin (after dialysis of the eluted protein in PBS and 
filter-sterilization) was concentrated and the final amount was about 200 µg 
recombinant protein from one liter of E. coli culture. 
 The low amount of Immunotoxin purified and the low binding to the resin 
suggest that under native conditions the His6-tag is masked, thus not allowing 
efficient retention by the resin. For this reason we next tried to purify the 
Immunotoxin following a protocol in which the recombinant protein was first 
purified and than refolded. 
 
3.2.3 Immunotoxin extraction: purification under denaturing conditions and 
refolding 
 To prevent the loss of  the IL4PE40 during the purification step, an 
alternative purification protocol was tested. The pellet of the induced culture was 
lysed, purified and then the eluted protein was refolded. For this protocol the 
denaturing agent used was  6M guanidine. 
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Fig. 3.7: Coomassie staining of two SDS-PAGE gels of samples after IMAC chromatography 
purification under denaturing conditions. A) Immunotoxin purification from a culture induced 
at 30°C o.n.; B) Immunotoxin purification of a culture induced at 30°C for 3h. Abbreviations: FT: 
flow-through collected after sample binding to the resin; BSA: bovine serum albumin; Ind: 
induction. 
 
 Figure 3.7 shows the IL4PE40 purification after o.n. induction or after 3h 
of induction at 30°C. As observed for the purification under native conditions, the 
Immunotoxin obtained after o.n. induction was less pure than that produced with a 
3h induction, likely because the high culture density leads to the non specific 
accumulation of a high amount of bacterial proteins interacting with the resin. 
Adding 10% glycerol and 1 mM DTT in the lysis, wash and elution buffers, the 
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non-specific interactions between contaminant proteins and the resin decrease, 
and the purity degree of the Immunotoxin increases (Fig 3.8). 
FT W FR
72 kDa
55 kDa
36 kDa
28 kDa
95 kDa
1    2  
µg BSA
Lisate
 
 The best yield of purified Immunotoxin, after dialysis and concentration, 
was 600 µg from 1 litre of E. coli culture (data not shown). 
 
3.3 Characterization of Immunotoxins produced by E. coli  
3.3.1 Binding assay 
 To test if the Immunotoxin was correctly refolded in its active form, 
different amounts of recombinant proteins were incubated with 3 different cell 
lines: LNCaP (IL4R negative), U251 (IL4R positive) and PT45 (IL4R positive) 
(Fig. 3.9). 
mol/l IL4PE40
1e-8 1e-7 1e-6
M
FI
0
5000
10000
15000
20000
25000
Legend:
U251 
PT45 
LNCaP
 
Fig. 3.9: Binding of the recombinant Immunotoxin on U251 (blue), PT45 (red) and LNCaP 
(black) cells. The curve was created by plotting MFI data from staining of U251 and PT45 cells 
(IL4R+) vs increasing amounts of Immunotoxin, and plotting MFI value from staining of  LNCaP 
cells (IL4R-) at the highest tested concentration of Immunotoxin. 
 
 The binding assay showed that increasing the Immunotoxin concentration, 
the MFI value increases in the IL4R positive cell lines, whereas at the highest 
Immunotoxin concentration tested, the MFI value for LNCaP (IL4R-) was 
Fig. 3.8: Coomassie staining of the SDS-PAGE gel of 
samples from IMAC chromatography purification 
under denaturing conditions.  Twenty microliters of 
lysate, FT, W and FR were loaded on the SDS PAGE. 
Abbreviations: FT: flow-through collected after sample 
binding to the resin; W: wash; FR: fractions collected;  
BSA: bovine serum albumin. 
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approximately zero. This means that the refolded Immunotoxin binds the cell lines 
that express IL4R, but not the IL4R negative cell line. 
 
3.3.2 Cytotoxicity assay 
 The cytotoxic potential was evaluated by testing on selected cell lines the 
effect of increasing concentrations of the Immunotoxin using the XTT assay. XTT 
is a reagent that develops an orange colour when it is metabolised by the 
mitochondria. The orange colour intensity is proportional to the amount of 
mitochondria and to the vitality of the cell culture. 
 For comparison, also wt PE, the native Pseudomonas exotoxin A, and the 
PE40 fragment (from bacterial culture) were tested. The curves in figure 3.10 
clearly show that the Immunotoxin can inhibit the proliferation of cells expressing 
the IL4R. The concentrations of Immunotoxin that are capable to reduce by half 
the proliferation of the treated cells (IC50) are reported in table 3.1. Remarkably, 
the Immunotoxin has a more potent action as compared to PE40 fragment which 
does not show cytotoxicity in the concentration range tested. This indicates that 
by adding the IL4 carrier molecule to the toxic domain, the new molecule is able 
to bind the receptor and to deliver the toxic domain, which in turn kills the cells.  
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(A) LNCaP 
 
 
(B) U251 
 
 
(C) PT45 
 
 
Fig 3.10: Cytotoxic assay. Effect of treatment with IL4PE40 Immunotoxin (red line), native PE 
(black line) or fragment PE40 (blue line) on the viability of LNCaP (A), U251 (B), PT45 (C) cells. 
The horizontal red line indicates the IC50. Data are expressed as percentage of control sample 
(untreated cells). 
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 LNCaP U251 PT45 
 IC50 
IL4PE40 2*10-7 6*10-9 5*10-7 
PE wt 10-9 10-10 4*10-8 
PE40 >10-6 >10-6 >10-6 
 
Table 3.1: Value of concentration inhibiting 50% of the maximal proliferation (IC50) for 
IL4PE40 Immunotoxin, native PE (PE wt) and the fragment PE40 on IL4R+ lines U251 and PT45 
and IL4R- cell line LNCaP. 
 
 The IC50 value of LNCaP (IL4R-) is comparable to that of PT45 (table 
3.1). However, analyzing the native PE toxic activity in both cell lines, it is 
possible to observe that LNCaP cells are more sensitive to PE toxicity than PT45. 
This can explain the similar IC50. In figure 3.11 the IC50 of IL4PE40 and native 
PE were compared: the specificity of the Immunotoxin is in inverse relation to the 
length of the red arrow and proportional to the specificity factor value. 
PT45
U251
LNCaP 5*10-3
1.6*10-2
8*10-2
IC50 TOX
IC50 IT
1
3.2
16
SPECIFICITY 
FACTOR
of
IL4PE40
 
Fig. 3.11: Relationship between the toxin and Immunotoxin IC50 values in the different cell 
lines. The difference between the IL4PE40 IC50 and native PE IC50 on each cell line is shown with 
the red arrow. The specificity of the Immunotoxin is expressed as the normalization ratio between 
toxin or Immunotoxin IC50 values on positive cell lines (PT45 and U251) and IC50 on negative cell 
line (LNCaP). Abbreviations: TOX: toxin; IT Immunotoxin. 
 
 Binding and cytotoxicity data indicate that the IL4PE40 purified from E. 
coli is expressed in its active form. 
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3.4 Cloning of IL4(38-37)PE40 Immunotoxin in the yeast system. 
 
3.4.1 Amplification of IL4(38-37)PE40 and cloning into pPICZalpha plasmid 
 The DNA sequence used to express the Immunotoxin in the bacterial 
system was utilised without modifications in the first pilot expression experiment 
in P. pastoris to verify the ability of these host cells to produce the Immunotoxin. 
 To clone the IL4PE40 gene into the pPICZalpha plasmid using the XhoI 
and XbaI restriction sites, a site specific mutagenesis was needed to remove the 
XhoI site within the Immunotoxin sequence. Six colonies were screened for 
restriction with 3 different enzymes: EcoRI recognizes 2 sequences into the 
bacterial expression vector, HindIII linearizes the plasmid and XhoI cuts once in 
the IL4PE40 wild type sequence but does not digest the mutagenized sequence. 
The EcoRI and HindIII restriction enzymes were used as a control. 
MW
3000 bp
IT wt
not
digest
EcoRI HindIII XhoI
IT wt digest
EcoRI HindIII XhoI
Colony 1
IT digest
EcoRI HindIII XhoI
Colony 2 
IT digest
* *
A B C
 
Fig 3.12: Screening of the colonies from mutagenesis reaction. A) In the first lane the MW 
standard was loaded. Sunsequent lanes: uncut IL4PE40, EcoRI digest, HindIII digest and XhoI 
digest, respectively; B, C) The DNA derived from colonies 1 and 2 was digested with EcoRI, 
HindIII and XhoI. The asterisks indicate uncut DNA. Abbreviation: MW: molecular weight; IT: 
IL4PE40 Immunotoxin. 
 
 As shown in figure 3.12, the non digested DNA appears with a typical 
pattern of the supercoiled DNA; the plasmid containing the IL4PE40 wild type 
sequence shows two bands at about 1300 bp and 3200 bp after cleaving with 
EcoRI whereas HindIII and XhoI linearize the vector (Fig. 3.12A). The figure 
3.12 panel B shows that XhoI does not digest the colony 1 plasmid (second 
asterisk) whereas it linearizes the colony 2 DNA (fig. 3.12C).  This means that in 
colony 1 the plasmid was mutagenized correctly. To confirm the mutagenesis the 
plasmidic DNA of colony 1 was sequenced by BMR Genomics. 
 The mutated IL4PE40 gene was amplified through PCR to insert the XhoI 
and XbaI restriction sites at the 5’ and 3’ respectively (fig 3.13B). The use of 
XhoI as restriction enzyme allows to produce the Immunotoxin with its native N-
terminal (Par. 1.3.1.4.2.12  of Introduction ). 
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Fig. 3.13: A) The pPICZα-IL4PE40 expression vector for P. pastoris; B) IL4PE40 amplified 
through PCR; C) After screening of colonies derived from the ligation reaction, three colonies 
were digest with EcoRI and XhoI and XbaI as a further control.  
 
 The digested PCR fragment was inserted into the pPICZα plasmid. This 
expression plasmid contains the α-mating factor signal sequence (αMf) that drives 
the secretion of the recombinant proteins in the culture medium. The new gene 
was inserted at the 3’ of αMf, without native ATG (Fig. 3.13A). 
 Twenty colonies derived from the ligation reaction were screened and the 
colonies 1, 3 and 5 were found positive. To confirm the presence of the 
Immunotoxin gene in the vector, the DNA plasmid of these colonies was digested 
with EcoRI that linearized the construct and with XhoI/XbaI that cut within the 
cloning restriction sites (Fig. 3.13C); moreover one construct was also sequenced 
also by BMR Genomics. For the electroporation of P. pastoris the colony 1 was 
chosen.  
 
3.4.2 Screening of P. pastoris transformed with IL4PE40 construct 
 The yeast transformation protocols are described in the par. 2.3.4 of 
Materials and Methods. 
 Thirteen colonies were induced to identify the clone with the best yield 
(fig.3.14). The clone 5 was chosen for the medium and large scale inductions. 
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Fig. 3.14: Screening of 13 clones derived from transformation by electroporation. 
 
3.4.3 Purification and quantification of IL4PE40 from 1L of culture  
 To quantify the Immunotoxin production, the IL4PE40 clone 5 was 
induced in 1 liter of BMMY medium. After 72h of induction, the culture was 
centrifuged and the supernatant was collected. To load the supernatant in the 
IMAC chromatography, sample concentration is needed. To identify the correct 
percentage of saturation of ammonium sulphate allowing the Immunotoxin 
precipitation, a fractionated precipitation was conducted (Fig. 3.15) 
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Fig. 3.15: Western blotting of ammonium suphate-precipited proteins. The WB was stained 
with the rabbit anti-PE as primary antibody and with the anti-Rabbit-HRP as secondary antibody. 
The different precipitated samples were loaded concentrated 10-fold as compared with the culture 
supernatant. Abbreviation: SN, culture supernatant; 20%: culture supernatant precipitated with 
20% of saturation of ammonium sulphate; 40%: 20% supernatant precipitated with final 40% of 
saturation of ammonium sulphate; 60%: 40% supernatant precipitated with final 60% of saturation 
of ammonium sulphate; 80%: 60% supernatant precipitated with final 80% of saturation of 
ammonium sulphate; SN after last precipitation, 10X concentrated supernatant after centrifugation 
of 80% saturated of supernatant. 
 
 The Immunotoxin precipitates between the 40% and 60% of saturation of 
ammonium sulphate. Since in a Coomassie staining 20% of saturation does not 
result in proteins precipitation (data not shown), the supernatant of induced 
Immunotoxin inducted was precipitated directly with a 60% ammonium sulphate 
saturation. 
 After 1h incubation with ammonium sulphate at 4°C and centrifugation of 
the solution the proteins pelleted were resuspended in binding buffer, and dialyzed 
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o.n. against the same binding buffer to remove the ammonium sulphate traces. 
The supernatant equilibrated with binding buffer was incubated 1-2 h with the 
resin that binds the his6-tag and, after washing the resin with 20 mM imidazole, 
the Immunotoxin was eluted with 500 mM imidazole. Since the SDS-PAGE 
stained with Coomassie does not show the band corresponding to the molecular 
weigh of the Immunotoxin (data not shown), the fractions were analysed by 
Western blotting (Fig 3.16). 
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 As shown in figure 3.16 traces of Immunotoxin are present in the flow-
through, the amount of purified protein is very low and mostly degraded. In fact, 
after dialysis carried out to remove the imidazole and concentration, the final 
Immunotoxin yield was 1 µg from 1 liter of culture.   
 
3.4.4 IL4PE40 optimization for the production in P. pastoris 
 
3.4.4.1 IL4PE40 codon optimization for production in P. pastoris  
 To increase the recombinant protein amount produced by yeast, DNA 
sequence was optimized to the host strain codon usage. 
 The IL4PE40 sequence was codon optimized by GenScript Corporation 
(Piscataway, USA). The OptimumGeneTM algoritm used takes into consideration 
a variety of critical factors involved in different stages of protein expression, such 
as codon adaptability, mRNA structure and various cis-elements involved in 
transcription and translation.  
 Before IL4PE40 gene codon optimization, some features, such as the 
glycosylation sites and the restriction sites important for the subsequent cloning, 
were studied.  
Fig. 3.16: Western blotting of samples 
from IMAC purification step of P. 
pastoris supernatant. Twenty microliters 
of each sample were loaded. 
Abbreviations: FT: flow-through collected 
after sample binding to the resin; BSA: 
bovine serum albumin; Ind: induction. 
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 To identify the glycosylation sites the IL4PE40 sequence was inserted into 
the prediction servers named NetNGlyc and NetOGlyc 
(www.cbs.dtu.dk/services/) to search for N- or O- glycosylation sites respectively. 
The NetOGlyc server did not find any target sequence, however 2 putative N-
glycosylation sites are present in the Immunotoxin sequence (Fig. 3.17A-B). To 
confirm the presence of glycosylation sites, 10 µl of supernatant of IL4PE40 
culture were incubated with 1 µl of PNGaseF and 1 µl of EndoH, two N-
glycosydases that remove the carbohydrate residues from proteins. As shown in 
the western blotting of figure 3.18C in the lines without the enzyme (-) the 
Immunotoxin shows 2 bands (corresponding to two different glycosylation 
conditions), moreover when the enzymes were added to the recombinant protein 
only 1 band is evident because the sugar chains were removed. To exclude a 
possible in vivo immune reaction against the sugar chains of the recombinant 
Immunotoxin, the N residues recognized by the software of prediction were 
changed in two Q residues that maintain the negative charge of amino group. 
A
B
72 kDa
- +
PNGaseF
- +
EndoH
C
 
Fig.3.17: N-glycosilation sites prediction study. A) The putative N-glycosilation sites are written 
in blue. The N residue with higher probability to bind the sugar chains are written in red. B) The 
plot summarizes the position of N-glycosilation sites and their N-glycosilation 
potential.(www.cbs.dtu.dk/services/). C) Glycosylation assay. Twenty microliter of each reaction 
mix were loaded in the Western blotting. The sign (-) and the sign (+) indicate the absence or the 
presence of enzyme respectively.  
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 In the IL4PE40 sequence the restriction enzymes of pPICZα multi cloning 
sites were removed (XhoI, XbaI, PmeI, SacI, SfiI, PstI and EcoRI) (Fig. 3.18). 
XhoI, EcoRI, 
SfiI, etc. NotI XbaI
IL4(37-38) PE40αMF
Symbols:
His6
AlaSerGly2ProGlu linker
 
Fig. 3.18: Structure of IL4PE40 optimized. 
 
 With the sequence optimization the codon usage bias in P. pastoris was 
increased by upgrading the CAI (Codon Adaptation Index) from 0.48 to 0.98. The 
GC content and unfavourable peaks were optimized to prolong the half-life of the 
mRNA. The Stem-Loop structures, which impact on ribosomal binding and 
stability of mRNA, were broken.  
A 
 
B 
 
C 
 
Fig. 3.19: IL4PE40 optimized: GenScript analysis. A) The distribution of codon usage 
frequency along the length of the gene sequence. A CAI of 1.0 is considered to be optimal in the 
desired expression organism, and a CAI of >0.9 is regarded as very good, in terms of high gene 
expression level. B) The percentage distribution of codons in computed codon quality groups. The 
value of 100 is set for the codon with the highest usage frequency for a given amino acid in the 
desired expression organism. C) The ideal percentage range of GC content is between 30-70%. 
Peaks of percentage of GC content (%GC) in a 60 bp window have been removed. 
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3.4.4.1.1 Screening of P. pastoris transformed with IL4PE40-opti construct 
 The IL4PE40 optimized gene (IL4PE40-opti) was provided by GeneScript 
inserted into the pUC57 plasmid. Therefore it was cloned in the pPICZα plasmid 
with the same strategy used from the non optimized gene.  
 Six zeocin positive clones were screened (72h of induction), and 200 µl of 
each supernatant were precipitated with 10% TCA and analysed in SDS-PAGE 
(Fig. 3.20). The clone that produced the highest amount of Immunotoxin is the 
number 5. 
72 kDa
55 kDa
36 kDa
clone n.        1       2       3      4       5        6     
 
 
 To verify if the sequence optimization increases the Immunotoxin yield, 
IL4PE40 and IL4PE40-opti expression was compared. (Fig. 3.21). 
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Fig. 3.21: Comparison between the IL4PE40-opti and IL4PE40 production. For each sample 
300µl of induced supernatant, precipitated with 10% TCA, were analysed in Western blotting. In 
the table at right the ratio between the amount of IL4PE40-opti and IL4PE40 are reported. 
 
 As shown in the table at right of figure 3.21, the ratio between the amount 
of IL4PE40-opti and IL4PE40 produced by P. pastoris is always greater than 1, 
indicating that the IL4PE40-opti amount produced at each time point is higher 
than IL4PE40.  
 
 
 
Fig. 3.20: Screening of 6 zeocin 
positive clones of IL4PE40-opti 
produced by GS115 P. pastoris 
strain. For each sample 200 µl, 
precipitated with 10% TCA, were 
analysed. 
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3.4.4.2 IL4PE40 production optimization in P. pastoris 
 To increase the yield of protein produced in P. pastoris, several steps of 
induction condition optimization were needed. The condition changes aim at 
decreasing the proteolysis of recombinant protein. To identify the best condition 
for each variable tested, 500 µl of culture medium were precipitated with 10% of 
TCA, and analysed by Western blotting. 
 
1) Time of induction. During the induction of a recombinant protein in P. pastoris 
the methanol was added at the culture every 24 h. At each time point (24h, 48h 
and 72h) a sample of supernatant was collected. As shown in figure 3.22 the best 
condition is the 24h time point, because the Immunotoxins are expressed with 
lower degradation. 
24h 48h   72h
IL4PE40-opti 
72 kDa
55 kDa
36 kDa
 
 
2) Temperature of induction. To minimize the proteolysis of recombinant 
proteins secreted in the culture medium the amount of Immunotoxin was analysed 
at three temperature: 20°C, 25°C and 30°C [Li Z., et al., 2001; Curvers S., et al., 
2001]. As shown in figure 3.23 at 20 and 25°C the Immunotoxin was not 
produced, whereas at 30°C the Immunotixin is expresses. 
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Fig. 3.22: Western blotting of different time 
points of IL4PE40-opti production. For each 
sample 300µl of supernatant, precipitated with 10% 
TCA, were analysed. 
Fig. 3.23: Western blotting of 
IL4PE40-opti production at 
different temperatures. For 
each sample 300µl of 
supernatant, precipitated with 
10% TCA, were analysed. 
Abbreviation: αA: GS115 strain 
transformed with pPICZαA 
vector (empty vector). 
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3) Effect of cell density at the induction start. The production of recombinant 
proteins is often proportional to the density of the host cells [Cregg J.M., et al., 
2000; Brierley R.A., et al., 1990; Cregg J.M., et al.,  1995]. However, high cell 
density preparations are costly to prepare, increase the concentration of 
extracellular proteases, and may have detrimental effects on cell physiology in 
turn limiting the amount of desired product. As shown in figure 3.24, the best 
condition is the 1 OD600 cell density where the Immunotoxin amount is higher and 
the proteolysis is lower. 
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Fig. 3.24: A) Curve of growth culture starting at 1 OD600 or 10 OD600.  B) Western blotting of 
IL4PE40-opti production at different initial cell density. For each sample 300µl of supernatant 
after 48h of induction, precipitated with 10% TCA, were analysed. Abbreviation: OD: optic 
density. 
 
4) Presence of glycerol during the induction. P. pastoris is a methilotrophic 
yeast, able to grow with the methanol as unique carbon source. Literature data 
[Zhang W, et al., 2003] show that the presence of glycerol during the induction 
support the growth of the culture, with a higher cell accumulation. But sometimes, 
as described before for the optimization of starting cell density, the culture 
concentration can be proportional to the degradation level of recombinant protein. 
Indeed figure 3.25 shows that the whole Immunotoxin is produced only when the 
glycerol was not added. 
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Fig. 3.25: A) Curve of growth culture of IL4PE40 induced with or without 1% glycerol.  B) 
Western blotting of IL4PE40-opti production with or without 1% glycerol. For each sample 
300µl of supernatant after 48h of induction, precipitated with 10% TCA, were analysed. 
Abbreviation: OD: optical density. 
 
5) Methanol concentration.  P. pastoris expression system uses the methanol 
both for the induction of the proteins and as the main carbon source for cell 
growth following induction [Cai H. et al., 2009]. Generally a lower methanol 
concentration limits cell growth due to carbon limitations, and a higher methanol 
concentration is toxic because of accumulation of its metabolic products [J.M. 
Cregg et al., 1993]. Then the methanol concentration resulting in the highest 
amount of expressed Immuntoxin was investigated. 
 The figure 3.26A shows that, after 48h of induction, a methanol feed of 
0,25% (v/v) led to the highest amount of Immunotoxin, and a methanol feed of 
1% (v/v) led to the lowest yield of Immunotoxin. The corresponding cell growth 
curves (Fig. 3.26B) during the induction phase showed that growth culture was 
not affected by the different inductor concentrations. This means that in the 
concentration range tested the influence of methanol regards only the induction 
pathway. In fact increasing the amount of methanol (3% and 5%) both the 
expression and the cell growth were inhibited (data not shown). 
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Fig. 3.26: A) Western blotting of IL4PE40-opti with different methanol concentration. For 
each sample 300µl of supernatant after 48h of induction, precipitated with 10% TCA, were 
analysed. B) Cell growth curves of IL4PE40 induced with three different methanol 
concentration.  Abbreviation: MetOH: methanol. 
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6) Medium pH. Under constant pH conditions, cells can grow more efficiently 
[Chiruvolu V., et al., 1998]. The effect of pH on cell growth and Immunotoxin 
expression was examined in BMMY induction medium buffered with 100 mM 
potassium phosphate at different pH values (5.0, 6.0, 7.0), so as to limit protease 
activity (Fig. 3.27) 
time of induction
0 24 48 72
O
D
60
0
0
5
10
15
20 pH5 
pH6 
pH7 72 kDa
55 kDa
36 kDa
pH 5 pH 6 pH 7
A B
 
Fig. 3.27: A) Western blotting of IL4PE40-opti expresses in BMMY buffered at pH 5, 6 and 
7. For each sample 300µl of supernatant after 48h of induction, precipitated with 10% TCA, were 
analysed. B) Cell growth curves of ILePE40-opti expresses in BMMY buffered at pH 5, 6 and 
7. 
 
 The Immunotoxin production does not increase for any pH value, but at 
pH 7 the degradation level increases (Fig 3.27A). Moreover the culture growth 
was not affected by the pH values tested (Fig. 3.27B). The induction medium at 
pH 6 was therefore considered as the best condition. 
 
7) Presence of 5 mM EDTA. Recombinant proteins expressed in P. pastoris 
systems have also been found to be degraded rapidly if they contain PEST 
sequences. These sequences include the motifs XFXRQ or QRXFX, which are 
known to be degraded in the lysosome [Sreekrishna K, et al., 1989]. Additives 
such as 5 mM EDTA can also assist in stabilizing the recombinant expressed 
protein [Sreekrishna K, et al., 1997] and often increase the yield of the expressed 
protein. In the IL4PE40 protein sequence a PEST sequence is present (Fig. 
3.28A). But the Immunotoxin was not expressed with the EDTA in the induction 
medium (Fig. 3.28B), likely because the chelating action of EDTA does not 
support the synthesis pathway.  
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Fig.3.28: Vecton NTI software IL4PE40 sequence analysis, to identify the presence of PEST 
sequences (highlighted in blue). B) Western blotting of IL4PE40-opti expresses with or 
without 5 mM of EDTA. For each sample 300µl of supernatant after 48h of induction, 
precipitated with 10% TCA, were analysed. Abreviation: w/o: without. 
 
8) Culture conditions before induction. To produce the IL4PE40 the protocol 
suggested by Invitrogen catalogue was used: the GS115 inoculum containing 
IL4PE40 gene was grown in BMGY until the logarithmic (log) phase was reached 
(between 2 and 6 OD600), then the culture was centrifuged and resuspended in 
BMMY medium at the desired cell density. To produce an Immunotoxin in P. 
pastoris, Woo et al., used an alternative protocol: a single colony was grown in 
YPD until a saturation phase was reached (after 2 days), then the centrifuged 
culture was resuspended in two-thirds colture volume of BMMY medium and 
induced for 2 days, adding methanol every 24h. The figure 3.29 shows that the 
induction during the saturation phase produces more Immunotoxin than in the log 
phase, but with a highest degradation level. For this reason the best condition was 
considered the induction during the log phase of growth. 
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9) Yeast strain. Strains deficient in vacuolar proteases are sometimes effective at 
reducing protein degradation of recombinant proteins [Brierley, R. A., 1998; 
White, C. E., et al., 1995]. The protease-deficient strains SMD1163 (his4 pep4 
Fig 3.29: Western blotting of IL4PE40-opti 
expresses after inoculum during the log phase or 
during the  saturation phase. For each sample 300µl 
of supernatant after 48h of induction, precipitated with 
10% TCA, were analysed. Abreviation: log: 
logarithmic. 
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prb1), SMD1165 (his4 prb1), and SMD1168 (his4 pep4) are particularly useful 
for expression of heterologous proteins in fermenter cultures because with other 
strains the combination of high-cell density and lysis of a small percentage of 
cells results in a relatively high concentration of vacuolar proteases such as 
proteinase A (pep4) and proteinase B (prb1).  
 The IL4PE40 gene was inserted in the SMD1168 genomic DNA and 14 
zeocin resistant clones were screened (Fig.3.30). 
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Fig. 3.30: Screening of 14  clones derived from electroporation of SMD1168 strain with 
pPICZalphaIL4PE40opti construct. For each sample 300µl of supernatant after 48h of 
induction, precipitated with 10% TCA, were analysed. The best clone is indicated with the white 
arrow. 
 
 The best clone was the number 12. The Immunotoxin medium-scale 
production was analysed using both the induction during the log phase and during 
the saturation phase (Fig.3.31). 
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Fig. 3.31: Western blotting with SMD1168 transformed with IL4PE40-opti. Time course of  
IL4PE40-opti induced in “log phase” (white panel) and in “saturation phase” (yellow panel). As 
control 10 ng and 50 ng of PEwt were loaded. For each sample 300µl of supernatant after 48h of 
induction, precipitated with 10% TCA, were analysed. 
 
 As shown in figure 3.32 a higher amount of IL4PE40 was produced using 
the “saturation phase” protocol, even if the degradation pattern is the same derived 
with the GS115 strain. Comparing the intensity of IL4PE40 bands with those of 
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PEwt, it is possible to conclude that this P. pastoris  protease-deficient strain is 
not able to produce an undegraded Immunotoxin (10 µg from 1 liter of culture) at 
a yield higher than that obtained with the GS115 strain (30 µg from 1 liter of 
culture – data not shown). 
 
10) Presence of an antifoam additive. During the Immunotoxin induction the 
foam in the culture medium was always observed. It is possible that the interfacial 
foam leads to degradation of the recombinant protein  [Zeev-Ben-Mordehai T., et 
al., 2009]. To improve the Immunotoxin stability and yield an antifoam agent was 
added daily to the induced culture.  
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 From figure 3.32 it is possible to quantify the Immunotoxin yield at 120 
µg from 1 liter of culture; comparing this yield with the Immunotoxin amount 
produced without the antifoam (30 µg from 1 liter of culture) it is possible to 
conclude that the antifoam increased the yield of recombinant protein, even if the 
antifoam does not decrease the degradation level. 
  
 Table 3.2 shows the yield of IL4PE40 under optimized or non optimized 
conditions and the table 3.3 summarizes the best conditions tested for the 
IL4PE40-opti expression. 
 
Strains Non optimized sequence 
 
Optimized sequence 
 
 
 
Non 
optimized 
conditions 
Optimized 
conditions 
Non 
optimized 
conditions 
Optimized 
conditions 
GS115 20 µg n.d. 30 µg 120 µg 
SMD1168 n.d. n.d. 10 µg n.d. 
 
Table 3.2: IL4PE40 production under optimized or non optimized conditions. Abbreviation: 
n.d., not determined. 
Fig. 3.32: Western blotting with IL4PE40-opti 
induced in BMMY medium containing an antifoam 
agent. The sample derived by 660µl of supernatant, 
after 48h of induction, precipitated with 10% TCA. As 
control 20 ng of  PEwt were loaded. Abbreviation: 
Ind: Induction. 
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   Best 
condition 
  Best 
condition 
Time 24 h  Medium pH pH 6 
Temperature 30°C  5 mM EDTA no 
Starting cell density 1 OD600  Culture condition log phase 
1% Glycerol no  Strain GS115 
Methanol 0.25%  Antifoam yes 
 
Table 3.3: Best conditions to produce IL4PE40-opti. 
 
3.4.5 Purification of IL4PE40-opti by affinity chromatography. 
 As shown before in figure 3.14A, the IL4PE40-opti gene was cloned in 
frame with the His6-tag. After ammonium sulphate precipitation the culture 
medium was incubated 1-2 hours with the Ni-Sepharose resin. The mixture was 
loaded to the column, the resin was washed with the binding buffer with 20 mM 
imidzole and then the Immunotoxin was eluted with the same buffer containing 
500 mM imidazole (Fig. 3.33) . 
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3.33: Western blotting with the sample derived by the purification step. A: medium 
concentrated before binding to the resin; B: flow-through after binding; C: resin wash (20 mM 
imidazole); in blue: eluted fractions (500 mM imidazole). At righ of the figure, diagram 
representation of  possible Immunotoxin fragments. 
 
 The amount of Immunotoxin produced by P. pastoris is low; in fact it is 
not possible to detect the bands corresponding to the Immunotoxin in the SDS-
PAGE (Coomassie staining) (data not shown). From Western blotting analysis 
(fig. 3.34) it is possible to observe that in the flow-through the Immunotoxin is 
insted present, this likely means that the binding is not optimized; moreover the 
eluted fractions show 3 degradation products, as indicated at the right of figure 
3.33.  
 As described before in the introduction (1.2.2.2.2) the native PE toxin 
contains a furin cleavage site in the translocation domain that releases a PE 
fragment of 37 kDa.  
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 Furin-like enzymes recognize a RXXR polypeptide sequence and cleave 
after the last R residue.  
 We have hypothesized that proteases cleaving the recombinant molecules 
cold be present in the yeast medium.  
 To evaluate this hypothesis, the presence of furin-like cleavage sites was 
investigated by computer-based prediction (Fig.3.34). 
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Fig. 3.34: In silico study of furin-like cleavage sites in the IL4PE40 sequence. 
 
 As shown in figure 3.35, the IL4PE40 protein has 3 putative furin-like 
cleavage sites, and the molecular weight of released fragments corresponds to the 
weight of degradation bands present in the Western blotting pattern. 
 To verify this hypothesis a cleavage test of native PE was performed (Fig. 
3.35A).  The native PE was incubated for 1h with: 1) PBS as a control, 2) 
only BMMY induction medium that is not inoculated with GS115, 3) BMMY 
after 48h of induction of GS115 transformed with the empty vector (αA) and 4) 
BMMY with 1 mM PMSF (proteases inhibitor) after 48 h of induction of αA. 
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Fig. 3.35: A) Western blotting of native PE fragments derived from PE cleavage under 
different conditions. CTR: native PE incubated with PBS; αA BMMY: native PE incubated with 
cell-free BMMY after 48h of induction of GS115 transformed with the empty vector pPICZαA 
(αA); αA BMMY PMSF: native PE incubated with cell-free BMMY + 1 mM PMSF after 48h of 
induction of GS115 transformed with the αA. BMMY: induction medium only without P.pastoris. 
B) In silico study of furin-like cleavage sites in the native PE sequence. 
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 As shown in figure 3.35A the native PE incubated with non inoculated 
BMMY is comparable to the PE of the control lane. This means that the agents 
that cleave the recombinant protein, are not present in the medium of induction, 
but are produced by the yeast culture. Indeed, observing the lanes of samples 
where the PE was incubated with αA-BMMY or αA-BMMY+PMSF, 4 bands of 
degradation are present. These bands are less intense in the sample with PMSF. 
This means that the P. pastoris culture may secrete the proteases cleaving the 
native PE; indeed if a protease inhibitor was added the degradation decreased. An 
in silico study of the native PE sequence shows 5 putative cleavage sites (Fig. 
3.35B). The predicted C-terminal PE fragments have molecular weights similar to 
those showed in the Western blotting pattern. 
1mM 
EDTA
5mM 
EDTA
Complete 
1X
CTR
αA BMMY
72 kDa
55 kDa
36 kDa
28 kDa
 
 
 The cleavage test of native PE was carried out by incubating the toxin with 
the αA BMMY medium with 2 different concentrations of EDTA and with 
Complete 1X, an alternative inhibitor proteases mix (Fig. 3.36). In figure 3.36 it is 
possible to observe that the degradation pattern of native PE is the same in all 
conditions, indicating that the cleaving agents degrading the toxin are not 
inhibited by EDTA or by Complete. 
 
 To analyse the presence and the nature of cleaving agents 3 IL4PE40  site 
specific mutageneses were planned: 3 arginines (Arg21, Arg170, Arg243) were 
mutated in 3 alanines using the Quik Change Multi Site-Directed Mutagenesis Kit 
(Stratagene). 
 Preliminary studies demonstrate that the mutated Immunotoxins do not 
show the degradation band at 37 kDa (data not shown). Further analysis will be 
needed to verify if the Immunotoxin is expressed without degradation products 
and if its cytotoxic activity is maintained.  
Fig. 3.36: A) Western blotting with the 
cleavage test of native PE.  The native PE 
was incubated with:  αA BMMY with 1 mM 
EDTA, αA BMMY with 5 mM EDTA, αA 
BMMY with inhibitors mix Complete 1X 
and only αA BMMY.  
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This work was done to set out the optimal conditions for the expression of 
heterologous proteins in the methylotrofic yeast pichia pastoris, in particular to 
optimally express a cytotoxic macromolecular therapeutic utilizable in the 
management of pancreas tumors. 
In this work, I subcloned the gene encoding the IL4(38-37)PE40 Immunotoxin 
into the pPICZα- vector, and it was expressed in P. pastoris. After preliminary 
induction the Immunotoxin was successfully secreted into the supernatant. 
However the amount of recombinant protein expressed was very low (20 µg from 
1 liter of culture). This result however was not considered sufficient for the 
obtainment of Immunotoxin by the P. pastoris system. Several steps of  
optimization conditions were needed to increase the protein production (120 µg 
from 1 liter of culture) in the P. pastoris expression system. 
 
4.1 Gene codons optimization 
Many works show that the gene codon optimization increases the recombinant 
protein expression in P. pastoris [Jung Hee Woo., et al., 2002; Da Teng, et al., 
2007; Huoqing Huang, et al.,  2008; Zhaorong Wei, et al., 2008; Hui Wanga, et 
al., 2008]. The IL4PE40 gene was therefore optimized. The optimization process 
changed not  only the rare codons for the yeast, but it increased the mRNA half-
life with the reduction of percerntage of GC content (from 67% to 41%) and cis-
acting elements. The sequence optimization increased the Immunotoxin 
expression of about 1.8 fold compared with the non optimized version. 
 
4.2 Optimization of the induction conditions  
Under the optimized conditions (induction time, 24 h; temperature of 
induction, 30°C; initial inoculum, 1 OD600; pH 6.0; 0.25% methanol 
concentration; induction in log phase; production with GS115 strain; presence of 
an antifoam agent), approximately 120 µg of protein were recovered from 1 L of 
the culture. 
To increase the amount of recombinant proteins produced by P. pastoris, it 
was considered necessary also to decrease the proteolysis of new proteins secreted 
in the supernatant. 
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- Medium pH 
X. Shi et al. (2003) demonstrated that several protease families were secreted 
from P. pastoris and that they were activated at different pH values. In Shi’s work 
the media at pH 5, pH 6 and pH 8 show lower proteases activity. Since some 
proteins are specifically susceptible to proteases secreted in the medium of P. 
pastoris, I examined whether the pH of the culture medium would affect the 
IL4PE40 expression. IL4PE40 production was most efficient at pH 5.0–6.0; at pH 
7 the immunotoxin was produced but with a higher level of degradation. For this 
reason I maintained the culture at pH 6.0, as advised by the P. pastoris expression 
protocols provided with the P. pastoris strains used. 
 
- Effect of cell density at the induction start 
 Generally, very high cell densities are employed to produce heterologous 
proteins, since production is roughly proportional to cell density [J.M. Cregg, J., 
et al., 2000; R.A. Brierley, et al., 1990; J.M. Cregg, and D.R. Higgins., 1995]. 
With IL4PE40 expression the high cell density or the addition of glycerol as a 
better carbon source than methanol increase the degradation level, probably 
because a high amount of cells secretes more proteins, including proteases. 
 
- Presence of EDTA 
Recombinant proteins expressed in P. pastoris could be degraded more 
rapidly if they contain PEST sequences. These sequences include the motifs 
XFXRQ or QRXFX, which are known to be degraded in the lysosomes 
[Sreekrishna K., et al., 1989]. The presence of 5 mM EDTA can also assist in 
stabilizing the recombinant expressed protein [Sreekrishna K., et al., 1997] and 
thus increase its expressed yield. IL4PE40 contains one PEST sequence, but the 
EDTA addition inhibits protein production. The EDTA additive can indeed assist 
the degradation under certain conditions but it is also toxic to the cell culture. To 
overcome this problem decreased concentrations of EDTA can be tested to find 
the best amount that does not inhibit the protein production and that reduces 
Immunotoxin degradation. 
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- Culture conditions before induction 
The IL4PE40 expression was performed as described in the protocol for P. 
pastoris handling. The yeast culture was grown in BMGY medium to reach the 
logaritmic phase; the cells were then centrifuged and resuspended in BMMY 
medium to induce the protein. Woo et al. (2002) produced an Immunotoxin in P. 
pastoris, using another protocol: the yeast culture was grown in YPD medium for 
two days to reach the saturation phase; to induce the Immunotoxin the pelleted 
culture was resuspended more concentrated in BMMY. Again the higher cell 
density leads to a higher degradation of proteins.  
 
- Yeast strain 
To decrease IL4PE40 degradation I used the SMD1168 protease deficient 
strain (pep4-). However, the use of SMD1168 did not solve the degradation 
problem, likely because the proteinase A was not involved in the Immunotoxin 
degradation. Moreover the yield of Immunotoxin in SMD1168 was lower than in 
the GS115 strain, as described in other works showing a lower ability of the 
proteases deficient strains to produce high amounts of recombinant proteins 
[Cereghino J.L and Cereghino G.F.L., Methods in Molecular Biology, vol. 389: 
Pichia Protocols, Second Edition]. 
 
- Presence of an antifoam additive 
The foam produced during the culture agitation can unfold proteins found in 
the medium. To decrease the loss of active Immunotoxin secreted into the 
induction medium an antifoam agent was added daily to reduce the air/liquid 
interfacial foam area. This increased the amount of expressed Immunotoxin of 
about 10-fold. 
 
- Methanol concentration   
In the case of the P. pastoris expression system, methanol is used both for the 
induction of the protein expression and as the main carbon source for cell growth 
following induction. Hence, an optimal concentration of methanol is an important 
factor that affects the yield of the heterologous protein produced by P. pastoris. 
According to the manual of the P. pastoris expression system provided by 
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Invitrogen, 0.5% of methanol is recommended to induce protein expression. In 
our experiment, I observed that IL4PE40 expression was induced by a daily 
addition of methanol  0.25% to 1.0% final concentration. However, the maximal 
accumulation of immunotoxin in the supernatant was obtained at a methanol 
concentration of 0.25%. The protein was not induced by 3.0% or 5.0% methanol 
and the cell growth was halted by higher concentrations of methanol. Then the 
IL4PE40 production was induced by the lowest percentage of methanol.  
 
- Time and temperature of induction 
 The time and temperature of induction are other variables that may reduce 
the proteolysis. In fact it is important to find an equilibrium between the highest 
amount of produced protein and the lowest degradation level. To overcome this 
problem it is possible to use  the medium substitution procedure during the protein 
induction (reiterative induction). In our case the best expression of IL4PE40 
(highest amount, lowest degradation) was at 24h of induction. Since no tested 
condition prevents the proteolysis at 48h of induction, the reiterative induction of 
the same cell preparation every 24h could partially solve the degradation problem. 
 
4.3 Toxicity of IL4PE40 in the host cells 
Observing the results of the induction optimization, the best yields of 
Immunotoxin were obtained under the conditions that slow down the cellular 
growth. In fact, the high cell concentration seems to lead to a decreased 
Immunotoxin production. This feature disagrees with the results obtained from the 
optimization of other non toxic proteins where the best yield was obtained in the 
high density cultures. However the Immunotoxin yield after optimization is 
against very low. 
IL4PE40 is a molecule which is toxic also to the yeast system, because the 
catalytic domain of PE is able to ADP-ribosylate the EF-2 of all eukaryotic cells. 
It cannot be excluded that the Immunotoxins or the toxin fragments reach the 
yeast cytosol ribosomes. The Immunotoxins could therefore translocate to the 
cytosol from the endoplasmic reticulum or re-enter the cells after secretion. 
The C-terminal REDLK endoplasmic reticulum retention sequence of PE40 
could retain the Immunotoxin in the vesicles pathway, decreasing the secreted 
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protein and increasing the possibility of toxin translocation to the cytosol. But the 
C-terminal his6-tag of the recombinant Immunotoxin likely prevents the REDLK 
recognition by the vesicle receptors. 
The yeast expression system is a good host to produce the mammalian 
proteins because it lacks the mammalian receptors such as IL4R. For this reason 
the receptor-mediated endocytosis of the Immunotoxin is unlikely. However it is 
possible that non specific pinocytosis events may lead to the internalization of the 
Immunotoxins which would then reach the endoplasmic reticulum and 
subsequently the cytosolic ribosomes.  
To overcome this problem with a DT-based immunotoxin Woo and co-
workers chose to express the catalytic A chain of Diphtheria toxin (DT) within the 
cytosolic compartment of P. pastoris. The colonies that grow after induction have 
a DT resistant EF-2. To evaluate if the IL4PE40 reaches the cytosol during the 
induction, leading to inactivation of protein synthesis with consequent low 
production of secreted Immunotoxin, I analysed the different yeast compartments 
by Western blotting. The Immunotoxin was accumulated mostly in the 
supernatant. Traces of Immunotoxins were present also in the insoluble fraction of 
the cytosol (data not shown). The insoluble fraction corresponds to the inactive 
and unfolded inclusion bodies of E. coli. Since the PE is a powerful toxin, it is 
possible that an amount undetectable by Western blotting reaches the cytosol and 
inhibits the protein sinthesys. For this reason it could be interesting to analyze the 
Immunotoxin expression in a PE resistant strain.  
 
4..4 Other assay conditions 
Other factors which I have not yet tested might affect the yield of 
heterologous proteins produced in P. pastoris.  
 
- Medium composition 
 Several reports indicate that medium composition influences heterologous 
protein expression in yeast by affecting cell growth and viability [Kang H.A., et 
al., 2000; Shiba Y., et al., 1998; Chen D.C., et al., 2000] or the secretion of 
extracellular proteases [Sreekrishna K., et al., 1997; Chung B.H., et al., 1997]. Shi 
X. and co-workers [Shi X., et al., 2003], demonstrated that the addition of 2% of 
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casamino acids or of 0.4 M L-arginine in the BMMY medium increased the 
protein accumulation. Particularly L-arginine addition decreased cell growth, but 
increased protein accumulation. The study of this condition could be interesting in 
our case, where the amount of IL4PE40 was higher when the cell growth was 
lower.  
 Propagation of E. coli under high osmotic pressures was reported to 
increase production of soluble, heterologous enzyme several hundred fold 
[Blackwell J.R., et al., 1991]. Culturing P. pastoris in hypertonic media 
containing either 0.35 M potassium acetate or 0.35 M sodium chloride prior to 
induction increases protein production [Shi X., et al., 2003]. During the induction 
the hypertonicity of BMMY medium led to rapid cell lysis and little protein 
production [Shi X., et al., 2003]. Moreover, sorbitol and alanine in the BMMY 
medium were reported to be adequate carbon sources, supporting cell growth 
while not suppressing the AOX promoter [Sreekrishna K., et al., 1997]. 
 
- Presence of the protease inhibitors during the induction 
 The addition of PMSF (mix of protease inhibitors) in the induction culture 
medium could decrease the protein degradation and  then increase its yield [Woo 
JH, et al., 2004]. I added 1 mM PMSF during the immunotoxin induction but the 
yield of protein dramatically decreased (< 5µg from 1 liter of culture) and the 
degradation problem was not solved (data not shown). Also in this case it will be 
necessary to test different PMFS concentrations to find the equilibrium between 
the proteases inhibition and the toxicity of PMSF for the cultures cells. 
- Intracellular expression 
The toxicity of IL4PE40 does not allow an efficient intracellular expression. 
For this reason I have chosen the pPICZα expression vector driving the 
recombinant proteins through the secretion pathway thanks to the α-mating factor 
signal sequence. To direct the proteins into the secretion pathway of P. pastoris, 
several signal sequences can be chosen.   
 
- Signal sequences for the secretion pathway 
 IL4PE40 was expressed only with the α-mating factor signal sequence. It is 
possible to test the secretion ability of other yeast signal sequences, such as PHO 
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(acid phosphatase signal sequence) or SUC2 (invertase signal sequence). The IL4 
immunotoxin carrier portion is a secretory molecule, therefore it has a native 
secretory sequence. The IL4 moiety could be cloned in frame with its native 
signal sequence to test the yeast ability to drive the protein through the secretory 
pathway. Indeed some proteins were produced successfully with the native 
secretory sequence [Barr, K.A, et al., 1992; Ridder, R., et al., 1995].  
 
- Promoters 
IL4PE40 gene was cloned into the pPICZα plasmid containing the AOX1 
promoter and terminator. Although the AOX1 promoter has been successfully 
used to express several foreign genes, to optimize the Immunotoxin production it 
is possible to test the protein expression using alternative promoters, such as GAP, 
FLD1, PEX8, and YPT1.  
The GAP gene promoter provides strong constitutive expression on glucose. 
The advantage of using the GAP promoter is that methanol is not required for 
induction, nor is it necessary to shift cultures from one carbon source to another. 
However, since this is constitutively expressed, it is not a good choice for the 
production of proteins that are potentially toxic to the yeast such as an 
Immunotoxin.  
The FLD1 gene encodes a glutathione-dependent formaldehyde 
dehydrogenase, a key enzyme required for the metabolism of certain methylated 
amines as nitrogen sources and methanol as a carbon source [Shen S., et al., 
1998]. The FLD1 promoter can be induced with either methanol as a sole carbon 
source (and ammonium sulphate as a nitrogen source) or methylamine as a sole 
nitrogen source (and glucose as a carbon source) and than offers the flexibility to 
induce high levels of expression using either methanol or methylamine, an 
inexpensive nontoxic nitrogen source. 
For certain foreign genes, the high level of expression from AOX1 promoter 
may overwhelm the post-translational machinery of the cell, causing a significant 
proportion of foreign protein to be misfolded, unprocessed, or mislocalized [Thill 
G.P., et al., 1990; Brierley R.A., 1998]. For some proteins such as on 
Immunotoxin, moderately expressing promoters could be desirable. The P. 
pastoris PEX8 and YPT1 promoters may be used. The PEX8 gene encodes a 
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peroxisomal matrix protein that is essential for peroxisome biogenesis [Liu H., et 
al., 1995]. It is expressed at a low but significant level on glucose and it is 
induced modestly when the cells are shifted to methanol. The YPT1 gene encodes 
a GTPase involved in secretion, and its promoter provides a low but constitutive 
level of expression in media containing either glucose, methanol, or mannitol as 
carbon sources [Sears I.B., et al., 1998]. 
 
- Yeast strains 
The IL4PE40 construct was produced by two different host strains: GS115 
and SMD1168 (Mut+). The Mut+ strains grow on methanol at the wild-type rate. 
However, two other types of host strains are available which vary with regard to 
their ability to utilize methanol because of deletions in one or both AOX genes. 
Strains with AOX mutations are sometimes better producers of foreign proteins 
than wild-type strains [Tschopp J.F., et al., 1987; Cregg J.M., et al., 1987; 
Chiruvolu V., et al., 1997]. Additionally, these strains do not require the large 
amounts of methanol routinely used for Mut+ strains. KM71 is a strain where 
AOX1 has been partially deleted and replaced with the S. cerevisiae ARG4 gene 
[Cregg J.M. and Madden K.R., 1987]. Since the strain must rely on the weaker 
AOX2 for methanol metabolism, it grows slowly on this carbon source (Muts, 
methanol utilization slow phenotype). Another strain, MC100-3, is deleted for 
both AOX genes and is totally unable to grow on methanol (Mut-, methanol 
utilization minus phenotype) [Cregg J.M., et al., 1998].  
The SMD1168 strain used to produce IL4PE40 is a protease-deficient strain 
that lacks of PEP4 vacuolar protease. As previously described in the Results 
chapter, Immunotoxin production with this P. pastoris strain does not solve the 
degradation problem; moreover the yield of protein decreases. In addition to lower 
viability, it possesses a slower growth rate and it is more difficult to transform. 
SMD1163 strain is another protease-deficient strain that lacks of PEP4 and PRB1 
proteases. It is possible that this strain would decrease the IL4PE40 degradation 
level. Therefore, the use of protease-deficient strains is only recommended in 
situations where other measures to reduce proteolysis yield unsatisfactory results. 
Another possibility to increased the IL4PE40 yield is that to created PE 
resistant mutant strains using the strategy of Liu Y.Y. et al. (2003). The 
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eukaryotic elongation factor-2 (EF-2) contains a post-translationally modified 
histidine residue, known as diphthamide, which is the specific ADP-ribosylation 
target of diphtheria toxin and Pseudomonas aeruginosa exotoxin A [Zhang Y et 
al., 2008]. Introducing the specific mutations in the EF-2 and inserting by 
homologous recombination the mutated gene into the yeast genome, it is possible 
to select PE resistant clones to produce higher amounts of the PE-based 
Immunotoxins. 
 
4.5 The cleavage of IL4PE40 by P. pastoris 
In  2005, Gurkan C. and Ellan D. summarized the different bacterial toxins, or 
their portions, that were successfully express by P. pastoris. They  report the 
ability of P. pastoris to produce the tetanus toxin fragment C (TeNT) and the 
heavy fragment C of the botulinum neurotoxin (BoNT). In both TeNT and the 
BoNT variants, the carboxyl-terminal domain of the heavy chain (HC) is non-
toxic and associated with binding to specific receptors present on the target nerve 
cells, and since it is antigenic, it has been exclusively used for the development of 
vaccines [Smith LA, et al., 1998; Byrne MP and Smith LA., 2000]. P. pastoris 
also proved very useful in the development of vaccines for the heat-labile 
enterotoxin (LT) of E. coli and the cholera toxin (CT) of Vibrio cholerae 
[Harakuni T, et al., 2005; Fingerut E., et al., 2005]. As previously described in the 
Introduction (Table1.12), P. pastoris  is able to produce the fusion proteins with 
bacterial toxic protein such as DT and Cyt2Aa1 (δ-endotoxin from the Bacillus 
thuringiensis), but PE-based fusion proteins produced by P. pastoris were not 
described in the literature.  
 
4.5.1 Degradation 
After IL4PE40 affinity chromatography purification from P. pastoris 
supernatant, the eluted fractions show several degradation products bearing the 
his6-tag (Fig. 3.33 of Results). Therefore, I hypothesized the presence of agents 
cleaving the proteins secreted by yeast.  
The native PE has a furin-cleavage site that releases a C-terminal 37 kDa 
fragment (II and III domains). This cleavage is essential for the toxin enzymatic 
activity. The IL4PE40 degradation pattern shows a 37 kDa band. Therefore I 
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searched the furin-cleavage sites in the IL4PE40 protein sequence. The minimal 
cleavage-site recognized from furin-like enzymes is RXXR. In the immunotoxin 
sequence three furin-like cleavage sites are present. Moreover the released C-
terminal fragments have a molecular weight comparable to that of the degradated 
bands (Fig. 3.34). To confirm this hypothesis I carried out the same in silico study 
of furin-like cleavage sites in the native PE (Fig. 3.35B). Also the native toxin has 
the cut sites for the furin-like enzymes releasing five C-terminal fragments with 
the molecular weights comparable to that of degradated bands pointed out in the 
Western blotting of  figure 3.35. The cleavage test reported in figure 3.35, shows 
that the PMSF inhibitor decreases the degradation level. Moreover, the second 
cleavage test (Fig. 3.36) shows that 5 mM EDTA does not inhibit the protein 
cleavage. The PMSF inhibits the serin proteases, but not the furin-like proteases, 
whereas the EDTA inhibits the furin-like proteases but not the serine proteases 
[Chiron M.F. et al., 1994].  
The serine proteases are enzymes cutting peptide bonds in which one of the 
amino acids at the active site is serine. Serine proteases are grouped into families 
that share structural homology such as the chymotrypsin-like. Interestingly 
chymotrypsin-like enzyme is the trypsin that is responsible for cleaving peptide 
bonds following a positively-charged amino acid residues (arginines and lysines) 
[Jesper V., et al., 2004]. As previously describe, the furin-like cleavage site 
contains two arginines; it is possible that these residues are recognized by the 
serine proteases such as trypsin. P. pastoris‘s pro-proteins, activated by the cut of 
trypsin-like cleavage sequence, were described in several works and confirm the 
existence of trypsin-like enzymes in the yeast [Manjithaya R., et al., 2010; 
Reverter D.,et al., 1998; Ohi H. et al., 1996]. As previously described in the 
optimization of Immunotoxin production, L-arginine addition in the induction 
medium is able to increase the protein accumulation. In fact it is able to inhibit the 
extracellular trypsin-like proteases [Chung B.H., et al., 1997].  
Shi X. and colleagues (2003) described the proteases activity in the P. pastoris 
supernatants (Fig. 4.1). The induction medium was buffered with the potassium 
phosphate at different pH values. 
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Fig. 4.1: Protease activities from P. pastoris culture supernatants. The graphic shows 
protease activity toward azoalbumin relative to the pH of medium. [Modified by Shi X., et al., 
2003] 
 
The figure 4.1 shows three proteases typologies active at different pH values 
of culture supernatant. The IL4PE40 optimal production was at pH 6. When 
IL4PE40 was induced in the BMMY medium at pH 7 the proteolysis increased 
(Fig. 3.27). We supposed that the cleavage of serine proteases (active between pH 
7 and pH 10) is supported by the cysteine proteases activity (active between pH 5 
and pH 7). But if the IL4PE40 protein sequence was inserted in the 
“PeptideCutter” tool (http://www.expasy.ch/tools/peptidecutter/) the cysteine 
protease cleavage sites were not identified.  
The recombinant proteins secreted by P. pastoris were synthesized in frame 
with the α-mating factor signal sequence (αMF). Thanks to αMF, the new protein 
was driven through the secretory pathway and than released in the culture 
medium. Kex2 is a trans-Golgi membrane serine protease, specific for the 
cleavage of basic amino acids. The αMF cleavage allows the release of 
recombinant protein in the extracellular environment. The figure 4.2 shows the 
Kex2 cleavage site contained in the IL4PE40 protein sequence (K47R48) that 
released a 50 kDa fragment. 
….FLK47R48LDRN….
Kex2 cut
 
Fig. 4.2: Kex2 cleavage sequence inside of IL4PE40. 
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Some time, after 24h of induction it is possible to observe a 50 kDa 
degradation product in Western blotting (Fig. 3.21). It can be supposed that Kex2 
can contribute to the proteolysis of IL4PE40 before the protein reaches the culture 
medium [Werten M.W.T. and de Wolf  F.A., 2005].  
To characterized better the nature of proteases that cut IL4PE40, several 
cleavage tests with single and specific protease inhibitors will be need. 
 
4.5.2 Preventing the IL4PE40 degradation 
After the native PE cleavage tests and the in silico studies of toxin and 
immunotoxin, I devised three mutageneses to change three IL4PE40 Arg residues 
(Arg21, Arg170, Arg243) to alanine. However these mutageneses could inactivate 
the Immunotoxin; particularly the Arg170 that is responsible for the release of the 
translocation domain is essential for the cytotoxicity of the protein. Chiron M.F et 
al. (1994) reported that the arginine-to-glycine PE mutant (Agr279 of PE furin-like 
cleavage site) was not cleaved by furin-like proteases and it was approximatelly 
500-fold less active than the native toxin. However the lack of cleavage of PE40 
from the IL4 carrier may not inhibit the Immunotoxin ability to intoxicate the 
treated cells. Indeed some SAP- and  PAP-based Immunotoxins have not a 
cleavage site that releases the toxic portion, but equally they are able to kill the 
target cells [Lombardi A, et al., 2010; Flavell DJ, et al., 2001; Schlick J, et al., 
2000]. 
The IL4PE40 mutagenesis Arg243-to-Ala is inside the catalytic domain of 
PE40. The residues essential to the native PE toxic action are: His440, Arg458, 
Gln460, Glu553 [Xiang Y., et al., 1995; Li M., et al., 1996]. The native PE Arg458 
correspond to the Arg349 of Immunotoxin, therefore the IL4PE40 Arg243 
mutagenesis would not inhibit the toxin ADP-ribosylation activity. 
 
The characterization of the P. pastoris proteases involved in the immunotoxin 
cleavage could lead to active and proteases resistant PE40 development. 
If I will not succed in the generation of proteases-resistant PE40, I will have in 
any case demonstrated that it is possible to express a full-length PE based 
immunotoxin in the P. pastoris supernatant, although so far only at a low yield.  
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